

Post-hepatectomy liver regeneration in the context of bile acid homeostasis and the gut-liver signaling axis

Lianne de Haan¹, Sarah van der Lely¹, Anne-Loes K. Warps¹, Quincy Hofsink¹, Pim B. Olthof¹, Mark J. de Keijzer¹, Daniël A. Lionarons², Lionel Mendes-Dias¹, Bote G. Bruinsma^{1,3,4}, Korkut Uygün^{3,4}, Hartmut Jaeschke⁵, Geoffrey C. Farrell⁶, Narci Teoh⁶, Rowan F. van Golen¹, Tiangang Li^{5#}, Michal Heger^{1,7#}

¹ Department of Experimental Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands

² Oncogene Biology Laboratory, Francis Crick Institute, London, United Kingdom

³ Center for Engineering in Medicine, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States

⁴ Shriners Hospitals for Children, Boston, Massachusetts, United States

⁵ Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, United States

⁶ Liver Research Group, Australian National University Medical School at the Canberra Hospital, Canberra, Australian Capital Territory, Australia

⁷ Membrane Biochemistry and Biophysics, Bijvoet Center for Biomolecular Research, Institute of Biomembranes, Utrecht University, Utrecht, the Netherlands

Shared senior authorship

* Address correspondence to:

Tiangang Li | Department of Pharmacology | Toxicology & Therapeutics | Kansas University Medical Center | University of Kansas | Kansas City | KA | United States | tli@kumc.edu


Michal Heger | Department of Experimental Surgery | Academic Medical Center | University of Amsterdam | Meibergdreef 9 | 1105AZ Amsterdam | the Netherlands | m.heger@amc.uva.nl | +31-20-5665573

Abstract

Background: Liver regeneration following partial hepatectomy (PHx) is a complicated process involving multiple organs and several types of signaling networks. The bile acid-activated metabolic pathways occupy an auxiliary yet important chapter in the entire biochemical phenomenon. PHx is characterized by rapid but transient bile acid overload in the liver, which constitutes the first wave of proliferative signaling in the remnant hepatocytes. Bile acids trigger hepatocyte proliferation through activation of several nuclear receptors. The enterocytes reabsorb the bile acids, which results in the activation of farnesoid X receptor (FXR), the consequent excretion of fibroblast growth factor (FGF)19/FGF15, and its release into the enterohepatic circulation. FGF19/FGF15 subsequently binds to its cognate receptor, fibroblast growth factor receptor 4 (FGFR4) complexed with β -klotho, on hepatocytes, which initiates the second wave of proliferative signaling. Because bile acids are potentially toxic, the remnant hepatocytes must resolve the potentially detrimental state of bile acid excess. Therefore, the hepatocytes orchestrate a bile acid detoxification and elimination response as a protective mechanism in concurrence with the proliferative signaling. The response results in the excretion of (biotransformed) bile acids into the canalicular system, causing the bile acids to end up in the intestine.

Benefit for patients: Recently, FXR agonists have been shown to promote regeneration via the gut-liver axis. This type of pharmacological intervention may prove beneficial for patients with hepatobiliary malignancies undergoing PHx. In light of these developments, this review provides an in-depth account of the pathways that underlie post-PHx liver regeneration in the context of bile acid homeostasis in the liver and the gut-liver signaling axis.

Graphical abstract



List of abbreviations

AKT	protein kinase B
AP-1	activator protein 1
ATF2	activating transcription factor 2
BSEP	bile salt export pump
CA	cholic acid / cholate
CAR	constitutively active / androstane receptor
CDCA	chenodeoxycholic acid / chenodeoxycholate
CDK	cyclin-dependent kinase
C/EBP	CCAAT-enhancer-binding protein
c-Met	hepatocyte growth factor receptor
CPF	CYP7A promoter-binding factor
CREB	cAMP response element-binding protein
CYP7A1	cholesterol 7 alpha-hydroxylase
DAMPs	damage-associated molecular patterns
DCA	deoxycholic acid / deoxycholate
E2f	E2f transcription factor
ECM	extra cellular matrix
EGF	epidermal growth factor
ER	endoplasmic reticulum
ERK	extracellular signal-regulated kinases
FAS receptor	apoptosis antigen I
FGF	fibroblast growth factor
FGFR	fibroblast growth factor receptor
FOXM1B	forkhead box M1B
FOXO3	forkhead box O3
FTF	fetoprotein AFP transcription factor
FXR	farnesoid X receptor
GADD45 β	growth arrest and DNA-damage-inducible, beta
H ₂ O ₂	hydrogen peroxide
HGF	hepatocyte growth factor
HNF	hepatocyte nuclear factor
HSP	heat shock protein
IGFBP1	insulin-like-growth-factor binding-protein 1
IL	interleukin
IRE1 α	inositol-requiring enzyme-1 α
JNK	c-Jun amino-terminal kinase
JUN	JUN proto oncogene
JAK	Janus kinase
LCA	lithocholic acid / lithocholate
LPS	lipopolysaccharide
LRH-1	liver receptor homolog 1
LXR	liver X receptor
MAPK	mitogen-activated protein kinase
MDR-1	multidrug resistance protein 1
miRNA	microRNA
MMP-9	matrix-metalloproteinase 9
mRNA	messenger ribonucleic acid
MRP	multidrug resistance protein

mTOR	mammalian target of rapamycin
NF- κ B	nuclear factor kappa-light-chain-enhancer of activated B cells
NRF2	nuclear factor (erythroid-derived 2)-like 2
NRIP1	nuclear receptor-interacting protein 140
NTCP	Na ⁺ -taurocholate co-transporting polypeptide
OST	organic solute transporter
p21	cyclin-dependent kinase inhibitor 1
PAMPs	pathogen-associated molecular patterns
PCNA	proliferating cell nuclear antigen
PG	prostaglandin
PHx	partial hepatectomy
PI3K	phosphoinositide 3-kinase
PKC	protein kinase C
PPAR	peroxisome proliferator-activated receptor
pRB	phosphorylated retinoblastoma protein
PRR	pattern recognition receptor
PXR	pregnane X receptor
ROS	reactive oxygen species
RXR	retinoid X receptor
SHP	small heterodimer partner
SIRT1	sirtuin1
SOCS	suppressor of cytokine signaling
STAT3	signal transducer and activator of transcription 3
TCA	taurocholic acid / taurocholate
TGF	transforming growth factor
TGR5	G protein-coupled bile acid receptor
TLR4	Toll-like receptor 4
TNF- α	tumor necrosis factor alpha
VEGF	vascular endothelial growth factor
VEGFR	vascular endothelial growth factor receptor
UDCA	ursodeoxycholic acid / ursodeoxycholate
UGT	UDP-glucuronosyltransferase
uPA	urokinase plasminogen activator
UPR	unfolded protein response

1. Introduction

The liver strictly maintains its size at a predefined setpoint in order to optimally fulfill its detoxification-, synthesis-, immunological-, and endocrinological functions [1]. Under pathological conditions that affect the liver, the host is not only able to sense a loss of viable liver tissue, but also to mount a regenerative response so as to rapidly restore original liver size and function. Factors that control the liver-to-body weight ratio, or the ‘hepatostat,’ are only partially understood [2].

The prototypical stimulus for liver regeneration is the surgical removal of part of the organ (partial hepatectomy, PHx), as is routinely performed by surgeons most often in case of hepatobiliary malignancies [3]. Rodent PHx models have been extensively employed to study the mechanisms that underlie post-PHx liver regeneration. Owing to these models we now know that, immediately after PHx, the activation of early response transcription factors [4,5] and mitogen-activated protein kinases [6] leads to hepatocyte proliferation and compensatory liver regrowth. These growth factors are activated directly after PHx by hemodynamic changes [7], inflammation [8-10], and cell damage [11-14]. Proliferation is perpetuated until the liver size reaches a mass that complies with the hepatostat, at which point liver growth is terminated [15,16].

The regenerative capacity of the liver after PHx is not inexhaustible. As a reduced number of hepatocytes have to uphold all metabolic functions whilst the liver reclaims its original size, there is a risk of developing liver failure if the remnant is too small or too frail [17], a condition which is often referred to as small-for-size syndrome [18]. Several sensors involved in hemodynamic changes [7], inflammation [8-10], cell damage [11-14], and bile acid metabolism [19,20] are embedded to foster successful liver regeneration and prevent liver failure [21]. Sensors that are involved in bile acid metabolism are especially important in proregenerative signaling through the gut-liver axis [22-25]. Bile acid receptors such as farnesoid X receptor (FXR) promote liver regeneration and prevent liver failure by (i) modulating the bile acid pool size, composition, and compartmentalization [21,26], (ii) governing the production of mitogens such as fibroblast growth factor 15/19 (FGF15/19, signifying rodent/human orthologues) [22,23], and (iii) rewiring mitochondrial metabolism to fuel liver growth [27]. In addition to coordinating liver regeneration after PHx, bile acids are also able to override the hepatostat and consequently expand liver size to larger than normal without concurrent mitogenic triggers [28,29], underscoring their prolific role in compensatory liver regrowth.

As (semi-)synthetic selective agonists of bile acid- and other nuclear receptors have become available [30-33], the metabolic components of liver regeneration could be exploited to pharmacologically enhance liver growth, which in turn could benefit numerous medical scenarios. This review therefore summarizes the molecular pathways that lie at the basis of post-hepatectomy liver regeneration in the context of bile acid homeostasis and the gut-liver signaling axis.

2. General mechanisms of liver regeneration following partial hepatectomy

PHx-induced liver regeneration involves all cell types in the liver, including hepatocytes, Kupffer cells, stellate cells, biliary epithelial cells, and endothelial cells [34]. The time lapse of proliferation is distinct for every cell type. In the rat liver, hepatocytes begin DNA synthesis at 12 hours after PHx, which peaks at 24 hours. The onset of hepatocellular DNA synthesis is initiated in the vicinity of the portal veins and subsequently spreads towards the central veins [35]. The peak of DNA synthesis in non-parenchymal cells is later. Kupffer cells start to proliferate at 48 hours, and biliary epithelial cells and endothelial cells at 96 hours after PHx. The most profound increase in liver mass in rats occurs during the first 3 days after PHx, and restoration of the remnant liver to its original liver mass is completed within 7-14 days [24,36,37]. In humans, functional recovery of pre-operative liver function takes place within the first 10 days after PHx [38], but complete regrowth of the remnant human liver occurs 3-6 months after PHx [39]. Although all cell types contribute to the increase of liver mass after PHx, this review will primarily focus on the cell cycle progression and proliferation of hepatocytes.

Liver regeneration entails the activation of multiple regulatory pathways that include cytokine-, growth factor-, and metabolic networks [40]. More specifically, PHx induces differential regulation of genes that coordinate cell cycle regulation, chromatin reorganization, transcriptional regulation, signal transduction, protein targeting, metabolism, transport, xenobiotic metabolism, surface receptors, inflammation, and acute phase responses [41]. These pathways are well-coordinated to allow proper restoration of the tissue while maintaining vital liver functions. A global overview is reviewed in the next subsections. For more detailed information, interested readers are referred to specialized publications [36,37,42,43].

2.1. Initial triggers of liver regeneration: changes in hepatic hemodynamics, sterile and non-sterile inflammation, and a shift in intracellular redox state

The first physiological change during PHx is the redirection of portal and arterial blood supply to the remnant liver instead of the entire liver [44]. As a result, hepatocytes become exposed to a 3-fold greater amount of proregenerative factors [44], mainly supplied by the portal vein [2] (Figure 1). The post-PHx hemodynamic heterogeneity [45-47] and portal hypertension [25] facilitate platelet-endothelial cell interactions during both stasis and flow [48,49]. Moreover, the fenestrations between the sinusoidal endothelial cells widen after PHx [50], allowing more facile passage of blood-borne signaling molecules but also platelets into the space of Disse [51,52].

Secondly, the surgical trauma after PHx causes damaged and dying cells to leak their intracellular content [11,12], which contains damage-associated molecular patterns (DAMPs), into the extracellular compartment. The DAMPs bind pattern recognition receptors (PRR) such as Toll like receptors (TLRs) on Kupffer cells and trigger a sterile immune response [13,14], characterized by the release of tumor necrosis factor- α (TNF- α) and interleukin-6 (IL-6) from Kupffer cells [8], as illustrated in Figures 1 and 2. These cytokines trigger proliferative signaling in hepatocytes and subsequent liver regeneration [36,53-55]. PHx-induced injury also triggers C3a (mice and humans) and C5a (mice) complement activation [8-10], which bind to complement receptors on Kupffer cells and neutrophils and amplify the sterile immune response [8,10]. The consequent immune cell activation, cytokine production, and release of proregenerative factors contribute to liver regeneration through various cascades [2,36,56-59], as highlighted in sections 2.2 and 2.3.

Simultaneously, the immune response is also fueled by pathogen-mediated inflammation emanating from the gut-liver axis [60,61]. PHx induces endotoxemia as a result of surgical ligation of part of the portal vein output, portal hypertension [25], and consequent perturbation of the intestinal mucosal barrier [62,63]. This results in microbe-derived blood-borne lipopolysaccharide (LPS) – a pathogen-associated molecular pattern (PAMP) [64] – triggering liver regeneration by binding PRRs such as TLR4 on Kupffer cells [65]. LPS-PRR binding leads to Kupffer cell activation and the release of TNF- α and IL-6 [36,54,66]. The endotoxemia further facilitates the accumulation of platelets in the remnant liver [51,52], where the platelets locally orchestrate a pro-regenerative stimulus via degranulation and possibly sequestration by sinusoidal endothelial cells and hepatocytes [42] (section 2.3).

Thirdly, a shift in hepatocellular redox state is responsible for the onset of liver regeneration (Figure 1). The temporary pro-oxidative state post-PHx, which is characterized by an overproduction of reactive transients such as hydrogen peroxide (H_2O_2), can be caused by liver surgery encompassing ischemia/reperfusion [67,68], cholestasis [69] and other liver diseases [70], and a temporary post-PHx bile acid overload (section 3). Bai et al. showed that H_2O_2 at a specific intracellular concentration range promotes liver regeneration in rats during the first 24 hours after PHx [71], which has also been reported by others in mice [72,73], albeit with contradictory results [74].

Intracellular H_2O_2 acts as a cell cycle regulator that, depending on its intracellular concentration, signals quiescence or proliferation in hepatocytes. As illustrated in Figure 1, the process is regulated by the ERK-cyclin D1-pRB pathways [71] as well as Notch signaling [75]. ERK stands for extracellular regulated kinase (a mitogen-activated protein kinase, MAPK), pRB signifies phosphorylated (i.e., activated) retinoblastoma protein (RB), and Notch is a cell surface protein that acts as an auxiliary mitogen in liver regeneration [76] (section 2.4). ERK signaling promotes cell cycle activity and ultimately proliferation, during which cyclin D1 and pRB, a cell cycle inhibitor in non-phosphorylated form [77,78], enable cell cycle progression and ultimately mitosis [79-81]. The transient increase in H_2O_2 levels is facilitated by a temporary suppression of antioxidant enzymes and upregulation of pro-oxidant enzyme activity through nuclear factor erythroid 2-related factor 2 (NRF2), particularly during the early regeneration phase [71]. In support of this, NRF2-null mice exhibit stalled liver regeneration [82]. To protect the hepatocytes from oxidative stress while undergoing reactive oxygen species (ROS)-mediated mitosis, heat shock proteins may be upregulated [83].




Figure 1. Changes in hepatic hemodynamics that lead to liver regeneration. Three physiological changes following PHx trigger liver regeneration. Altered hepatic hemodynamics (1) lead to increased hepatic exposure to pro-regenerative factors originating from the portal circulation. Additionally, platelets accumulate in the space of Disse and release pro-regenerative molecules. The hepatocellular redox state (2) shifts to a pro-oxidative state due to ischemia/reperfusion, cholestasis, and bile acid overload. NRF-2 upregulates pro-oxidant enzymes and downregulates antioxidant enzymes, leading to increased levels of H₂O₂, which promotes cell proliferation through both ERK-cyclin D1-p-RB and Notch signaling. PHx induces hepatocyte proliferation through an immune response (3), resulting from endotoxemia, intestine-derived PAMPs, and damaged cells leaking DAMPs. PAMPs and DAMPs bind PRRs on Kupffer cells, triggering the release of cytokines such as TNF-α and IL-6. Complement factors C3a and C5a are also triggered by the immune response and activate TNF-α and IL-6 release

through complement receptors. Abbreviations: SEC = sinusoidal endothelial cell; I/R = ischemia and reperfusion; BA = bile acid; NRF-2 = nuclear factor (erythroid-derived 2)-like 2; H₂O₂ = hydrogen peroxide; ERK = extracellular signal-regulated kinase; pRB = phosphorylated retinoblastoma protein; DAMPs = damage-associated molecular patterns; PAMPs = pathogen-associated molecular patterns; IL-6 = interleukin 6; TNF- α = tumor necrosis factor alpha.

2.2. Cytokines in liver regeneration

Acting on the numerous environmental cues (section 2.1 and Figure 1), Kupffer cells become activated and release two important cytokines for liver regeneration, namely TNF- α and IL-6 [36,84,85]. While IL-6 is chiefly responsible for the mitogenic effects in hepatocytes, TNF- α predominantly serves an autocrine function in that it stimulates the production of IL-6 by Kupffer cells via nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) [36,86] (Figure 2). However, it was shown that quiescent rat liver epithelial (LE6) cells also exhibit mitogenic activity following TNF- α stimulation, which proceeds through NF- κ B and concurs with the upregulation of IL-6, signal transducer and activator of transcription 3 (STAT3, see below), and c-myc (an immediate-early gene that regulates cell cycle progression [84]) [87,88], suggesting direct mitogenic signaling by TNF- α . Furthermore, the release of sphingosine 1-phosphate from activated platelets [89] prompts human sinusoidal endothelial cells to secrete IL-6 and thereby amplify the proliferative response in hepatocytes [90,91].

Hepatocytes normally reside in the quiescent (G0) phase, but after PHx the hepatocytes enter the G1 phase following a multitude of stimuli, which includes IL-6 binding to its cognate receptor on the hepatocyte membrane [92,93]. As is illustrated in Figure 2, this triggers Janus kinase (JAK) signaling and the consequent transcription and translation of immediate-early target genes involved in DNA synthesis, cell proliferation, cellular hypertrophy, metabolic homeostasis, and cell survival by two major pathways [36,37,94,95]. Firstly, JAK activates the extracellular-signal-regulated kinase (ERK)-1/2 MAPK cascade via RAS and its complexation partners, culminating in cell proliferation [6]. Secondly, JAK activates STAT3 and the transcription of a plethora of immediate-early target genes [84,95,96], which mediate numerous liver regeneration-related processes [97].

2.3. Growth factors (complete mitogens) in liver regeneration

Liver regeneration is propagated by growth factors, whereby hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and ligands that bind epidermal growth factor (EGF) receptor (EGFR) occupy key roles [36,37,98-102]. Growth factor signaling encompasses several cell types and organs [36].

In the early phase of post-PHx liver regeneration, platelets accumulate in the remnant liver [103,104] via interactions with sinusoidal endothelial cells [42]. The platelets locally release an armament of mitogenic (HGF, EGF) and co-mitogenic growth factors (insulin-like growth factor-1 (IGF-1), VEGF, and platelet-derived growth factor (PDGF)) from their α -granules [47,105,106] as well as the proliferation-curtailing transforming growth factor β (TGF- β) [105,107]. Platelet degranulation also causes the release of non-growth factor mediators of liver regeneration [42], including serotonin [108] and nucleotides [105,106]. Moreover, extravasated platelets in the liver parenchyma induce proliferative AKT and ERK-1/2 signaling in hepatocytes through HGF, VEGF, and IGF [109,110].

An intricate signaling relationship exists between HGF and VEGF in the regenerating liver. HGF is released in its precursor form pro-HGF by stellate cells [111] and serotonin-activated sinusoidal endothelial cells [112]. Activated sinusoidal endothelial cells secrete VEGFA (hepatic VEGF) [112,113] that, upon autocrine binding to VEGF receptors (VEGFR1 [113] and VEGFR2 [114]), triggers the release of pro-HGF from sinusoidal endothelial cells [113]. At the same time, VEGFA drives the chemotaxis of bone marrow-derived sinusoidal progenitor cells to the liver, which are replete with HGF [115]. These progenitor cells not only differentiate into fenestrated sinusoidal endothelial cells as part of the regeneration process [99] but also locally release HGF [115]. Accordingly, rat plasma levels of (pro-)HGF increase rapidly by 10- to 20-fold following PHx [116]. Pro-HGF is converted to its active form by urokinase plasminogen activator (uPA) [117-119] that is hyperactivated after extracellular matrix (ECM) damage from the resection [2,34]. HGF acts in a paracrine and endocrine fashion with respect to hepatocytes, on which HGF binds its cognate receptor c-Met [120-122], inducing proliferative signaling and DNA synthesis through the ERK-1/2 MAPK pathway [123,124] and hepatoprotective signaling through AKT [125,126]. HGF-mediated proliferative signaling in rats was further shown to be amplified by the LPS [127] that is abundantly present in the enterohepatic circulation after PHx [60-63].

The HGF/c-Met pathway is amplified by ligands that bind epidermal growth factor receptor (EGFR), which include EGF, TGF- α , heparin-binding EGF-like growth factor (HBEGF), and amphiregulin [37,128,129], culminating in hepatocyte proliferation (Figure 2). Plasma levels of EGF, which is constitutively produced in the duodenum by the glands of

Brunner [130], increase in response to increased shear stress in the portal circulation [34] as well as norepinephrine signaling in the gut [131,132]. Plasma levels of norepinephrine increase within 20 min after PHx in rats [131,133] and may therefore fuel EGF signaling within the gut-liver signaling axis. TGF- α is produced by proliferating hepatocytes and relays proliferative signals to hepatocytes through an autocrine mechanism via EGFR [134-136]. HBEGF is produced by monocytes and macrophages [137,138] and converted to its active form by specific metalloproteinases [139]. In rats, plasma levels of this hepatocellular mitogen [140,141] are rapidly elevated after PHx [141,142] and expressed on or associated with sinusoidal endothelial cells and Kupffer cells as early as 90 minutes after PHx [141,143], reflecting early-onset proliferative cross-talk between the sinusoidal cells and EGFR-bearing hepatocytes via HBEGF. Amphiregulin is an autocrine growth factor and a mitogen for several cell types, including hepatocytes [144]. Accordingly, amphiregulin-null mice exhibit impaired hepatocellular proliferation [144]. The protein is induced in the early regeneration phase, triggered by prostaglandin E₂ (PGE₂) and IL-1 β [144]. The latter was shown to be rapidly released after PHx in both mice and rats [145-147]. Similarly, PGE₂ levels rise in the rat liver in the early phase of liver regeneration [148]. The release of IL-1 β and PGE₂ by Kupffer cells is stimulated by post-PHx endotoxemia [149]. Although both mediators induce amphiregulin and thus hepatocyte proliferation, IL-1 β [145-147] and PGE₂ concurrently inhibit liver regeneration. Whereas PGE₂ inhibits liver regeneration through downmodulation of IL-6 by Kupffer cells [150], IL-1 β inhibits expression of β -klotho and FGFR4, that together form the FGF15/19 receptor [151] (see section 4.2.2). Their inhibitory effects are evidently offset by the other proliferation-promoting processes after PHx [152].

Of the factors addressed above, HGF, EGF, TGF- α , HBEGF, and amphiregulin are classified as so-called ‘complete hepatic mitogens’ because these proteins trigger mitosis in cultured hepatocytes and induce liver hypertrophy and hepatocyte DNA synthesis *in vivo* [44]. By definition, ‘incomplete mitogens’ or ‘auxiliary mitogens’ are not mitogenic in cultured hepatocytes; they do not induce hepatocellular DNA synthesis and liver growth *in vivo*. Nonetheless, their inhibition (or inhibition of downstream targets) delays liver regeneration but does not abrogate it [44]. Some (potential) auxiliary mitogens are briefly addressed next.

2.4. Auxiliary mitogens in liver regeneration

The auxiliary mitogens TNF- α and IL-6 [36,84,85] (section 2.2), complement proteins [9] (section 2.1), serotonin [108] (section 2.3), and norepinephrine [153] (section 2.3) have been discussed above and elsewhere [2,36,37,44,56,98] in the framework of liver regeneration. Other putative auxiliary mitogens are the receptors of some of these compounds, which include VEGFR [113] (section 2.3), TNF receptor (TNFR) [93,154], serotonin receptors [108], and the norepinephrine receptor α 1 adrenergic receptor [131]. Additional auxiliary mitogens that are thought to play a role in liver regeneration comprise FGF1 and FGF2 [155,156], PDGF [157], macrophage inflammatory protein (MIP)-2 alpha (CXCL2) and its receptor IL-8 receptor beta (CXCR2) [158], the cell surface proteins NOTCH1 and JAG1 [76], leptin [159], insulin [160], hyaluronic acid [161-164], Wnt2 [114], and insulin-like growth-factor binding-protein 1 (IGFBP1) [165-167]. Their role has been reviewed in a broader context in [2,36,37,43,44,56,98]. The multiplicity of this non-exhaustive list of auxiliary mitogens clearly illustrates the complexity of signals that modulate post-PHx liver regeneration.

In addition to these putative auxiliary mitogens, some underexposed or more recently discovered auxiliary mitogens deserve to be highlighted. First, it was shown that PHx in mice leads to endoplasmic reticulum (ER) stress and the unfolded protein response (UPR) [168], which is triggered to resolve ER stress [169]. The UPR is mediated by inositol-requiring enzyme-1 α (IRE1 α) [170] and exacerbated by TNF- α and ROS [171]. This is also shown in Figure 2. As addressed in sections 2.1 and 2.2, ROS and TNF- α are hallmarks of post-PHx liver regeneration and may therefore lie at the basis of the ER stress observed in hepatectomized mice [168]. More importantly, mice with *Ire1 α* -null livers exhibit impaired hepatocyte proliferation and liver regeneration as a result of dampened IL-6-mediated STAT3 signaling [168]. It was further found that IRE1 α interacts directly with STAT3 in the early phase of liver regeneration (6-12 hours), independently of IL-6 stimulation [168]. These results underscore the cytokine-driven as well as constitutive regulation of early, UPR-based mitogenic responses following PHx, and identify IRE1 α as an auxiliary mitogen.

A related but relatively underexposed auxiliary mitogen is cyclooxygenase 2 (COX-2) [172], an enzyme that regulates prostaglandin synthesis. COX-2 is controlled by multiple processes [173] that occur during liver regeneration. These processes are also summarized in Figure 2. For instance, the post-PHx endotoxemia [60-63] drives COX-2 activation in rat Kupffer cells [174] that subsequently orchestrate cytokine signaling (section 2.2). Endotoxemia also positively affects hepatocyte COX-2 expression in mice [175]. Furthermore, ROS are a trigger for COX-2 upregulation [176,177]. COX-2-modulating

pathways entail NF- κ B [87] (section 2.2), ERK1/2 [36,178,179] (via e.g., transcriptional regulation of *PTGS2* [173], the gene encoding COX-2), and MEK in the MAPK pathway [6,178,179] (through e.g., the phospholipase A2 \rightarrow arachidonic acid connection [173]), which are all established in post-PHx liver regeneration. As a result, COX-2 promotes hepatocyte proliferation during early regeneration, with maximum hepatocellular expression at 16 hours after PHx in rats [172]. The upregulation of COX-2 in regenerating livers is associated with decreased CCAAT-enhancer binding protein (C/EBP) α levels and increased expression of C/EBP β and C/EBP δ [172,180]. C/EBPs are transcription factors involved in cell proliferation, growth, differentiation, and metabolism [181,182]. C/EBP α inhibits proliferation [183,184] while the β and δ isoforms promote proliferation [180,185,186]. There is also a potential link between ER stress and COX-2. ER stress has been shown to stimulate murine COX-2 expression via activation of NF- κ B and p38 MAPK [187]. In turn, p38 MAPK is induced by LPS and pro-inflammatory cytokines (e.g., TNF- α , IL-1 β) [188-191] as well as by reactive transients such as hydrogen peroxide [191,192] and nitric oxide [193]. Similarly, NF- κ B is under positive cytokine [194] and redox control [195]. These mechanisms connect post-PHx ER stress to COX-2 signaling in terms of hepatocyte proliferation, which are stimulated by liver regeneration-specific inflammation- and redox-modulated processes.

An auxiliary role in liver regeneration has further been ascribed to microRNAs (miRNAs) [196,197], whereby some miRNA types are overexpressed (usually mildly; e.g., miR-21, miR-33, miR-153, and miR-743b [198,199]) while others are underexpressed (usually intensely; e.g., let-7b, let-7f, let-7g, miR-22a, miR-23b, miR-26a, miR-30b, and miR-122a [200,201]) after PHx [197]. Experiments in mice lacking the enzyme dicer 1 in the liver, which is responsible for generating miRNA [202], demonstrated that these animals exhibit a proliferative liver phenotype [203], indicating that miRNAs are essentially inhibitors of liver regeneration [200,204,205]. This inverse correlation is biochemically logical given that miRNAs inhibit the translation of messenger RNA (mRNA) to a functional protein; in many cases cell cycle regulators [206,207] and mediators of proliferation [200,208,209]. However, there are several examples of miRNAs that are upregulated during liver regeneration yet amplify the regenerative response, suggesting that these transcriptomic regulators inhibit repressors of hepatocellular proliferation. Specific examples include miR-21 [207,210-213], miR-221 [214], miR-378 [210], and miR-382 [215].

The expression patterns of miRNA are species-dependent [216], dynamic over time, and the peak expression levels do not temporally overlap [198,217,218], underscoring the phasic nature and pleiotropic signaling of miRNAs as has been reported for cytokines (section

2.2) and growth factors (section 2.3). In that respect, the temporal heterogeneity of intrahepatic and plasma cytokine levels [36,37,56,84] are partly responsible for the differential miRNA expression profiles inasmuch as cytokines modulate miRNA expression [219]. In addition to changes in their quantitative expression, the miRNAs, which are associated with polysomes (mRNA-ribosome complexes formed during active translation), also exhibit spatial translocation during liver regeneration [197]. Corroboratively, the expression levels of the miRNAs let-7a, miR-21, miR-195, and miR-215 increased in the membrane-bound polysomes relative to the free polysomes after PHx [197].

Platelets accumulate in the space of Disse and release an armament of growth factors, including HGF, from their α -granules. Pro-HGF is released from SECs and HSCs and is converted to HGF by uPA, which is activated as a result of ECM damage after PHx. Platelets also release serotonin, which stimulates SECs, and sphingosine-1-phosphate to stimulate IL-6 release (**B**). PGE₂ and IL-1 β coming from Kupffer cells stimulate amphiregulin production in hepatocytes. HGF binds its receptor c-Met and activates hepatocyte proliferation through ERK-1/2 MAPK. IL-6 binds the IL-6 receptor and activates JAK, which induces hepatocyte proliferation through STAT3 and through RAS-ERK-1/2 MAPK. EGF, TGF- α , HBEGF, and amphiregulin enhance the effect of HGF through EGFR2. EGF is produced in the duodenum and reaches the liver through the portal circulation. TGF- α is produced by proliferating hepatocytes. HBEGF is released from monocytes and macrophages and converted to its active form by metalloproteinases. TNF- α (from Kupffer cells) and ROS enhance the UPR that is mediated by IRE1 α . The UPR inhibits ER stress that in turn activates COX-2 expression. COX-2 is also stimulated by ROS, PAMPs, and DAMPs. Enhanced COX-2 expression increases C/EBP β and C/EBP δ expression and decreases C/EBP α expression, thereby stimulating hepatocyte proliferation (**C**). Abbreviations: DAMPs = damage-associated molecular patterns; PAMPs = pathogen-associated molecular patterns; NF- κ B = nuclear factor kappa-light-chain-enhancer of activated B-cells; COX-2 = cyclo-oxygenase 2; PGE₂ = prostaglandin E₂; IL-1 β = interleukin 1 β ; IL-6 = interleukin 6; TNF- α = tumor necrosis factor alpha; SEC = sinusoidal endothelial cell; HSC = hepatic stellate cell; HGF = hepatocyte growth factor; uPA = urokinase plasminogen activator; C/EBP α , β , and δ = CCAAT enhancer binding protein alpha, beta, and delta; TGF- α = tumor growth factor alpha; EGF = epidermal growth factor; EGFR2 = epidermal growth factor receptor 2; JAK = Janus kinase; ERK = extracellular signal-regulated kinase; MAPK = mitogen-activated protein kinase; STAT3 = signal transducer and activator of transcription 3; IRE1 α = inositol-requiring enzyme-1 α ; UPR = unfolded protein response; ROS = reactive oxygen species.

3. Bile acids co-regulate post-hepatectomy liver regeneration in the early phase

Studies in the recent years have shown that bile acid metabolism and signaling are directly involved in the liver regeneration process [21,28,220-222]. After PHx, the remaining liver is subject to acute overload of bile acids returning via the portal circulation [22,24-26]. Bile acids are complete mitogens by binding to nuclear receptors or activating intracellular signaling pathways [19,20]. During the regeneration phase, the liver also activates multiple adaptive mechanisms to prevent bile acid toxicity and restore bile acid homeostasis since prolonged exposure to bile acids at higher concentrations may promote liver injury or tumorigenesis in chronic liver injury-repair processes [223]. The effect of bile acid metabolism on liver regeneration, regulation of liver proliferation by bile acid signaling, and the mechanisms regulating bile acid homeostasis during regeneration are further discussed in the following sections.

3.1. Bile acid synthesis in the enterohepatic circulation

3.1.1. Bile acid synthesis

Daily, 0.2 to 0.6 g of bile acids (Figure 3, placed at the end of the manuscript) is synthesized from cholesterol in the human liver via two pathways: the neutral pathway and the acidic pathway [224]. Bile acid synthesis pathways involve multi-step reactions catalyzed by enzymes in the endoplasmatic reticulum, mitochondria, cytoplasm, and peroxisomes. The enzyme cholesterol 7 α -hydroxylase (CYP7A1) catalyzes the first rate-limiting step in the neutral pathway and converts cholesterol into 7 α -hydroxycholesterol, which eventually leads to the synthesis of the primary bile acids cholic acid (CA) or chenodeoxycholic acid (CDCA) [225,226]. In the acidic pathway, the enzyme 27 α -hydroxylase (CYP27A1) converts cholesterol to 27 α -hydroxycholesterol, which leads to the synthesis of CDCA [224]. After excretion into the biliary system, bile acids are first deconjugated and then biotransformed by enteral bacteria through phase I reactions (oxidation, hydroxylation), forming secondary bile acids, including deoxycholic acid (DCA), lithocholic acid (LCA), and ursodeoxycholic acid (UDCA) [227-229]. Ninety five percent of all biliary excreted bile acids are resorbed and transported back to the liver via the portal vein. This process is termed the enterohepatic circulation [230]. However, most LCA is not recycled and the small amount of circulating LCA is rapidly conjugated by sulfation, a phase II reaction, and secreted into the biliary system [228]. Sulfation increases bile acid solubility, as a result of which sulfated LCA is less likely to be intestinally reabsorbed [231]. For this reason, the human bile acid pool mainly consists of the primary bile acids CA and CDCA and the secondary bile acid DCA. The liver efficiently conjugates both primary and secondary bile acids to taurine or glycine (ratio 3:1 in humans) by amidation, then commonly referred to as bile salts, which promotes solubility and prevents passive diffusion across cell membranes [232]. Throughout this review, the term 'bile acids' is used for both bile acids and bile salts.

In the mouse and rat liver, the majority of CDCA is further converted to the more hydrophilic muricholic acids (MCAs) α -muricholic acid and β -muricholic acid. Consequently, the mouse and rat bile acid pool consists of approximately equal amounts of CA and MCAs, with relatively low levels of CDCA. While in humans glycine-conjugated bile acids are most common, most bile acids in mice and rats are conjugated with taurine [233]. Thus, the mouse bile acid pool is much more hydrophilic compared to the human bile acid pool. This is the main reason for the direct cytotoxicity of bile acid during cholestasis in humans but not mice [234,235]. Nevertheless, similar mechanisms of bile acid metabolism likely apply to most species.

3.1.2. Bile acid transport in the enterohepatic circulation

Bile acids produced in hepatocytes are efficiently secreted into the bile and stored in the gallbladder. Upon food intake, the gallbladder contracts in response to cholecystokinin secreted by the epithelial cells in the duodenum, causing bile acids to be released into the small intestine [236]. In the small intestine, bile acids emulsify dietary lipids to form micelles, allowing pancreatic lipases to hydrolyze lipids for absorption.

After reabsorption by enterocytes, bile acids in the portal circulation are imported into hepatocytes across the basolateral membrane, after which they are secreted into the bile canaliculi, a process referred to as first pass metabolism (summarized in Figure 4). The liver first pass extraction rate for conjugated bile acids is about 90%, with little bile acids spilled into the systemic circulation. The Na⁺-dependent taurocholate transporter (NTCP) is a major bile acid uptake transporter in the basolateral membrane of hepatocytes [237-241]. In addition, organic anion transporter (OATP) isoforms mediate Na⁺-independent bile acid uptake at the basolateral membrane of the hepatocytes. At the canalicular side of the hepatocytes, the bile salt export pump (BSEP, *ABCB11/Abcb11*; human/rodent gene) mediates bile acid secretion against the concentration gradient. Consequently, canalicular bile acid export is a rate-limiting step in bile formation [242]. The multidrug resistance-associated protein-2 (MRP2, *ABCC2/Abcc2*) can also mediate the canalicular secretion of certain sulfated and conjugated bile acids, besides bilirubin conjugates, glutathione, and drugs [243]. Hepatobiliary free cholesterol secretion into the bile is mediated by the ATP-binding cassette transporters ABCG5 and ABCG8 [244]. Phosphatidylcholine, the major phospholipid in the bile, is secreted via the multi-drug resistance protein (MDR3, *ABCB4/Abcb4*) [245]. Cholesterol, bile acids, and phospholipids are the major constituents of bile. They form micelles in the canaliculi to increase cholesterol solubility and decrease bile acid damage to the bile duct.

In the intestine, bile acids are imported into the enterocytes via the apical sodium dependent bile acid transporter (ASBT, *SCLC10A2/Slc10a2*) [246] and subsequently excreted into the portal circulation via the organic solute and steroid transporter (OST) α and OST β heterodimer [247,248]. Whereas most of the conjugated bile acids are efficiently reabsorbed in the small intestine via active transport systems, some unconjugated primary bile acids and secondary bile acids, mainly DCA and to a much less extent LCA, can also be reabsorbed in the colon via passive diffusion and returned to the liver via the portal circulation.




Figure 4. Hepatocellular bile acid transporters. Basolateral import of bile acids is mediated by NTCP (Na⁺-dependent) and OATP isoforms (Na⁺-independent). Bile acids are exported through the basolateral exporters MRP3, MRP4, the OST α and OST β heterodimer, and through the canalicular exporters BSEP, MRP2, and possibly MDR1. Bile acids regulate their own efflux through hepatic farnesoid X receptor (hFXR). Bile acid-activated hFXR induces the OST α and OST β heterodimer and MRP2 and, as heterodimer with RXR, BSEP. hFXR also activates SHP that inhibits the importers NTCP, the OST α and OST β heterodimer, LXR, and LRH-1. LXR and LRH-1 normally inhibit CYP7A1, CYP8B1, and CYP27A1, but as a consequence of SHP activation by hFXR, bile acids are synthesized from cholesterol. Additionally, LRH-1 normally stimulates the expression of BSEP and the OST α and OST β heterodimer, while induction of SHP by hFXR results in inhibition of those exporters. Abbreviations: BA = bile acid; OATP = organic anion transporter; NTCP = Na⁺-taurocholate co-transporting polypeptide; MRP3/4 = multidrug resistance protein 3 and 4; OST α / β = organic solute transporter; BSEP = bile salt export pump; MDR1 = multidrug resistance associated protein 1; SHP = small heterodimer partner; LRH-1 = liver receptor homolog 1; LXR = liver X receptor; hFXR = hepatic farnesoid X receptor; RXR = retinoid X receptor; PXR = pregnane X receptor; CAR = constitutively active/androstane receptor; CYP = cytochrome p450.

3.1.3. Bile acid-activated signaling

Besides the digestive function, bile acids are also signaling molecules that regulate various physiological and pathophysiological processes, including metabolic homeostasis, tumorigenesis, and immunity. In the enterohepatic system, bile acids exert regulatory functions by activating either intracellular ligand-activated nuclear receptors or cell surface receptors that activate intracellular signaling [249-251]. One of the major functions of the nuclear receptors is to maintain bile acid homeostasis through coordinated regulation of bile acid synthesis, transport, and detoxification.

The best studied nuclear receptor, farnesoid X receptor (FXR), is primarily expressed in the liver and intestines and, as shown in Figures 5 and 6, distinct pathways are initiated by hepatocellular FXR (hFXR) [252] and enterocytic FXR (eFXR) [253] that are involved in post-PHx liver regeneration and bile acid homeostasis [28,254]. In the liver, hFXR regulates bile acid metabolism through a feedback and feedforward mechanism. Once activated by bile acids, hFXR mediates a negative feedback loop through inhibition of the bile acid synthesis genes CYP7A1, CYP8B1, CYP27A1, and the bile acid uptake transporter NTCP [224,255] (Table 1). Additionally, bile acid-activated hFXR regulates bile acid homeostasis through a feedforward mechanism by stimulating the expression of the bile acid efflux transporter [256]. In the intestine, eFXR inhibits ASBT and induces OST α and OST β to reduce bile acid accumulation in the enterocytes. Bile acid activation of eFXR also induces the endocrine hormone fibroblast growth factor 15 (FGF15, FGF19 in humans) (Table 1). FGF15 can bind to its cognate receptor FGFR4 on the surface of hepatocytes and inhibits CYP7A1 and bile acid synthesis through various mechanisms activated by FGFR4, such as the MAPK-ERK pathway.

Recent studies have shown that this bile acid activated gut-to-liver signaling axis plays an important part in the liver regeneration process [22,257] (Figure 5). In response to bile acid overload, PXR and CAR play important roles in activating numerous bile acid detoxification mechanisms. More recently, these two nuclear receptors have also been implicated in the regulation of liver regeneration.




Figure 5. Chronological flowchart of mitogenic signaling by bile acids.

Table 1. Transcription factors and nuclear receptors involved in liver regeneration triggered by bile acids.

Legend: - = downregulation, + = upregulation

Transcription factor	Regulator	Target	Function
Liver receptor homologue 1 (LRH-1) <i>fetoprotein AFP transcription factor (FTF), CYP7A promotor-binding factor (CPF)</i>	- CDCA [258], SHP [259,260] + TNF- α [261]	- <i>Osta-Ostβ</i> [262] - <i>CYP7A1/Cyp7a1</i> [260,263-266] - <i>CYP8B1/Cyp8b1</i> [266-268] + <i>ABCG5/Abcg5</i> and <i>ABCG8/Abcg8</i> [269] + <i>Abcc3</i> (MRP3)[258] + <i>ABCB11</i> (BSEP)[269]	Bile acid homeostasis [262,269]
Enteral Farnesoid X receptor (eFXR)	+ bile acids [270-272]	+ <i>OSTα-OSTβ/Osta-Ostβ</i> [273-275] + <i>Fgf15</i> [276] + <i>FGF19</i> [277]	Regulation of bile acid pool size, governing the production of mitogens and regulation of lipid and glucose metabolism [17,22,23,26]
Hepatic farnesoid X receptor (hFXR)	+ bile acids [270-272]	+ <i>Osta-Ostβ / OSTα-OSTβ</i> [273,278] + <i>ABCB11</i> (BSEP), as FXR/RXR heterodimer [256] + <i>ABCC2/Abcc2</i> (MRP2), as FXR/RXR heterodimer [279] + <i>UGT2B4</i> [280]	Regulation of bile acid pool size, governing the production of mitogens and regulation of lipid and glucose metabolism [21-23,26,27]

		- <i>UGT2B7</i> [281]	
Forkhead box M1B (FOXM1B)	+ hFXR [254,282-288] + STAT3 [289]	+ <i>Cdk1</i> and <i>Cdk2</i> [288] + <i>Cdc25b</i> [22] + <i>Ccnd1</i> (cyclin D1) [22] + <i>Pcna</i> [22]	Regulation of DNA replication and mitosis [285,288]
Retinoid X receptor (RXR)	+ 9-cis retinoic acid	+ <i>Cdk1</i> , <i>Cdk2</i> , <i>Cdk 6</i> , and cyclin D genes [290] + CYP3A4, as PXR/RXR heterodimer [291] + <i>ABCB11</i> (BSEP), as FXR/RXR heterodimer [256] + <i>ABCC2/Abcc2</i> (MRP2), as FXR/RXR, PXR/RXR, or CAR/RXR heterodimer [292]	Activation of mitotic and proliferative activity [290,293]
Pregnane X receptor (PXR) <i>steroid and xenobiotic sensing nuclear receptor</i>	+ bile acids [294,295] + pregnenolone 16 α -carbonitrile [296] - IL-6 [297]	+ CYP3A4, as PXR/RXR heterodimer [291] - Cyp7A1 [298] + <i>ABCC2/Abcc2</i> (MRP2), as PXR/RXR heterodimer [279] + <i>Abcc3</i> (MRP3) and <i>Abcc3</i> (MRP4) [299] + <i>Pparγ</i> and <i>Cd36</i> [300,301]	Identification of toxic substances and upregulation of expression of proteins involved in their detoxification and clearance [302]
Constitutively active/androstane receptor (CAR)	+ LCA [303] + TCPOBOP (selective) (phenobarbital) [304]	+ <i>Cyp2b</i> , <i>Cyp2c</i> , <i>Cyp3a</i> sulfotransferases, glutathione transferases gene [299,305-311] + <i>ABCC2/Abcc2</i> (MRP2), as CAR/RXR heterodimer [279] + <i>Abcc4</i> (MRP4) [312] - <i>UGT2B7</i> [313]	Identification of toxic substances and upregulation of expression of proteins involved in their detoxification and clearance [314]
Growth arrest and DNA-damaga-inducible beta (GADD45β)		+ <i>RXR</i> , <i>CAR</i> , <i>PPARs</i> [315,316]	Cell proliferation [317], anti-inflammatory signaling [318], and positive transcriptional regulation of nuclear receptors (RXR, CAR, PPARs) [315,316]
Liver X receptor (LXR)	the sterols 24(S),25-epoxycholesterol, 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol,	+ <i>Abcg5</i> , <i>Abcg8</i> [321]	Proliferation-repressive effects [293]

	several metabolized bile acid species, including hyodeoxycholic acid, taurohyodeoxycholic acid, and cholestenoic acid [319,320], GW3965 (selective) [293]		
Hepatocyte nuclear factor (HNF)-4 α	- CAR [322]	+ <i>CYP7A1</i> / <i>Cyp7a1</i> [323,324] + <i>CYP8B1</i> / <i>Cyp8b1</i> and <i>CYP27A1</i> / <i>Cyp27a1</i> [325-327] + <i>UGT2B7</i> [313]	Lipid and glucose metabolism [328,329]
Nuclear factor erythroid 2-related factor 2 (NRF2)		+ <i>Bsep</i> [330,331] + <i>Abcc3</i> (MRP3) and <i>Abcc4</i> (MRP4) [331] + <i>Osta</i> [331] - <i>Cyp7a1</i> and <i>Cyp8b1</i> [331]	Regulation of bile acid pool size [331]
Peroxisome proliferator-activated receptor (PPAR) α		+ <i>UGT2B4</i> [332]	Metabolic sensor [319]
Signal transducer and activator of transcription 3 (STAT3)		+ <i>Foxm1b</i> [289]	Activation of mitogenic pathways [23]
Vitamin D receptor (VDR)	+ LCA [333]	?	?

3.2. Impact of bile acid pool alteration on liver regeneration

PHx causes acute but temporary bile acid overload in the liver [22,24-26] and the systemic circulation [21]. The bile acid overload in rat hepatocytes occurs within several hours after PHx [26] and peaks around 24 hours [22]. Bile acids are cytotoxic at high concentrations [334,335], and hepatic bile acid levels are quite quickly restored to pre-PHx status, namely within 24-48 hours after resection [22,24,26]. Initial evidence suggesting that bile acid signaling was involved in liver regeneration came from studies showing that experimentally altering the bile acid pool size could significantly modulate the liver regeneration rate in mice after PHx [28]. Rats that lack intestinal bile acid reabsorption due to external bile drainage showed lower proliferative activity in the liver and slower liver regrowth after PHx compared to rats that underwent bile drainage into the duodenum before PHx [21,221]. Huang, et al. [28] further showed that mice that had been supplemented with

0.2% CA for 5 days exhibited more rapid liver regeneration, while mice fed 2% cholestyramine for 5 days showed delayed liver regeneration after PH [28]. In rats that had undergone PHx, dietary supplementation with the bile acids UDCA and tauroursodeoxycholate induced hepatocyte proliferation [220]. A more recent clinical study showed that patients who underwent hemihepatectomy without external bile drainage had about ~3-fold more liver regrowth volume on day 7 than patients who underwent hemihepatectomy with external bile drainage [222,336].

The importance of bile acids in liver regeneration is also manifested in more circumstantial evidence. For example, liver regrowth elicited by CA feeding was reduced in mice lacking the basolateral bile acid exporter multidrug resistance-associated protein 3 (MRP3, *Abcc3*, Figure 6) [337,338], and this was associated with decreased portal bile acid concentration and FXR activation [339]. Similarly, delayed regeneration was also reported in mice lacking CYP27A1 [340] and in mice lacking ASBT [21,339,341-343]. Moreover, transcriptomic analysis revealed that activator protein 1 (AP-1), a heterodimeric early response transcription factor composed of c-Jun and c-Fos and in control of cell cycle activity and proliferation [344,345], is downregulated in the absence of bile acids in hepatectomized rats [21]. Finally, experiments with 'hypertransgenic' FRGN mice bearing humanized livers demonstrated a positive correlation between the size of the intrahepatic bile acid pool and the degree of liver growth [29]. These studies altogether support the prominent role of bile acids in post-PHx liver regeneration.

3.3. The role of nuclear receptors in post-hepatectomy liver regeneration and bile acid signaling

Nuclear receptors are transcription factors that serve as metabolic sensors in that they bind xenobiotics and metabolic intermediates (e.g., fatty acids, sterols, bile acids [319]) to regulate their levels and signaling effects as well as a plethora of metabolic pathways. A fraction of the mitogenic signals relayed by bile acids are moderated through nuclear receptors [19,20] - a process that is associated with translocation of specific bile acids from the cytoplasm to the nucleus [24]. The nuclear receptors involved in liver regeneration can exert bidirectional effects on hepatocellular proliferation, entailing both promotion and suppression of liver regeneration [19,20]. In terms of PHx, the promoters encompass FXR [28,254,346], retinoid X receptor (RXR) [347,348], pregnane X receptor (PXR) [349], and constitutively active/androstane receptor (CAR) [28,350] and their common heterodimer

partner, retinoid X receptor (RXR) [347,348]. Contrastingly, the suppressors encompass the peroxisome proliferator-activated receptors (PPARs) [351] PPAR- α [352] and PPAR- γ [353,354]. Genetic ablation of liver X receptor (LXR) in mice has no notable effect of post-PHx liver regeneration. However, the receptor is not necessarily mitogenically neutral since treatment with its agonist GW3965 in wild type mice hampers several effectors of proliferation and moderately retards liver regrowth [293]. LXR hence exhibits an inclination to repress liver regeneration. Liver receptor homologue 1 (LRH-1), alternatively referred to as fetoprotein AFP transcription factor (FTF) and CYP7A promoter-binding factor (CPF), is also a nuclear receptor in the liver [258]. The activities of LRH-1 revolve mainly around bile acid homeostasis [262,269] rather than induction of proliferation during post-PHx liver regeneration [355]. LRH-1 therefore fulfills a detoxification function during bile acid overload. A similar role is currently ascribed to the vitamin D receptor (VDR). This nuclear receptor is also expressed in hepatocytes [356] and regulates bile acid metabolism through CYP-based [333,357] and sulfotransferase-based bile acid detoxification [358-360] and bile acid transporter control [361].

FXR, LXR, PXR, PPARs, and LRH-1 are metabolic sensors in that they can be bound and activated by bile acids [319], and consequently regulate the levels and signaling intensity of the end-products through downstream effectors. Although CAR and VDR do not bind bile acids with the exception of LCA (in vivo) [303,333], the receptors are amenable to bile acid signaling, since they are activated by ancillary bile acid-induced processes to mediate biological effects that are, or could be, pertinent in liver regeneration [319,333,357-363].




Figure 6. Hepatocyte-enterocyte interplay after PHx. Bile acids are taken up in the intestine by the enteral importer ASBT and exported into the portal circulation by the OST α and OST β heterodimer and MRP3. In the enterocyte, bile acids activate eFXR that activates the OST α and OST β heterodimer and induces the transcription of FGF15/19. FGF15/19 binds to the FGFR4/ β -klotho receptor complex that in turn stimulates mitosis through pathways involving hFXR/FOXM1b, JAK/STAT3/FOXM1B, MAPK, and NF- κ B. In the hepatocyte, bile acids can bind PXR and hFXR that stimulate mitosis through STAT3 and FOXM1B, respectively. Bile acids bound to RXR complexed with PPAR- α can also induce hepatocyte proliferation. Abbreviations: BA = bile acid; ASBT = apical sodium dependent bile acid transporter; FGF15/19 = fibroblast growth factor 15/19; eFXR = enteral farnesoid X receptor; LRH-1 = liver receptor homolog 1; OST α / β = organic solute transporter; MRP3 = multidrug resistance protein 3; FGFR4 = fibroblast growth factor receptor 4; JAK = Janus kinase; ERK = extracellular signal-regulated kinase; MAPK = mitogen-activated protein kinase; STAT3 = signal transducer and activator of transcription; NF- κ B = nuclear factor kappa-light-chain-enhancer of activated B-cells; FOXM1B = forkhead box M1B; hFXR = hepatic farnesoid X receptor; PXR = pregnane X receptor; RXR = retinoid X receptor; PPAR- α = peroxisome proliferator-activated receptor.

3.3.1. Farnesoid X receptor signaling

Of all nuclear receptors, FXR is the best studied in the context of post-PHx liver regeneration. The bile acids CDCA, DCA, and LCA are physiological ligands of FXR [270-272], with a relative FXR potency of CDCA > DCA = LCA > CA [271]. The prime function of FXR is to regulate bile acid metabolism and homeostasis [319,364-366]. On top of that, FXR governs lipid and glucose metabolism [319,364-366] that are essential in liver regeneration [367,368]. With respect to bile acid homeostasis, the receptor regulates genes the control bile acid synthesis, secretion, uptake, transport, and endobiotic metabolism [369-372]. FXR is expressed at high levels in the liver [252] and intestines [253] and as such constitutes an integral part of enterohepatic communication, especially in case of liver regeneration. The individual effects of liver hFXR and intestinal eFXR will be described in detail in the following sections.

3.3.1.1. Mitogenic and metabolic signaling triggered by bile acids in the liver through hepatocellular farnesoid X receptor

Liver-specific FXR-null mice exhibit stalled liver regeneration compared to animals with functional hepatic FXR [28,254]. Similarly, FXR activity is significantly impaired and its downstream target genes *Shp*, *Cyp7a1* (section 4.2), and *Abcb11* (BSEP) (section 4.3.3) are afflicted in transgenic mice that overexpress the endogenous FXR inhibitor sirtuin 1 (SIRT1) [373]. PHx in these mice resulted in a debilitated regenerative response and bile acid-induced toxicity [373].

Mechanistically, activated hFXR signals proliferation through FOXM1B [254,282-288] (Table 1), a transcription factor that regulates DNA replication and mitosis by stimulating the expression of proteins that are responsible for cyclin-dependent kinase 2 (CDK2) and CDK1 cell cycle activity [285,288]. CDK2 is crucial for the G1/S transition [374], whereas CDK1 enables cell cycle progression from the S-phase to mitosis (M-phase) [375]. CDK2 complexes with cyclins and other CDKs to activate RB [376,377] (section 2.1) and is under positive control of CDC25a [376], which in turn is antagonized by the cyclin-dependent kinase inhibitor p21 [378]. Hepatectomized *Foxm1b*^{-/-} mice showed increased hepatocellular nuclear p21 levels, reduced Cdc25a expression, and consequently decreased

activation of CDK2 and RB [285]. Moreover, *Foxm1b*^{-/-} mice exhibited increased levels of phosphorylated CDK1 [285], which is normally dephosphorylated by CDC5B to promote M-phase progression [379-381], as well as no expression of nuclear CDC25B protein [285]. These findings demonstrate that hepatocyte proliferation is controlled at the level of the cell cycle by hepatocellular FOXM1B, which is induced by hFXR that in turn is activated by bile acids (Table 1).

In addition to mitogenic signaling, hFXR-steered liver regeneration after PHx may be metabolically supported as a result of hFXR activation of the pyruvate dehydrogenase lipoamide kinase isozyme 4 (PDK4) [27,382] that resides in mitochondria and regulates pyruvate metabolism as part of gluconeogenesis [383]. PDK4 is induced by hyponutrition and facilitates the utilization of alternative carbon sources for gluconeogenesis [384]. PDK4 was upregulated following FXR activation and downregulated after FXR knockdown in HepG2 cells [27]. Induction of such a switch is analogous to the Warburg effect in highly proliferative cancer cells, typified by a metabolic shift towards converting glucose and certain amino acids into biomass [385,386]. Activation of FXR in human hepatocellular carcinoma (HepG2) cells by the agonists GW4064 and CDCA resulted in increased PDK4 accumulation of lactic acid, pyruvic acid, and glucose-6-phosphate (i.e., citric acid cycle metabolites), increased glucose uptake and glycolysis, and augmented production of glycine and serine [27], which are important in cell proliferation [387,388]. Conversely, siRNA knock-down of FXR abrogated or inverted these processes [27]. Cells in which FXR was knocked down proliferated poorly and did not exhibit the PDK4-mediated metabolic reprogramming [27]. It should be noted that although FXR-induction of PDK4 is in line with anabolic demand during the liver regrowth phase, hitherto no study has shown that PDK4 enzyme activity is increased after PHx in wild type and FXR null mice [27]. These studies are still needed to establish a role of the FXR-PDK4 axis in liver regeneration, especially given that PDK4 is transcriptionally regulated by complex signaling mechanisms, and that PDK4 enzyme activity is positively regulated by cellular ATP and NADH levels, which may be increased after PHx.

3.3.1.2. Mitogenic signaling triggered by bile acids in the intestines through enterocytic farnesoid X receptor

Hepatectomized mice in which *eFxr* was genetically deleted exhibit a considerable reduction in ileal *Fgf15* transcript levels and increased hepatic transcript of downstream target *Cyp7a1* [254] (*Cyp7a1* is negatively regulated by hepatic FXR, sections 4.1 and 4.2 and

Table 1). These effects coincided with elevated plasma bile acid concentrations and stalled hepatocyte proliferation [254], the latter as a result of impaired cell cycle progression [257]. The deficiency in hepatocyte proliferation could be restored in *Fgf15*^{-/-} mice by adenoviral transduction of FGF15 [254], underpinning the involvement of intestinal FGF15 in liver regeneration. The results were reproduced in subsequent mouse PHx studies regarding ileal FGF15-mediated hepatocyte and cholangiocyte proliferation [22,257].

As mentioned earlier, activation of eFXR transcriptionally induced FGF15. Using primary hepatocytes, Holt et al. [277] showed that the promoter region of human *FGF19* contains an FXR-responsive element in isolated primary hepatocytes. Inagaki et al. [276] followed up with an investigation in mice, demonstrating that, in conjunction with RXR, murine FXR binds to the *Fgf15* IR1 motif, a conserved FXR binding site. FXR directly regulates *Fgf15* transcription, leading to FGF15 upregulation in intestinal epithelium following oral administration of the FXR agonists GW4064 and CA. Upon production of the functional protein, FGF15 is secreted basolaterally into the portal circulation [276,389] and subsequently binds to fibroblast growth factor receptor 4 (FGFR4)/ β -klotho receptor complex on the outer hepatocyte membrane [390-393] (Figure 6).

Mechanistically, FGFR4-induced mitogenic pathways have been investigated in only a few studies in the context of post-PHx liver regeneration, although proliferative signaling by FGFR4 has been established outside of this context (e.g., [394]). Uriarte et al. [22] observed impaired hepatocyte proliferation in *Fgf15*^{-/-} mice compared to wild type mice, which was associated with reduced *hFxr* (6-36 hours post-PHx) and *Foxm1b* transcript levels (44-48 hours post-PHx) as well as decreased levels of FOXM1B downstream gene targets, including *Cdc25b* (36-44 hours post-PHx), *Ccnd1* (codes for cyclin D1, 24 hours post-PHx), and *Pcna* (proliferating cell nuclear antigen, involved in DNA replication and repair and chromatin remodeling [395], 36-44 hours post-PHx) compared to wild type mice (Table 1). Interestingly, transcript levels of the complete hepatic mitogens *Hgf* (44 and 72 hours post-PHx), *Hbegf* (6-44 hours post-PHx), and *Areg* (gene that encodes amphiregulin, 24-36 hours post-PHx) (section 2.3) were upregulated in *Fgf15*^{-/-} mice [22]. The authors attributed this counter-regulation to the concomitant induction of alternative pro-proliferation pathways (e.g., EGFR signaling) as a reason for the observed, although latent, liver regeneration in *Fgf15*^{-/-} mice.

Kong et al. [257] observed similar effects in *Fgf15*^{-/-} mice and identified additional pathways. *Fgf15*^{-/-} mice exhibited reduced protein expression of the MAPKs JNK and p38 and c-Myc (although p-ERK protein levels were elevated compared to wild type controls), confirming earlier reports on FGF15-induced MAPK signaling [396]. The knock-out mice

also had decreased protein levels of Janus kinase (JAK)1, JAK2, and STAT3, indicating that FGF15 modulates proliferation through the JAK/STAT3 pathway [397,398]. As FXR, STAT3 is a positive regulator of *Foxm1b* [289] (Table 1), and is apparently activated by FGFR4 to induce cell cycle activity through FOXM1B in an IL-6- and TNF- α -independent manner [23]. Interestingly, STAT3 downregulation in *Fgf15*^{-/-} mice occurred at augmented plasma IL-6 levels (a STAT3 inducer [84,95,96]) as well as increased hepatocellular SOCS3 levels (a STAT3 inhibitor [399]). Lastly, nuclear p65 protein (RELA, a functional unit of NF- κ B [400]) was elevated in wild type animals but absent in *Fgf15*^{-/-} mice, demonstrating that FGF15 promotes hepatocyte proliferation through NF- κ B signaling [87,88] following PHx.

Tissue-specific knock-down and knock-out studies have also been performed for the FGF15 receptor FGFR4 to examine the underlying signaling pathways. Padrissa-Altés et al. [23] employed liposome-delivered siRNA to knock down hepatic FGFR4 in mice and observed comparable gross effects as in the *Fgf15*^{-/-} mice [22,257] after PHx. Hepatocytes in the FGFR4 knock-down group exhibited reduced and latent proliferation, and, besides decreased expression of *Foxm1b* (48 hours post-PHx) and *Stat3* (24 hours post-PHx), decreased levels of *Ccnal* and *Ccnb1* (codes for cyclins A2 and B1, respectively, 48 hours post-PHx) were also reported. It should be noted that Padrissa-Altés et al. used liver-specific FGFR4 knock-down mice and that these results were not reproducible in *Fgfr4*^{-/-} mice (which had genetically deleted FGFR4), which did not exhibit aberrant liver morphology or regeneration pattern [401].

Taken together, the studies suggest that at least 4 proliferative pathways are activated by eFXR-induced FGF15 in post-PHx liver regeneration (Figure 6 and Table 1)

1. FGF15/hFXR/FOXM1B → mitosis
2. FGF15/FGFR4/JAK/STAT3/FOXM1B → mitosis
3. FGF15/MAPK (JNK/p38/ERK?) → mitosis
4. FGF15/NF- κ B → mitosis.

How FGFR4 is linked to FGF15 and STAT3-, MAPK-, and NF- κ B signal transduction, and how FGF15 feeds (direct) signals into these pathways remains to be determined. Moreover, it is important to understand the influence of cytokines and growth factors on these pathways, as these play prominent roles in liver regeneration (sections 2.2 and 2.3).

Several pertinent inflammatory stimuli such as LPS and IL-1 β have been reported to inhibit hepatic β -klotho and FGFR4 expression in mice. In human cell lines (Huh-7 and

HepG2), IL-1 β suppressed β -klotho transcription in a JNK- and NF- κ B-dependent manner and blocked FGF19-induced ERK1/2 activation and cell proliferation [151]. Finally, a very recent study [402] using human liver tissue slices demonstrated a 20-fold transcriptional upregulation of FGF19 following incubation with obeticholic acid, a potent FXR agonist [403]. To date, FGF19 expression in hepatocytes following FXR stimulation has been quite elusive. These new data, however, suggest that hepatocellular FGF19 may also facilitate autocrine proliferative signaling in the early phase of liver regeneration after PHx.

As a side note, FXR-activated downstream cascades may also amplify liver regeneration by peripheral mechanisms. For example, the human complement C3 gene contains FXR response elements in the proximal promoter region [404]. Complement C3a is elevated after PHx in mice and humans [8-10], possibly in part by the perturbed bile acid homeostasis that ensues after liver surgery [24-26]. C3a activates innate immune cells such as Kupffer cells and neutrophils to stimulate the sterile immune response [8-10] that triggers liver regeneration via IL-6 and TNF- α [36,84,85]. Complement proteins are therefore auxiliary hepatomitogens [9] (section 2.4) induced in part by bile acid-FXR signaling after PHx.

3.3.1.3. Mitogenic and metabolic signaling through hepatic farnesoid X receptor in humans

The promoter of the human *FGF19* gene contains an FXR response element [277]. Accordingly, upon FXR stimulation by obeticholic acid, transcriptional upregulation of FGF19 was seen in human enterocytes [402]. Therefore, it is likely that, activated human eFXR induces *FGF19* expression in enterocytes. It should be noted that, under cholestatic conditions, FGF19 expression in human hepatocytes has been reported [405]. FGF19 activates ERK1/2 through the FGFR4/ β -klotho receptor complex and subsequently induces hepatocyte proliferation, similar to FGF15 induced cell proliferation in rodents. Whereas β -klotho expression in mice is inhibited by LPS and IL-1 β , human β -klotho expression is only affected by IL-1 β but not by LPS [151].

Besides regulation of cell cycle progression, human hFXR has additional effects. Due to FXR response elements in the human complement C3 gene [404], complement C3a expression increases after PHx in hepatocytes, enhancing the effect of earlier induced cytokines. Also, FXR is essential for metabolic support of the liver after PHx. PDK4, an FXR target gene, regulates pyruvate metabolism and thus gluconeogenesis. Xie, et al. [27] showed that FXR stimulation by both CDCA as well as GW4064 resulted in production of lactic acid,

pyruvic acid, and glucose-6-phosphatase in human HepG2 cells. SiRNA knock-down inverted these processes. These results suggest that FXR is important for generation of glucose and amino acids is essential for biomass generation

3.3.2. Retinoid X receptor signaling in liver regeneration

RXR is a nuclear receptor comprising α , β , and γ isoforms, is activated by mainly 9-cis retinoic acid. Given that RXR is often an obligated heterodimer partner for other nuclear receptors, loss of RXR is expected to affect various nuclear receptor signals in the liver [406]. The proliferative and cell cycle regulatory properties of RXR have been corroborated in vitro [407], in rodents treated with RXR agonists [408,409], and in rodents with genetically deleted *Rxr* [348]. Principally, pharmacological induction of RXR leads to hepatomegaly, whereas genetic ablation of *Rxr* leads to hepatocyte hypoproliferation.

In terms of post-PHx liver regeneration in mice, genetic deletion of *Rxra* (codes for RXR- α) translated to a 20-hour delay in hepatocyte proliferation that coincided with reduced transcript and protein levels of hepatomitogens (HGF, FGF2 [410], and PDGF) and latent onset of pro-proliferative signaling [347]. Similar results were obtained in lecithin:retinol acyltransferase-deficient (*Lrat*^{-/-}) mice [411], which lack hepatic retinoid stores and hence possess minimal RXR activation potential. In contrast to the *Rxr*^{-/-} genotype [347], *Lrat*^{-/-} mice had decreased levels of *Tgfa* (codes for TGF- α , a regeneration-promoting growth factor, section 2.3) [411]. Also, the replication forks were stalled in the G1 phase in *Rxra*^{-/-} mice as a result of compromised PPAR- α /BMAL1/REV-ERB/p21 cell cycle regulation. This stalled cell cycle was characterized by decreased levels of cyclins A2, -B1, -D1, and -E1 as well as CDK1, -2, and -4 at 48 hours after PHx compared to wild type animals [347]. In mice, PPAR- α is an obligate binding partner of RXR during hepatocyte proliferation [412], so the effects of RXR deletion on PPAR- α signaling and associated cell cycle regulators are warranted. Although supplementation with the endogenous ligand retinoic acid only increased cyclin E1 levels in *Rxra*^{-/-} mice, wild type mice fed retinoic acid showed RXR- α /RXR- β binding to *Cdk1*, *Cdk2*, *Cdk6*, and cyclin D genes [290], suggesting genetic and epigenetic control of liver regeneration by RXR when all results are considered. Moreover, PHx-induced liver regeneration in wild type mice was associated with RXR- β activation [290] and increased mitotic and proliferative activity via upregulation of cyclins D and E, *Cdc25b*, *c-Myc/c-Myc*, and *Foxm1b* [290,293] (Table 1), despite the fact that retinoic acid levels in the liver drop

somewhat after PHx [411]. At this point, no data are available on the role of bile acids in RXR-induced liver regeneration after PHx.

3.3.3. Pro-regenerative signaling by pregnane X receptor

PXR, also referred to as steroid and xenobiotic sensing nuclear receptor, has a plethora of endogenous and exogenous ligands, including bile acids [413]. As the name implies, the chief function of this receptor is to identify toxic substances and consequently upregulate the expression of proteins involved in their detoxification and clearance [302]. The detoxification machinery predominantly entails CYP3A4, which is upregulated by PXR in conjunction with RXR [291]. The potency with which bile acids activate PXR is DCA > LCA > CDCA [414] (Table 1). PXR activation leads to hepatocyte proliferation [295,298].

Dai et al. [349] reported a temporary delay of liver growth in hepatectomized *Pxr*^{-/-} mice at 36 hours post-PHx and persistently slows liver growth from post-PHx day 5 onward, culminating in a 17% reduction in liver mass on post-PHx day 10, which was associated with significantly reduced hepatocyte proliferation and decreased STAT3 protein levels. Wild type livers exhibited transient steatosis post-PHx, which was absent in *Pxr*^{-/-} mice. PXR is known to positively regulate hepatic lipogenesis via transcriptional induction of PPAR γ and CD36 [300,301] (Table 1). Expression of genes that mediate lipid metabolism (*Ppar- α* , *Ppar- γ* , fatty acid translocase, acetyl-CoA-carboxylase 1, and long-chain free fatty acid elongase) was lower in *Pxr*^{-/-} mice after PHx, indicating that impaired fatty acid uptake and lipogenesis may account for delayed liver regeneration in PXR-null mice. Furthermore, a recent liver regeneration study in mice suggested that PXR activation by pregnenolone 16 α -carbonitrile accelerated cell cycle activity via inhibition of forkhead box O3 (FOXO3) [296], a transcription factor that negatively regulates cell growth, proliferation, and differentiation in the phosphoinositide 3-kinase (PI3K) pathway [415]. Presently, no data are available on the role of bile acids in PXR-induced liver regeneration after PHx, but taken that PHx is followed by a transient bile acid-overload [22,24-26] and PXR is activated by bile acids [414], enhanced PXR activity after PHx is not unlikely. However, PXR is under negative control of IL-6 [297] (Table 1), so the proliferative effects of activated PXR may be tuned down by certain cytokines. IL-6 itself is also a mitogen after PHx (section 2.4), and therefore the exact interplay remains to be investigated.

3.3.4. Pro-regenerative signaling by constitutively active/androstane receptor

CAR is a xenobiotic and endobiotic sensor and therefore transcriptionally regulates genes including CYP2B, CYP2C, CYP3A, sulfotransferases, and glutathione-S-transferases, amongst others involved in detoxification and elimination of such compounds [305-308,314] (Table 1). A unique feature of CAR, as opposed to other nuclear receptors, is that the receptor shows basal activity in absence of ligands in human hepatocytes, which can be enhanced by binding of agonists, such as LCA. Following ligand binding, CAR migrates to the nucleus and binds to DNA as a monodimer or CAR/RXR heterodimer to activate transcription of target genes [416]. Mice treated with CAR agonists develop hepatomegaly [417,418], but *Car*^{-/-} mice paradoxically exhibit only modestly impaired liver regeneration after PHx [28]. CAR also regulates the biogenesis of critical cell components in mice after PHx [419].

Several pathways lie at the basis of CAR-mediated proliferative signaling. One of the better studied pathways entails growth arrest and DNA-damage-inducible, beta (GADD45β), which is a transcription factor with pleiotropic functions that encompass cell proliferation [317], pro-inflammatory signaling [318], and positive transcriptional regulation of nuclear receptors (RXR, CAR, PPARs) [315,316] (Table 1), albeit strongly dependent on the cell type. In the murine liver, GADD45β is profoundly expressed during early compensatory regeneration [419]. Studies in wild type and *Tnfr*^{-/-} mice demonstrated that CAR activation with the selective CAR agonist TCPOBOP induced GADD45β and cyclin D1 in a TNF(R)-independent manner, which was abolished in *Car*^{-/-} mice [304]. Furthermore, TCPOBOP-primed mice with deleted *Gadd45b* (rodent gene for GADD45β) exhibited stalled liver regeneration and transcriptional repression of downstream CAR target genes after PHx, despite intact proliferative signaling [420]. This study further unveiled that both CAR and GADD45β bind the CAR regulatory element of the *Cyp2b10* gene, underpinning the signal amplifying role of GADD45β in terms of CAR signaling [420] (Table 1).

Another CAR signal amplifier is steroid receptor coactivator-3 (SRC-3) [421], a transcriptional co-activator that assists nuclear receptors in the upregulation of gene expression [422]. *Src*^{-/-} mice present with reduced liver hyperplasia and decreased c-Myc (section 2.2) and FOXM1B (section 3.1.1) expression upon CAR activation with TCPOBOP [421] (Table 1). The same applies to β-catenin that, when co-activated with CAR, induces hepatocyte proliferation and hepatomegaly in mice [423]. An additional proliferative trigger for CAR-controlled mitogenesis may be oxidative stress [424], which is induced in the early regeneration phase (section 2.1). Finally, the inhibition of the nuclear receptor hepatocyte nuclear factor 4 (HNF-4)α by TCPOBOP-activated CAR was shown to downregulate miR-

122 and upregulate corresponding promitogenic target genes (the transcription factor E2f1 and its downstream target *c-Myc*) in the murine liver [322]. This is in agreement with the data presented in section 2.4, where miR-122 downregulation was associated with a post-PHx pro-regenerative response [200,201]. It should be noted, however, that HNF-4 α levels remain relatively stable during the early phase of post-PHx regeneration, measured in rats [180].

Unfortunately, all abovementioned studies were conducted in the absence of PHx and relied solely on CAR activation, usually by TCPOBOP, as a result of which no definitive conclusions can be drawn on the role of CAR in post-PHx liver regeneration. The only study that used PHx in combination with *Car*^{-/-} mice, aside from Huang et al. [28], examined the role of type 1 deiodinase and thyroid hormone activity in liver regeneration [350]. This investigation demonstrated that reverse tri-iodothyronine (rT3) levels rise after PHx in wild type and *Car*^{-/-} mice, which could be reversed in wild type animals but not *Car*^{-/-} mice with phenobarbital, an indirect CAR agonist. Levels of T3, a thyroid hormone that acts as a hepatic (auxiliary) mitogen in the post-PHx liver regeneration setting [425,426], remained unaltered, independently of CAR. The activity and expression of type 1 deiodinase, the enzyme that catalyzes the production of the endocrinologically potent T3 as well as the endocrinologically less potent rT3 from thyroxine (T4), was reduced by PH and increased by phenobarbital in a CAR-dependent manner. The same applied to promitogenic T3 target genes, which were repressed after PHx as well as rT3 infusion but reactivated by phenobarbital, altogether implicating CAR in hormonal regulation of liver regeneration in mice. To add to the regulatory complexity, the proliferative activity of T3 is enabled by β -catenin [427], which in turn potentiates the mitogenic signaling of CAR in mice [423] as described in the previous paragraph. Evidently, the thyroid hormone/hepatic nuclear receptor signaling axes are still to be fully unraveled. How bile acids fit into these signaling networks is most elusive in terms of post-PHx liver regeneration.

3.3.5. Pro-regenerative signaling by suppression of liver X receptor

LXR exists as an α and β isoform [428] that forms obligate heterodimers with RXR upon ligand activation to regulate gene expression [429]. The cognate LXR ligands are the sterols 24(*S*),25-epoxycholesterol, 22(*R*)-hydroxycholesterol, 24(*S*)-hydroxycholesterol, but the receptor also binds several metabolized bile acid species, including hyodeoxycholic acid, taurohyodeoxycholic acid, and cholestenoic acid [319,320] (Table 1).

Although hepatectomized *Lxr*^{-/-} mice do not exhibit impaired hepatocyte proliferation and liver regeneration compared to wild type controls, LXR activation in wild type mice with the selective LXR agonist GW3965 (Table 1) reduced hepatic levels of pro-proliferative STAT3, the cell cycle regulators FOXM1B and CDC25B (section 3.3.1.1), and the tissue remodelling protein matrix metalloproteinase 9 (MMP-9) [293], indicating that LXR exerts proliferation-repressive effects. The cause for LXR inactivation after PHx is rooted in the considerable decrease in sterol-based LXR ligands, namely 24(*S*),25-epoxycholesterol, 24(*S*)-hydroxycholesterol, and 27-hydroxycholesterol (Table 1), which occurs in the early phase of post-PHx liver regeneration in mice [293].

How bile acids mediate post-PHx liver regeneration in terms of LXR signaling is unclear, although one study suggests that LXR downregulation in mice may be mediated by bile acid overload-induced overexpression of nuclear receptor-interacting protein 1 (NRIP1) [401]. NRIP1 is a nuclear receptor that represses the activation of transcription by LXR α /RXR α as well as PPAR α /RXR α heterodimers through its interaction with LXR α and PPAR α [430]. In a mouse model, NRIP1 is considerably induced by dietary CA [401], a bile acid that is substantially elevated after PHx during the early phase of liver regeneration [24]. Consequently, bile acid-induced overexpression of NRIP1 after PHx may contribute to suppression of LXR-mediated gene transcription and consequent promotion of hepatocyte proliferation and liver regeneration.

3.3.6. Pro-regenerative signaling by non-farnesoid X receptor nuclear receptors in humans

Pascussi, et al. [297] showed that IL-6 inhibits expression of *PXR* and *CAR* in primary human hepatocytes. However, in contrast to FXR signaling, there is hardly any information on the links between non-FXR nuclear receptors in humans and PHx. In few studies, human cell lines were used to investigate nuclear receptor activity. For example, Frank, et al. [416] showed that, in contrast to other nuclear receptors, *CAR* is continuously expressed in the cytoplasm of human breast cancer cells. Upon ligand binding, *CAR* translocates to the nucleus and activates transcription of target genes. Osabe and Negishi [431] used hepatocellular carcinoma cells to study ERK1/2-CAR interaction. Their results show that the ERK1/2 protein prevents *CAR* phosphorylation and subsequently avoids nuclear translocation of *CAR*. Yamamoto and Negishi [316] also studied *CAR* in the context of cell cycle progression. When *CAR* is stimulated, *GADD45B* gene expression in human HepG2 cells is

decreased. As described in section 3.3.4, GADD45 β is a transcription factor involved in cell cycle progression [317] and expression of several nuclear receptors [315,316] (Table 1).

3.4. Role of bile acid-activated TGR5 in post-PHx liver regeneration

In addition to intracellular nuclear receptors, bile acids also activate a cell surface G protein coupled receptor TGR5 [432]. Activation of TGR5 in most target cells results in increased intracellular cAMP and activation of PKA. TGR5 is expressed in the brown adipose tissue, muscle and the intestine where activation of TGR5 by agonists promotes energy expenditure and glucose homeostasis [433,434]. TGR5 is highly expressed in macrophages and activation of TGR5 inhibits cytokine production and inflammation [435-437]. Pharmacological activation of TGR5 has been shown to decrease inflammation and prevent atherosclerosis in mice [435]. In the liver and biliary system, TGR5 is highly expressed in cholangiocytes, Kupffer cells and gallbladder epithelial cells, but not hepatocytes [437-440]. Activation of TGR5 is known to decrease cytokine production and Kupffer cell activation to decrease hepatic inflammation in mice [436]. Compared to adipocytes, myocytes and macrophages that are usually exposed to low levels of bile acids in the systemic circulation, cholangiocytes are routinely exposed to high levels of bile acids, and bile acid signaling through TGR5 in cholangiocytes may be more pathophysiologically relevant. So far, studies have shown that TGR5 mediates the proliferative and anti-apoptotic role of bile acids in cholestatic liver diseases [26,441], which may on one hand protect cholangiocytes against bile acid toxicity but on the other hand promote cholangiocarcinoma development and progression. After PHx, TGR5 KO mice showed significantly impaired regeneration, with increased liver injury and inflammation. Such detrimental effects of TGR5 knockout could be attributed to cholestatic liver injury upon bile acid overload after PHx, suggesting an important role of TGR5 in regulating bile flow and cholangiocyte cell death [26]. In addition, TGR5 KO mice have been shown to have a more hydrophobic bile acid pool, which may further predispose TGR5 KO mice to bile acid-induced toxicity after PHx. The mechanisms by alterations in bile acid composition in TGR5 KO mice are caused still have to be elucidated.

4. Containment of post-hepatectomy bile acid toxicity in hepatocytes

To protect the liver from bile acid-induced hepatotoxicity [223], bile acid-laden hepatocytes have several mechanisms in place to curtail prolonged exposure to supraphysiological intrahepatic levels of bile acids. These mechanisms, which are an integral part of hepatocyte function [1,442-444] in terms of phase I-III endobiotic metabolism, entail:

- chemically altering the composition of the bile acid pool towards less toxic (more hydrophilic) species (phases I and II, section 4.1)
- regulation of substrate (cholesterol) availability for *de novo* bile acid synthesis (section 4.2)
- hepatobiliary transport (phase III, section 4.3)

These processes work in concert to gradually remove excessive bile acids from hepatocytes after PHx once the mitogenic signals have been relayed.

4.1. Modulation of hepatocellular bile acid composition during liver regeneration

Due to the transient bile acid overload after PHx [25,26], several nuclear receptors are activated and engage phase I and II metabolic processes to detoxify bile acids by chemical modification. Phase I bile acid detoxification is mediated mainly by CYP3A4, which hydroxylates the bile acids to more hydrophilic entities that are subsequently readily eliminated by the liver [445-448]. CYP3A4 expression is regulated by FXR [449] (section 3.3.1), PXR [291,295,414,450] (section 3.3.3), CAR [299,309-311] (section 3.3.4), and VDR [333,451]. The nuclear receptors are activated after PHx as described in the referenced sections. CYP3A11 is also induced by bile acids such as LCA [295,414,452], while CYP3A4 is induced by CDCA [449] - effects that have been mirrored in obstructive cholestasis in mice and human livers [453,454] - as a feed-forward protective mechanism against bile acid-induced hepatotoxicity.

Phase II metabolic neutralization of bile acid toxicity occurs through primarily sulfation and glucuronidation at the sterol's hydroxyl groups [455-457]. Sulfation is catalyzed by sulfotransferase (SULT)2A1 [458,459] that is under positive transcriptional control of PXR and CAR[312,358,460-463], although negative regulation of SULT2A1 by FXR has been reported in mice [459] (Table 1). Glucuronidation is restricted to LCA- and CDCA-derived 6 α -hydroxylated bile acids [295,414] and is catalyzed by UDP-glucuronosyltransferase (UGT)2B4 and UGT2B7 [464,465]. Several UGT isoforms in the

human liver are under control of PXR and CAR [466], whereby *UGT2B4* is positively regulated by FXR [280] and PPAR α [332]. *UGT2B7* seems to be repressed by bile acid-activated FXR [281]. In transgenic mice, the human *UGT2B7* gene was suppressed by CAR, which was subsequently shown to proceed via CAR-mediated inhibition of HNF-4 α binding to the *UGT2B7* promoter in HepG2 cells [313] (Table 1). Accordingly, CYP3A4 and UGT2B4 seem to contribute to hepatoprotection during post-PHx bile acid overload.

Some of the nuclear receptors that govern the detoxification processes also regulate the excretion of the biotransformed bile acids (transporters are discussed in detail in section 4.3). For example, CAR activation leads to the overexpression of MRP4 (basolateral export of sulfated sterols) [312] and MRP2 (canalicular export of glucuronidated bile acids [467]) in mice [299], while activated PXR upregulates the murine basolateral exporters MRP3 and MRP4 [299], which transport sulfate- and/or glucuronite-conjugated bile acids out of hepatocytes [312,338,468]. The regulation of bile acid transporters by nuclear receptors is also illustrated in Figure 4 and Table 1.

Finally, bile acid composition in mice is regulated by LRH-1 [263,267], but this regulation is expected to offset the hepatoprotection conferred by the nuclear receptors and TGR5. LRH-1 is a nuclear receptor in the liver [258] and intestines [469] that regulates bile acid homeostasis [258,260,263-267,470,471] through CYP7A1 [260,263-266] and CYP8B1 [267] (Table 1). CYP7A1 is the rate-limiting enzyme that catalyzes hepatic bile acid synthesis using cholesterol as substrate [225,472-474]. CYP8B1, abundantly expressed in hepatocytes [475], is also responsible for bile acid synthesis [225,474]. Murine LRH-1 is repressed by CDCA [258] but upregulated by TNF- α under cholestatic conditions [261] (Table 1). Accordingly, LRH-1 is expected to affect bile acid composition after PHx. Mice in which *Lrh1* has been deleted exhibit increased relative amounts of hydrophobic bile acid species at the expense of reduced CA and taurocholic acid (TCA) in the bile acid pool [267]. In light of the transient bile acid overload after PHx, LRH-1 levels are expected to drop because of augmented FXR and small heterodimer partner (SHP) activation by bile acids (next section). The subsequent SHP-induced repression of LRH-1 [259,260] may therefore lead to a shift in bile acids to more hydrophobic species and skew the beneficial effects imparted by nuclear receptors and TGR5. However, numerous bile acid exporters are also hyperactivated during bile acid overload, as explained in section 4.3, so saturated hepatocytes may not necessarily have to be afflicted by the LRH-1 downregulation and the more toxic bile acid pool. At this point the exact function of LRH-1 during post-PHx liver regeneration warrants further investigation, particularly in the context of bile acid composition and hepatotoxicity.

4.2. Regulation of bile acid synthesis during liver regeneration

PHx results in transient bile acid overload in hepatocytes [25,26] as well as extensive hepatocellular cholesterol accumulation [293,476]. While bile acids are instrumental in proliferative signaling and liver regeneration (section 3), they are also toxic to hepatocytes. This biochemical ambiguity also applies to cholesterol, the metabolic substrate for bile acid production [477]. On the one hand, cholesterol is exacted by mitotic hepatocytes for biomass generation and sustenance of various metabolic functions [412,478]. That is why, for instance, mitotic hepatocytes increase their chromatin cholesterol levels in order to facilitate proliferation (8-16 hours after PHx) [479] and why cholesterol metabolic pathways are hyperactivated after PHx [209,293,476,480,481]. On the other hand, high cholesterol levels feed into the production of (potentially toxic) bile acids in hepatocytes, especially since CYP7A1; the protein product of the *CYP7A1/Cyp7a1* gene) is strongly upregulated 24 hours after PHx [482]. CYP7A1 is the rate-limiting enzyme in the bile acid synthesis pathway, using cholesterol as substrate [225]. Its upregulation in combination with the elevated cholesterol levels [293,476] may therefore account for the temporarily increased bile acid pool early after PHx.

4.2.1. Increased hepatocellular cholesterol levels after partial hepatectomy

Hepatocytes control intracellular levels of cholesterol via synthesis and non-synthesis routes. The non-synthesis routes pertain to cholesterol import into and export out of hepatocytes. A study in rats found that the binding and uptake of cholesterol-enriched lipoproteins by hepatocytes isolated from the remnant liver was decreased early (16 hours) after PHx and restored to baseline levels in later phases of regeneration [483], suggesting that cholesterol uptake from the systemic circulation does not lie at the basis of post-PHx cholesterol loading in the early stages. However, there are at least 3 metabolic switches manifested at the level of synthesis and export during post-PHx liver regeneration.

In terms of the first metabolic switch, the increase in hepatocellular cholesterol is mediated by suppression of LXR signaling after PHx in a mouse model [293]. As addressed in section 3.3.5, LXR is inactivated after PHx in mice, associated with the promotion of liver regeneration. One potentially contributing factor to the inactivation of LXR is upregulation of NR1H3 [401] (section 3.3.5), while another contributing factor is the substantial post-PHx

reduction in LXR-activating ligands in hepatocytes [293]. The inactivation of LXR leads to increased cholesterol levels because LXR is a master regulator of cholesterol catabolism [484] and an inhibitor of cholesterol synthesis [485].

Second, intracellular cholesterol levels are coordinated by LRH-1, which positively modulates sterols through ABCG5 and ABCG8 [269]. Importantly, LXR also positively regulates the expression of *Abcg5* and *Abcg8* in mice [321] (Table 1). These ATP binding cassette half-transporters are replete in the liver and small intestine [244,486,487] and jointly transport cholesterol across the hepatocellular cell membrane into the canalicular system [319,321,488,489]. Indeed, ABCG5/ABCG8 deficiency in mice leads to augmented plasma sitosterol (a plant-derived cholesterol analogue) concentration and decreased cholesterol levels in bile [490]. Analogously, ABCG5/ABCG8 overexpression increases biliary cholesterol secretion and decreases cholesterol absorption [491]. Given that LRH-1 is negatively regulated by bile acid-activated FXR/SHP signaling [260,266] (Table 1), bile acids (e.g., DCA) may downregulate *Abcg5* and *Abcg8* [269] through FXR/SHP/LRH-1 during bile acid overload, a process that is aided by the concomitant downregulation of LXR in mice [293]. Although no information is available on LHR-1 in connection with *ABCG5* and *ABCG8* during post-PHx liver regeneration, it is anticipated that *ABCG5* and *ABCG8* are downregulated via bile acid-mediated suppression of LRH-1 signaling in early phases. Accordingly, Lo Sasso et al. demonstrated that *Abcg5* and *Abcg8* levels were dramatically decreased in hepatectomized mice [293], although in that study the repression was ascribed to LXR.

The third, albeit converse metabolic switch, is that hepatocytes reduce their cholesterol synthesis rate in the early phase of post-PHx liver regeneration (first 24 hours) [481,492]. Evidently, the net effect of the rate reduction is in itself not sizeable enough to decrease the hepatocellular cholesterol concentration in the very short term inasmuch as cholesterol levels peak at 1-3 days after PHx (in mice) [293]. However, in the longer term (72 hours after PHx and beyond) the cholesterol concentrations decline [293], as do intrahepatic bile salt levels [24].

In summary, the three metabolic switches after PHx are:

- ligand ↓ / NRIP1 ↑ → LXR ↓ → cholesterol synthesis ↑ / cholesterol catabolism ↓
- bile acids ↑ → FXR ↑ → SHP ↑ → LXR ↓ / LRH-1 ↓ → ABCG5 ↓ / ABCG8 ↓ → cholesterol export

- cholesterol synthesis ↓

In light of these pathways, it is clear that hepatocytes regulate bile acid synthesis by mainly enzymological means (i.e., regulation of CYP7A1, next section) and transport (section 4.3) rather than through substrate control.

4.2.2. Inhibition of bile acid synthesis during liver regeneration.

Bile acid production is susceptible to a negative feedback loop that reduces bile acid accumulation and decreases the bile acid pool size [260,265,266,493]. This is mainly achieved by transcriptional inhibition of *Cyp7a1/CYP7A1*, which encodes the rate-limiting enzyme in the neutral bile acid synthesis pathway [494,495]. As mentioned earlier, bile acid activation of hFXR induces SHP, which inhibits the transactivational activity of LRH-1 and HNF4 α that are key stimulators of *Cyp7a1/CYP7A1* transcription [259,260,266] (Table 1). In addition, elevated intestinal bile acid levels inhibit hepatic CYP7A1 via the FXR-FGF15/19 gut-to-liver signaling axis [266,276,277,496]. Accordingly, the post-PHx bile acid overload in the liver [25,26] coincides with pleiotropic transcriptional repression of *Cyp7a1* [28]. In vivo, intestinal FXR/FGF15/19 appears to be the dominant route by which bile acids repress CYP7A1 in comparison to the hepatic FXR/SHP/LRH-1 route. Using tissue-specific knockout mice, Kim et al. have demonstrated that FXR activation in the intestines but not the liver is necessary for short-term downregulation of hepatocellular *Cyp7a1* in mice [496].

In addition, murine hepatocellular *Cyp7a1* downregulation is also controlled by PXR, another nuclear receptor that is activated by LCA [295]. Correspondingly, bile acid species that have been reported to induce *Cyp7a1* repression include CDCA [324,497], DCA [498,499], and LCA [295], which constitute physiological ligands of FXR and/or PXR (section 3.3).

The bile acid response element of *CYP7A1/Cyp7a1* [323,324] is also targeted by HNF-4 α , a nuclear receptor involved in lipid and glucose metabolism [328,329] (Table 1). CDCA can decrease HNF-4 α -regulated downstream genes [325,326,500], implicating this nuclear factor is involved in bile acid-mediated repression of CYP7A1. Despite a single study reporting unperturbed HNF-4 α levels in the early post-PHx regeneration phase [180], mice in which *Hnf4a* (encodes HNF-4 α) was genetically deleted exhibit derailed bile acid homeostasis [328,329]. HNF-4 α further regulates *CYP8B1/Cyp8b1* and *CYP27A1/Cyp27a1*, that encode the acidic pathway regulating enzyme CYP27A1, via a HNF-4 α binding site in

the promotor region [325-327]. The promotor region of *CYP8B1* also contains a binding site for LRH-1 [268], which is increased on day 2-3 after PHx in mice [482]. Elevated levels of LRH-1 are therefore expected to augment CYP8B1 expression and promote bile acid synthesis. However, this signaling axis may be offset by negative *CYP8B1* regulation by FXR/SHP-dependent and independent pathways [501]. In vivo, HNF-4 α and LRH-1 facilitate SHP binding to the *Cyp7a1* promoter and drive FGF15-mediated repression of bile acid synthesis [471]. Taken together, bile acid synthesis is suppressed during the early phase of post-PHx liver regeneration (Table 1).

Other negative mediators of *Cyp7a1* include NRF2 [331] (Table 1), that is overexpressed during the early phase of liver regeneration following PHx in mice [71-73,82] (section 2.1) and in part activated by certain bile acids such as UDCA [502]. Cytokines such as TNF- α [498] and IL-1 β [497] (section 2.2) downmodulate *Cyp7a1* in rats through pathways involving FAS receptor/JNK/c-Jun [498,499] and the nuclear receptor HNF-4 α [324,497]. Additionally, the growth factors TGF- β 1 [503] and HGF [504] (section 2.3) downregulate *CYP7A1/Cyp7a1* through signaling cascades involving HNF-4 α (induced by TGF- β 1) [503] and protein kinase C (PKC)/ERK1 and 2/JNK (induced by HGF) [504], at least in human hepatocytes [505].

4.3. Regulation of bile acid transport during liver regeneration

To further deter the toxicity of bile acids [223], overloaded hepatocytes instate protective routes to limit bile acid influx at the basolateral end and eliminate excessive bile acids from the intracellular milieu via basolateral and canalicular exporters [355,506]. This process is also referred to as phase III metabolism.

4.3.1. Regulation of basolateral bile acid import

As described before, the extraction of bile acids from the portal circulation by hepatocytes is facilitated by NTCP (encoded by *SLC10A1/Slc10a1*), and OATP isoforms OATP1B1 (*SLCO1B1*), OATP1B3 (*SLCO1B3*), and OATP2B1 (*SLCO2B1*) [507-510], all located at the basolateral membrane of hepatocytes [238,509,510]. Studies in rats have shown that the expression of NTCP [506,511-513], OATP1 and OATP2 [506,512] considerably decline during post-PHx, early-phase liver regeneration (0.5-2 days). Additionally, expression of the specific isoforms OATP1B1 and OATP1B3 is decreased under cholestatic conditions

[437,514]. Therefore, NTCP and OATP isoforms may prevent bile acid loading from the enterohepatic circulation. Accordingly, a significant rise in plasma bile acids has been observed in mice and rats within several hours after PHx [25,26]. Similar to regulation of CYP7A1, NTCP is transcriptionally downregulated by bile acids (Figure 4). The route by which bile acids suppress NTCP is multilayered and complex, involving FXR/SHP/LRH-1, HNF-1 α , and HNF-4 α [355,515]. In addition, NTCP is negatively regulated by TNF- α , and IL-1 β [516] but not NRF2 [331]. The same applies to OAT1B in terms of IL-1 β [517] (Table 1). It therefore seems that, during regeneration, the net expressional effect on these transporters is chiefly dictated by cytokine networks rather than metabolic networks (i.e., bile acid signaling).

4.3.2. Regulation of basolateral bile acid export

Under normophysiological conditions, basolateral bile acid efflux is maintained at a very low rate, as most of the bile acids undergo canalicular secretion. Upregulation of basolateral bile acid efflux transporters is considered as an adaptive response to secrete bile acids into the systemic circulation for renal excretion. As is shown in Figure 4, the basolateral efflux of bile acids from hepatocytes is mediated by the transporters MRP3 (*ABCC3/Abcc3*) [518-520] and MRP4 (*ABCC4/Abcc4*) [468], both located at the basolateral membrane of hepatocytes [521,522] and both under positive control of e.g., NRF2 in mice [331] (section 2.1 and Table 1). Murine *Abcc3* is under negative control of IL-1 β [516] and positive control of CAR [523] (section 3.3.4 and Table 1) and TNF- α via LRH-1 [261] (section 3.3 and Table 1), both implicated in post-PHx liver regeneration, albeit to different degrees. Following PHx in mice, MRP3 and MRP4 levels were shown to have increased up to 3.1-fold [524,525], which was associated with increased plasma bile acid levels [524]. Similar results were found for MRP4 in both mice and rats [273,513]. Since OATPs are bilateral exchangers, the previously mentioned A and B isoforms may also mediate basolateral efflux of bile acids [355], albeit to a limited extent because of their post-PHx downregulation [506].

The OST α -OST β heterodimer is also located at the basolateral membrane of hepatocytes [278,526] and has been shown to transport bile acids [247] out of bile acid-overloaded hepatocytes [278]. As in the intestines (section 3.1.1), OST α and OST β are under positive transcriptional control by several bile acid-activated nuclear receptors, including FXR and LRH-1 [262,273,278] (section 3.3 and Figure 4). The transporter complex is further induced by nuclear receptor ligands that are not activated by bile acids but do play a role in

post-PHx liver regeneration, including glucocorticoid receptor (GR) [526]. Hepatic GR levels exhibit a considerable increase during the first 24 hours after PHx in rats [527], suggesting concomitant upregulation of OST α -OST β and facilitated export of (toxic) bile acids. Contrastingly, OST α -OST β are repressed by SHP [262] and IL-1 β in mice [516] (section 2.2). The positive and negative regulation notwithstanding, the involvement of OST α -OST β in bile acid flux modulation under conditions of PHx remains to be proven experimentally. Based on our knowledge and expertise, OST α -OST β are induced by FXR and bile acids, where LCA plays a marginal-to-no role in terms of liver regeneration. LRH likely maintains basal transcriptional activity of the OST isoforms, but does not play an important role in response to bile acids.

In sum, these basolateral transporters, or at least MRP3 and MRP4, ensure that bile acids are pumped out of the cell back into the systemic circulation. All the abovementioned basolateral transporters are capable of also removing sulfated and glucuronidated bile acids from hepatocytes [528], indicating that the transporters work in concert with the hepatocyte detoxification machinery (section 4.1) to remove (conjugated) bile acids. The conjugated bile acids can subsequently be removed from the circulation by renal clearance [529-531].

4.3.3. Regulation of canalicular bile acid export

Expression of BSEP, an export pump that traffics bile acids from hepatocytes into the circulation, is positively regulated by FXR [256,532,533], which heterodimerizes with RXR to bind the promotor region of *ABCB11* [256], as well as by NRF2 [330,331] and LRH-1 [259] (Table 1). While one study reported only slightly increased levels of BSEP after PHx in rats [506], FXR and NRF2 are activated during post-PHx liver regeneration [71-73,82,254,534] and thus may promote canalicular export of bile acids via BSEP in bile acid-congested hepatocytes post-PHx [370,506,534,535]. In support of the BSEP-mediated canalicular export of bile acids, Monte et al. demonstrated that bile acid levels in bile rise during the first 1-3 days after PHx in rats, and subsequently decline to near-baseline levels during the subsequent 11-13 days [24,482]. Correspondingly, mice fed CA and UDCA exhibit increased BSEP expression and elevated bile acid levels in bile [535,536].

In rats, increased canalicular export of bile acids from bile acid-overloaded hepatocytes also applies to MRP2 [506]. The same effect of CA and UDCA feeding to mice has been observed for hepatocellular MRP2 expression as was reported for BSEP expression [535,536]. Although this transporter is under negative control of IL-1 β [516] and only one

study reported unaltered or slightly increased BSEP mRNA levels after PHx [506], *Abcc2* (MRP2) is under positive control of several nuclear receptors that are activated during post-PHx liver regeneration (section 3.1), including RXR [292], FXR [279], PXR [279], and CAR [279,537], as well as the bile acids that activate these receptors and/or *Abcc2* directly [279,535,538,539] (Table 1). It therefore stands to argue that MRP2 is upregulated during the bile acid overload following PHx and assists in canalicular exporting of (toxic) bile acids. Finally, PHx in rats results in a considerable (up to 20-fold) increase in *Mdr1* mRNA levels in the remnant liver [540,541], but the significance of this upregulation in the context of bile acid trafficking during post-PHx liver regeneration is presently elusive.

4.4 Containment of post-hepatectomy bile acid toxicity in human hepatocytes

The modulation of hepatocellular bile acid composition during liver regeneration occurs through various enzymes that mediate phase I and II metabolic processes [445-448]. Phase I, hydroxylation, is mediated CYP3A4 that is under positive control of both bile acids and FXR in human hepatocytes [449]. Phase II metabolic reactions include sulfation, mediated by SULT2A1 [458,459] isoforms, and glucuronidation, mediated by UGT isoforms UGT2B4 and UGT2B7 [464,465]. While FXR [280] and PPAR α [332] positively regulate *UGT2B4* expression, FXR negatively regulates *UGT2B7* expression [281]. Inhibition of *UGT2B7* was also seen as a result of CAR mediated HNF-4 α inhibition in human HepG2 cells [313] (Table 1). These results suggest that bile acid metabolism is tightly regulated after PHx in humans in order to protect the liver from the post-PHx relative bile-acid overload. Besides, *CYP3A4*, *CYP3A11*, and human *CYP7A14*, the gene that encodes the enzyme that regulates bile acid synthesis from cholesterol, also contains a bile acid response element in its promotor region, suggesting that human hepatocytes also regulate bile acid synthesis after PHx through a negative feedback loop.

Additionally, basolateral bile acid import and export are well-controlled after PHx in humans. Human bile acid transporters have been identified and classified [239,508,510]. However, the expression of these transporters in humans has only been investigated in the context of cholestasis [278,542], and expression levels have not yet been measured after PHx. Chen, et al. [542] investigated the expression of hepatocyte transporters and nuclear receptors in children with biliary atresia, a disease that leads to cholestasis. In early-stage cholestasis, expression levels of *ABCB11* (BSEP), *ABCC2* (MRP2), and *SCLO*-isoforms (OATP) were increased, suggesting that in situations of increased relative exposure to bile acids, human

hepatocytes downregulate bile acid resorption. In HepG2 cells, FXR/RXR heterodimers positively regulate *ABCB11* (BSEP) [256,533]. CDCA induces *ABCB11* expression through FXR, whilst LCA works as a CDCA antagonist and decreases BSEP expression [533]. As a result of FXR activation, expression levels of OST α -OST β also increase due to cholestasis in humans [278]. Human OST α -OST β are also under positive control of GR, that is important after PHx [526].

5. Concluding remarks

Liver regeneration following PHx is a highly complicated process involving multiple organs and several types of signaling networks. The metabolic pathways that revolve around bile acid signaling occupy an ancillary yet important part in post-PHx liver regeneration.

The metabolic cues for liver regeneration are given off by bile acids directly after PHx, and are hence facilitated by the temporary bile acid overload that lasts for up to 48-72 hours. The bile acids induce hepatocyte proliferation and liver regeneration through several nuclear receptors, either by direct binding or by indirect activation. Inasmuch as bile acids are inherently toxic, the state of bile acid hypersaturation cannot be sustained by the remnant hepatocytes that, while proliferating, also have to properly execute all aspects of liver function. Consequently, once the proliferative signals have been relayed by the bile acids, hepatocytes activate a bile acid detoxification and elimination machinery in order to protect themselves. These processes, induced in part by bile acids and nuclear receptors, encompass phase I-III endobiotic metabolism that predominantly results in the excretion of (biotransformed) bile acids into the canalicular system.

The excreted bile acids subsequently translocate to the intestines, where they mount a secondary wave of proliferative signaling in the liver. This system is based on the enterocytic reabsorption of bile acids, activation of FXR and consequent production of FGF19/FGF15, its release into the enterohepatic circulation, and the basolateral binding of FGF19/FGF15 to its cognate receptor, a complex of FGFR4/FGFR4 and β -klotho, on hepatocytes.

6. Future implications

Further research on the abovementioned pathways may have beneficial implications for various liver diseases and surgical procedures such as PHx. This last chapter will highlight points of interest for further research.

Firstly, no data is available on the role of several nuclear receptors in liver regeneration after PHx. Additional research on the effects of RXR, PXR, CAR, and LRH-1 in PH-induced liver regeneration could help with understanding the role of bile acids in liver regeneration. It was shown that CAR influences thyroid hormone signaling [28,350], but further research has to be done to find out how the thyroid hormone/hepatic nuclear receptor signaling axes works. The kinetics of LRH-1 still have to be investigated, especially in the context of bile acid composition and hepatotoxicity. How bile acids influence liver regeneration remains unclear for all nuclear receptors except for FXR.

Secondly, several implications have been made on how bile acid flux is modulated under conditions of PHx. The significance of bile acid transporters in liver regeneration such as NTCP, OATP isoforms, MRP-2, -3 and -4, OST α -OST β , BSEP, and MDR-1 remains to be proven experimentally.

Thirdly, it remains unclear how FGFR4, the FGF15/FGF19 receptor, feeds signals into STAT3-, MAPK-, and NF- κ B pathways and how cytokines and growth factors fit into these pathways. Ligand binding to this receptor initiates proliferative signaling that has only been partially elucidated in terms of mechanisms. This aspect of liver regeneration therefore warrants further research, especially since several FXR agonists have recently become available that promote liver regeneration via the gut-liver axis. Since cytokines and growth factors play prominent roles in liver regeneration (section 2.2), it is important to elucidate these pathways.

Finally, it was shown that downregulation of PDK4, a protein that regulates pyruvate metabolism, promotes liver regeneration [543]. Another study reported upregulation of PDK4 as a result of bile acid induced FXR activation [27], a mechanism that is in line with the anabolic demand during the liver re-growth phase. It would be useful to further investigate the effects of PDK4 on liver regeneration in a PHx model, since no study has shown that PDK4 enzyme activity is increased after PHx. Other signals that need further investigation are the mechanism through which TGR5 confers biochemical protection during liver.

Both in vitro as well as in vivo studies are required for a better understanding of the importance of bile acids and their effects and effectors in the context of liver regeneration after PHx. Further elucidation of these pathways could be beneficial for patients with various liver diseases, including patients that have undergone a PHx.

Acknowledgements

The authors are grateful to Ms. Inge Kos for the illustrations and the reviewers for providing instrumental comments.

Conflict of interest statement

The authors declare that they do not have any conflict of interest. MH, RFvG, and PBO are conducting 2 liver regeneration-related projects with obeticholic acid that was provided by Intercept Pharmaceuticals under a non-commercial license agreement.

Financial support

MH is sponsored by a grant from the Dutch Anti-Cancer Society (grant # 10666).

REFERENCES

- 1 Hoekstra LT, de Graaf W, Nibourg GA, Heger M, Bennink RJ, Stieger B, van Gulik TM. Physiological and biochemical basis of clinical liver function tests: A review. *Ann Surg* 2013;257:27-36.
- 2 Michalopoulos GK. Advances in liver regeneration. *Exp Rev Gastroenterol Hepatol* 2014;8:897-907.
- 3 Bismuth H, Majno PE. Hepatobiliary surgery. *J Hepatol* 2000;32:208-224.
- 4 Togo S, Makino H, Kobayashi T, Morita T, Shimizu T, Kubota T, Ichikawa Y, Ishikawa T, Okazaki Y, Hayashizaki Y, Shimada H. Mechanism of liver regeneration after partial hepatectomy using mouse cDNA microarray. *J Hepatol* 2004;40:464-471.
- 5 Liao Y, Shikapwashya ON, Shteyer E, Dieckgraefe BK, Hruz PW, Rudnick DA. Delayed hepatocellular mitotic progression and impaired liver regeneration in early growth response-1-deficient mice. *J Biol Chem* 2004;279:43107-43116.
- 6 Talarmin H, Rescan C, Cariou S, Glaise D, Zanninelli G, Bilodeau M, Loyer P, Guguen-Guillouzo C, Baffet G. The mitogen-activated protein kinase kinase/extracellular signal-regulated kinase cascade activation is a key signalling pathway involved in the regulation of G1 phase progression in proliferating hepatocytes. *Mol Cell Biol* 1999;19:6003-6011.
- 7 Abshagen K, Eipel C, Vollmar B. A critical appraisal of the hemodynamic signal driving liver regeneration. *Langenbecks Arch Surg* 2012;397:579-590.
- 8 Markiewski MM, DeAngelis RA, Strey CW, Foukas PG, Gerard C, Gerard N, Wetsel RA, Lambris JD. The regulation of liver cell survival by complement. *J Immunol* 2009;182:5412-5418.
- 9 Strey CW, Markiewski M, Mastellos D, Tudoran R, Spruce LA, Greenbaum LE, Lambris JD. The proinflammatory mediators C3a and C5a are essential for liver regeneration. *J Exp Med* 2003;198:913-923.
- 10 Strey CW, Siegmund B, Rosenblum S, Marquez-Pinilla RM, Oppermann E, Huber-Lang M, Lambris JD, Bechstein WO. Complement and neutrophil function changes after liver resection in humans. *World J Surg* 2009;33:2635-2643.
- 11 van de Poll MC, Derikx JP, Buurman WA, Peters WH, Roelofs HM, Wigmore SJ, Dejong CH. Liver manipulation causes hepatocyte injury and precedes systemic inflammation in patients undergoing liver resection. *World J Surg* 2007;31:2033-2038.
- 12 van den Broek MA, Shiri-Sverdlov R, Schreurs JJ, Bloemen JG, Bieghs V, Rensen SS, Dejong CH, Olde Damink SW. Liver manipulation during liver surgery in humans is associated with hepatocellular damage and hepatic inflammation. *Liver Int* 2013;33:633-641.
- 13 van Golen RF, van Gulik TM, Heger M. The sterile immune response during hepatic ischemia/reperfusion. *Cytokine Growth Factor Rev* 2012;23:69-84.
- 14 Chen GY, Nunez G. Sterile inflammation: Sensing and reacting to damage. *Nat Rev Immunol* 2010;10:826-837.
- 15 Oe S, Lemmer ER, Conner EA, Factor VM, Leveen P, Larsson J, Karlsson S, Thorgeirsson SS. Intact signaling by transforming growth factor beta is not required for termination of liver regeneration in mice. *Hepatology* 2004;40:1098-1105.
- 16 Romero-Gallo J, Sozmen EG, Chytil A, Russell WE, Whitehead R, Parks WT, Holdren MS, Her MF, Gautam S, Magnuson M, Moses HL, Grady WM. Inactivation of TGF-beta signaling in hepatocytes results in an increased proliferative response after partial hepatectomy. *Oncogene* 2005;24:3028-3041.
- 17 Hammond JS, Guha IN, Beckingham IJ, Lobo DN. Prediction, prevention and management of postresection liver failure. *Br J Surg* 2011;98:1188-1200.
- 18 Dahm F, Georgiev P, Clavien PA. Small-for-size syndrome after partial liver transplantation: Definition, mechanisms of disease and clinical implications. *Am J Transplant* 2005;5:2605-2610.

- 19 Columbano A, Ledda-Columbano GM. Mitogenesis by ligands of nuclear receptors: An attractive model for the study of the molecular mechanisms implicated in liver growth. *Cell Death Differ* 2003;10 Suppl 1:S19-21.
- 20 Vacca M, Degirolamo C, Massafra V, Polimeno L, Mariani-Costantini R, Palasciano G, Moschetta A. Nuclear receptors in regenerating liver and hepatocellular carcinoma. *Mol Cell Endocrinol* 2013;368:108-119.
- 21 Naugler WE. Bile acid flux is necessary for normal liver regeneration. *PLoS One* 2014;9:e97426.
- 22 Uriarte I, Fernandez-Barrena MG, Monte MJ, Latasa MU, Chang HC, Carotti S, Vespasiani-Gentilucci U, Morini S, Vicente E, Concepcion AR, Medina JF, Marin JJ, Berasain C, Prieto J, Avila MA. Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. *Gut* 2013;62:899-910.
- 23 Padrisa-Altes S, Bachofner M, Bogorad RL, Pohlmeier L, Rossolini T, Bohm F, Liebisch G, Hellerbrand C, Kotliansky V, Speicher T, Werner S. Control of hepatocyte proliferation and survival by fgf receptors is essential for liver regeneration in mice. *Gut* 2015;64:1444-1453.
- 24 Monte MJ, Martinez-Diez MC, El-Mir MY, Mendoza ME, Bravo P, Bachs O, Marin JJ. Changes in the pool of bile acids in hepatocyte nuclei during rat liver regeneration. *J Hepatol* 2002;36:534-542.
- 25 Doignon I, Julien B, Serriere-Lanneau V, Garcin I, Alonso G, Nicou A, Monnet F, Gigou M, Humbert L, Rainteau D, Azoulay D, Castaing D, Gillon MC, Samuel D, Duclos-Vallee JC, Tordjmann T. Immediate neuroendocrine signaling after partial hepatectomy through acute portal hyperpressure and cholestasis. *J Hepatol* 2011;54:481-488.
- 26 Pean N, Doignon I, Garcin I, Besnard A, Julien B, Liu B, Branchereau S, Spraul A, Guettier C, Humbert L, Schoonjans K, Rainteau D, Tordjmann T. The receptor tgr5 protects the liver from bile acid overload during liver regeneration in mice. *Hepatology* 2013;58:1451-1460.
- 27 Xie Y, Wang H, Cheng X, Wu Y, Cao L, Wu M, Xie W, Wang G, Hao H. Farnesoid x receptor activation promotes cell proliferation via pdk4-controlled metabolic reprogramming. *Sci Rep* 2016;6:18751.
- 28 Huang W, Ma K, Zhang J, Qatanani M, Cuvillier J, Liu J, Dong B, Huang X, Moore DD. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. *Science* 2006;312:233-236.
- 29 Naugler WE, Tarlow BD, Fedorov LM, Taylor M, Pelz C, Li B, Darnell J, Grompe M. Fibroblast growth factor signaling controls liver size in mice with humanized livers. *Gastroenterology* 2015;149:728-740 e715.
- 30 Jansen PL, Schaap FG. Pandora's box opens for cholestatic liver disease. *Hepatology* 2015
- 31 Schaap FG, Trauner M, Jansen PL. Bile acid receptors as targets for drug development. *Nat Rev Gastroenterol Hepatol* 2014;11:55-67.
- 32 Olthof PB, Huisman F, Schaap FG, van Lienden KP, Bennink RJ, van Golen RF, Heger M, Verheij J, Jansen PL, Olde Damink SW, van Gulik TM. Effect of obeticholic acid on liver regeneration following portal vein embolization in an experimental model. *Br J Surg* 2017;104:590-599.
- 33 Beuers U, Trauner M, Jansen P, Poupon R. New paradigms in the treatment of hepatic cholestasis: From udca to fxr, pxx and beyond. *J Hepatol* 2015;62:S25-37.
- 34 Michalopoulos GK, DeFrances MC. Liver regeneration. *Science* 1997;276:60-66.
- 35 Grisham JW. A morphologic study of deoxyribonucleic acid synthesis and cell proliferation in regenerating rat liver; autoradiography with thymidine-h3. *Cancer Res* 1962;22:842-849.
- 36 Taub R. Liver regeneration: From myth to mechanism. *Nat Rev Mol Cell Biol* 2004;5:836-847.
- 37 Mao SA, Glorioso JM, Nyberg SL. Liver regeneration. *Transl Res* 2014;163:352-362.
- 38 Lock JF, Malinowski M, Seehofer D, Hoppe S, Rohl RI, Niehues SM, Neuhaus P, Stockmann M. Function and volume recovery after partial hepatectomy: Influence of preoperative liver function, residual liver volume, and obesity. *Langenbecks Arch Surg* 2012;397:1297-1304.

- 39 Nagasue N, Yukaya H, Ogawa Y, Kohno H, Nakamura T. Human liver regeneration after major hepatic resection. A study of normal liver and livers with chronic hepatitis and cirrhosis. *Ann Surg* 1987;206:30-39.
- 40 Riehle KJ, Dan YY, Campbell JS, Fausto N. New concepts in liver regeneration. *J Gastroenterol Hepatol* 2011;26:203-212.
- 41 Satyanarayana A, Geffers R, Manns MP, Buer J, Rudolph KL. Gene expression profile at the g1/s transition of liver regeneration after partial hepatectomy in mice. *Cell Cycle* 2004;3:1405-1417.
- 42 Meyer J, Lejmi E, Fontana P, Morel P, Gonelle-Gispert C, Buhler L. A focus on the role of platelets in liver regeneration: Do platelet-endothelial cell interactions initiate the regenerative process? *J Hepatol* 2015;63:1263-1271.
- 43 Kang LI, Mars WM, Michalopoulos GK. Signals and cells involved in regulating liver regeneration. *Cells* 2012;1:1261-1292.
- 44 Michalopoulos GK. Liver regeneration after partial hepatectomy: Critical analysis of mechanistic dilemmas. *Am J Pathol* 2010;176:2-13.
- 45 Marubashi S, Sakon M, Nagano H, Gotoh K, Hashimoto K, Kubota M, Kobayashi S, Yamamoto S, Miyamoto A, Dono K, Nakamori S, Umeshita K, Monden M. Effect of portal hemodynamics on liver regeneration studied in a novel portohepatic shunt rat model. *Surgery* 2004;136:1028-1037.
- 46 Lee S, Broelsch CE, Flamant YM, Chandler JG, Charters AC, 3rd, Orloff MJ. Liver regeneration after portacaval transportation in rats. *Surgery* 1975;77:144-149.
- 47 Starlinger P, Haegele S, Offensperger F, Oehlberger L, Pereyra D, Kral JB, Schrottmaier WC, Badrnya S, Reiberger T, Ferlitsch A, Stift J, Luf F, Brostjan C, Gruenberger T, Assinger A. The profile of platelet alpha-granule released molecules affects postoperative liver regeneration. *Hepatology* 2015
- 48 Zhang JN, Bergeron AL, Yu Q, Sun C, McIntire LV, Lopez JA, Dong JF. Platelet aggregation and activation under complex patterns of shear stress. *Thromb Haemost* 2002;88:817-821.
- 49 van Golen RF, Stevens KM, Colarusso P, Jaeschke H, Heger M. Platelet aggregation but not activation and degranulation during the acute post-ischemic reperfusion phase in livers with no underlying disease. *J Clin Transl Res* 2015;1:107-115.
- 50 Wack KE, Ross MA, Zegarra V, Sysko LR, Watkins SC, Stolz DB. Sinusoidal ultrastructure evaluated during the revascularization of regenerating rat liver. *Hepatology* 2001;33:363-378.
- 51 Nakamura M, Shibasaki M, Nitta Y, Endo Y. Translocation of platelets into disse spaces and their entry into hepatocytes in response to lipopolysaccharides, interleukin-1 and tumour necrosis factor: The role of kupffer cells. *J Hepatol* 1998;28:991-999.
- 52 Endo Y, Nakamura M. The effect of lipopolysaccharide, interleukin-1 and tumour necrosis factor on the hepatic accumulation of 5-hydroxytryptamine and platelets in the mouse. *Br J Pharmacol* 1992;105:613-619.
- 53 Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. *N Engl J Med* 2007;356:1545-1559.
- 54 Wuestefeld T, Klein C, Streetz KL, Betz U, Lauber J, Buer J, Manns MP, Muller W, Trautwein C. Interleukin-6/glycoprotein 130-dependent pathways are protective during liver regeneration. *J Biol Chem* 2003;278:11281-11288.
- 55 Iimuro Y, Fujimoto J. Tlrs, nf-kappab, jnk, and liver regeneration. *Gastroenterol Res Pract* 2010;2010
- 56 Michalopoulos GK. Principles of liver regeneration and growth homeostasis. *Compr Physiol* 2013;3:485-513.
- 57 Marshall KM, He S, Zhong Z, Atkinson C, Tomlinson S. Dissecting the complement pathway in hepatic injury and regeneration with a novel protective strategy. *J Exp Med* 2014;211:1793-1805.
- 58 DeAngelis RA, Markiewski MM, Kourtzelis I, Rafail S, Syriga M, Sandor A, Maurya MR, Gupta S, Subramaniam S, Lambris JD. A complement-il-4 regulatory circuit controls liver regeneration. *J Immunol* 2012;188:641-648.
- 59 DeAngelis RA, Markiewski MM, Lambris JD. Liver regeneration: A link to inflammation through complement. *Adv Exp Med Biol* 2006;586:17-34.

- 60 Liu HX, Keane R, Sheng L, Wan YJ. Implications of microbiota and bile acid in liver injury and regeneration. *J Hepatol* 2015;63:1502-1510.
- 61 Liu HX, Rocha CS, Dandekar S, Wan YY. Functional analysis of the relationship between intestinal microbiota and the expression of hepatic genes and pathways during the course of liver regeneration. *J Hepatol* 2015
- 62 Sakaguchi T, Nakamura S, Suzuki S, Baba S, Nakashima M. Endogenous endotoxemia after massive hepatectomy and portal vein stenosis: Beneficial effect of a prostaglandin i2 analogue on intestinal permeability. *Eur Surg Res* 1996;28:341-350.
- 63 Cornell RP. Gut-derived endotoxin elicits hepatotrophic factor secretion for liver regeneration. *Am J Physiol* 1985;249:R551-562.
- 64 Gao B, Jeong WI, Tian Z. Liver: An organ with predominant innate immunity. *Hepatology* 2008;47:729-736.
- 65 Cornell RP, Liljequist BL, Bartizal KF. Depressed liver regeneration after partial hepatectomy of germ-free, athymic and lipopolysaccharide-resistant mice. *Hepatology* 1990;11:916-922.
- 66 Cienfuegos JA, Rotellar F, Baixauli J, Martínez-Regueira F, Pardo F, Hernández-Lizoáin JL. Liver regeneration--the best kept secret. A model of tissue injury response. *Rev Esp Enferm Dig* 2014;106:171-194.
- 67 van Golen RF, van Gulik TM, Heger M. Mechanistic overview of reactive species-induced degradation of the endothelial glycocalyx during hepatic ischemia/reperfusion injury. *Free Radic Biol Med* 2012;52:1382-1402.
- 68 van Golen RF, Reiniers MJ, Vrisekoop N, Zuurbier CJ, Olthof PB, van Rheenen J, van Gulik TM, Parsons BJ, Heger M. The mechanisms and physiological relevance of glycocalyx degradation in hepatic ischemia/reperfusion injury. *Antioxid Redox Signal* 2014;21:1098-1118.
- 69 Kloek JJ, Marechal X, Roelofsen J, Houtkooper RH, van Kuilenburg AB, Kulik W, Bezemer R, Neviere R, van Gulik TM, Heger M. Cholestasis is associated with hepatic microvascular dysfunction and aberrant energy metabolism before and during ischemia-reperfusion. *Antioxid Redox Signal* 2012;17:1109-1123.
- 70 Reiniers MJ, van Golen RF, van Gulik TM, Heger M. Reactive oxygen and nitrogen species in steatotic hepatocytes: A molecular perspective on the pathophysiology of ischemia-reperfusion injury in the fatty liver. *Antioxid Redox Signal* 2014;21:1119-1142.
- 71 Bai H, Zhang W, Qin XJ, Zhang T, Wu H, Liu JZ, Hai CX. Hydrogen peroxide modulates the proliferation/quiescence switch in the liver during embryonic development and posthepatectomy regeneration. *Antioxid Redox Signal* 2015;22:921-937.
- 72 Dayoub R, Vogel A, Schuett J, Lupke M, Spieker SM, Kettern N, Hildt E, Melter M, Weiss TS. Nrf2 activates augmenter of liver regeneration (alr) via antioxidant response element and links oxidative stress to liver regeneration. *Mol Med* 2013;19:237-244.
- 73 Hu M, Zou Y, Nambiar SM, Lee J, Yang Y, Dai G. Keap1 modulates the redox cycle and hepatocyte cell cycle in regenerating liver. *Cell Cycle* 2014;13:2349-2358.
- 74 Kohler UA, Kurinna S, Schwitter D, Marti A, Schafer M, Hellerbrand C, Speicher T, Werner S. Activated nrf2 impairs liver regeneration in mice by activation of genes involved in cell-cycle control and apoptosis. *Hepatology* 2014;60:670-678.
- 75 Wakabayashi N, Shin S, Slocum SL, Agoston ES, Wakabayashi J, Kwak MK, Misra V, Biswal S, Yamamoto M, Kensler TW. Regulation of notch1 signaling by nrf2: Implications for tissue regeneration. *Sci Signal* 2010;3:ra52.
- 76 Kohler C, Bell AW, Bowen WC, Monga SP, Fleig W, Michalopoulos GK. Expression of notch-1 and its ligand jagged-1 in rat liver during liver regeneration. *Hepatology* 2004;39:1056-1065.
- 77 Goodrich DW, Wang NP, Qian YW, Lee EY, Lee WH. The retinoblastoma gene product regulates progression through the g1 phase of the cell cycle. *Cell* 1991;67:293-302.
- 78 Weintraub SJ, Prater CA, Dean DC. Retinoblastoma protein switches the e2f site from positive to negative element. *Nature* 1992;358:259-261.

- 79 Nelsen CJ, Rickheim DG, Timchenko NA, Stanley MW, Albrecht JH. Transient expression of cyclin d1 is sufficient to promote hepatocyte replication and liver growth in vivo. *Cancer Res* 2001;61:8564-8568.
- 80 Lavoie JN, Rivard N, L'Allemain G, Pouyssegur J. A temporal and biochemical link between growth factor-activated map kinases, cyclin d1 induction and cell cycle entry. *Prog Cell Cycle Res* 1996;2:49-58.
- 81 Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin d1 expression is regulated positively by the p42/p44mapk and negatively by the p38/hogmapk pathway. *J Biol Chem* 1996;271:20608-20616.
- 82 Beyer TA, Xu W, Teupser D, auf dem Keller U, Bugnon P, Hildt E, Thiery J, Kan YW, Werner S. Impaired liver regeneration in nrf2 knockout mice: Role of ros-mediated insulin/igf-1 resistance. *EMBO J* 2008;27:212-223.
- 83 Yan LJ, Rajasekaran NS, Sathyanarayanan S, Benjamin IJ. Mouse hsf1 disruption perturbs redox state and increases mitochondrial oxidative stress in kidney. *Antioxid Redox Signal* 2005;7:465-471.
- 84 Taub R. Liver regeneration 4: Transcriptional control of liver regeneration. *FASEB J* 1996;10:413-427.
- 85 Aldeguer X, Debonera F, Shaked A, Krasinkas AM, Gelman AE, Que X, Zamir GA, Hiroyasu S, Kovalovich KK, Taub R, Olthoff KM. Interleukin-6 from intrahepatic cells of bone marrow origin is required for normal murine liver regeneration. *Hepatology* 2002;35:40-48.
- 86 Akerman P, Cote P, Yang SQ, McClain C, Nelson S, Bagby GJ, Diehl AM. Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy. *Am J Physiol* 1992;263:G579-585.
- 87 Kirillova I, Chaisson M, Fausto N. Tumor necrosis factor induces DNA replication in hepatic cells through nuclear factor kappa b activation. *Cell Growth Differ* 1999;10:819-828.
- 88 FitzGerald MJ, Webber EM, Donovan JR, Fausto N. Rapid DNA binding by nuclear factor kappa b in hepatocytes at the start of liver regeneration. *Cell Growth Differ* 1995;6:417-427.
- 89 Yatomi Y, Ohmori T, Rile G, Kazama F, Okamoto H, Sano T, Satoh K, Kume S, Tigyi G, Igarashi Y, Ozaki Y. Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. *Blood* 2000;96:3431-3438.
- 90 Kawasaki T, Murata S, Takahashi K, Nozaki R, Ohshiro Y, Ikeda N, Pak S, Myronovych A, Hisakura K, Fukunaga K, Oda T, Sasaki R, Ohkohchi N. Activation of human liver sinusoidal endothelial cell by human platelets induces hepatocyte proliferation. *J Hepatol* 2010;53:648-654.
- 91 Nowatari T, Murata S, Nakayama K, Sano N, Maruyama T, Nozaki R, Ikeda N, Fukunaga K, Ohkohchi N. Sphingosine 1-phosphate has anti-apoptotic effect on liver sinusoidal endothelial cells and proliferative effect on hepatocytes in a paracrine manner in human. *Hepatol Res* 2014
- 92 Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, Poli V, Taub R. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. *Science* 1996;274:1379-1383.
- 93 Yamada Y, Kirillova I, Peschon JJ, Fausto N. Initiation of liver growth by tumor necrosis factor: Deficient liver regeneration in mice lacking type i tumor necrosis factor receptor. *Proc Natl Acad Sci U S A* 1997;94:1441-1446.
- 94 Li W, Liang X, Leu JI, Kovalovich K, Ciliberto G, Taub R. Global changes in interleukin-6-dependent gene expression patterns in mouse livers after partial hepatectomy. *Hepatology* 2001;33:1377-1386.
- 95 Haber BA, Mohn KL, Diamond RH, Taub R. Induction patterns of 70 genes during nine days after hepatectomy define the temporal course of liver regeneration. *J Clin Invest* 1993;91:1319-1326.
- 96 Levy DE, Lee CK. What does stat3 do? *J Clin Invest* 2002;109:1143-1148.
- 97 Columbano A, Shinozuka H. Liver regeneration versus direct hyperplasia. *Faseb j* 1996;10:1118-1128.
- 98 Michalopoulos GK, Khan Z. Liver regeneration, growth factors, and amphiregulin. *Gastroenterology* 2005;128:503-506.

- 99 Wang L, Wang X, Wang L, Chiu JD, van de Ven G, Gaarde WA, DeLeve LD. Hepatic vascular endothelial growth factor regulates recruitment of rat liver sinusoidal endothelial cell progenitor cells. *Gastroenterology* 2012;143:1555-1563 e1552.
- 100 Shimizu H, Miyazaki M, Wakabayashi Y, Mitsuhashi N, Kato A, Ito H, Nakagawa K, Yoshidome H, Kataoka M, Nakajima N. Vascular endothelial growth factor secreted by replicating hepatocytes induces sinusoidal endothelial cell proliferation during regeneration after partial hepatectomy in rats. *J Hepatol* 2001;34:683-689.
- 101 Taniguchi E, Sakisaka S, Matsuo K, Tanikawa K, Sata M. Expression and role of vascular endothelial growth factor in liver regeneration after partial hepatectomy in rats. *J Histochem Cytochem* 2001;49:121-130.
- 102 Mochida S, Ishikawa K, Inao M, Shibuya M, Fujiwara K. Increased expressions of vascular endothelial growth factor and its receptors, flt-1 and kdr/flk-1, in regenerating rat liver. *Biochem Biophys Res Commun* 1996;226:176-179.
- 103 Matsuo R, Nakano Y, Ohkohchi N. Platelet administration via the portal vein promotes liver regeneration in rats after 70% hepatectomy. *Ann Surg* 2011;253:759-763.
- 104 Murata S, Matsuo R, Ikeda O, Myronovych A, Watanabe M, Hisakura K, Nakano Y, Hashimoto I, Ohkohchi N. Platelets promote liver regeneration under conditions of kupffer cell depletion after hepatectomy in mice. *World J Surg* 2008;32:1088-1096.
- 105 Rendu F, Brohard-Bohn B. The platelet release reaction: Granules' constituents, secretion and functions. *Platelets* 2001;12:261-273.
- 106 Nurden AT, Nurden P, Sanchez M, Andia I, Anitua E. Platelets and wound healing. *Front Biosci* 2008;13:3532-3548.
- 107 Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. *J Biol Chem* 1983;258:7155-7160.
- 108 Lesurtel M, Graf R, Aleil B, Walther DJ, Tian Y, Jochum W, Gachet C, Bader M, Clavien PA. Platelet-derived serotonin mediates liver regeneration. *Science* 2006;312:104-107.
- 109 Hong F, Nguyen VA, Shen X, Kunos G, Gao B. Rapid activation of protein kinase b/akt has a key role in antiapoptotic signaling during liver regeneration. *Biochem Biophys Res Commun* 2000;279:974-979.
- 110 Matsuo R, Ohkohchi N, Murata S, Ikeda O, Nakano Y, Watanabe M, Hisakura K, Myronovych A, Kubota T, Narimatsu H, Ozaki M. Platelets strongly induce hepatocyte proliferation with igf-1 and hgf in vitro. *J Surg Res* 2008;145:279-286.
- 111 Nejak-Bowen K, Orr A, Bowen WC, Jr., Michalopoulos GK. Conditional genetic elimination of hepatocyte growth factor in mice compromises liver regeneration after partial hepatectomy. *PLoS One* 2013;8:e59836.
- 112 Furrer K, Rickenbacher A, Tian Y, Jochum W, Bittermann AG, Kach A, Humar B, Graf R, Moritz W, Clavien PA. Serotonin reverts age-related capillarization and failure of regeneration in the liver through a vegf-dependent pathway. *Proc Natl Acad Sci U S A* 2011;108:2945-2950.
- 113 LeCouter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber HP, Hillan KJ, Ferrara N. Angiogenesis-independent endothelial protection of liver: Role of vegfr-1. *Science* 2003;299:890-893.
- 114 Ding BS, Nolan DJ, Butler JM, James D, Babazadeh AO, Rosenwaks Z, Mittal V, Kobayashi H, Shido K, Lyden D, Sato TN, Rabbany SY, Rafii S. Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. *Nature* 2010;468:310-315.
- 115 DeLeve LD. Liver sinusoidal endothelial cells and liver regeneration. *J Clin Invest* 2013;123:1861-1866.
- 116 Lindroos PM, Zarnegar R, Michalopoulos GK. Hepatocyte growth factor (hepatopoietin a) rapidly increases in plasma before DNA synthesis and liver regeneration stimulated by partial hepatectomy and carbon tetrachloride administration. *Hepatology* 1991;13:743-750.
- 117 Currier AR, Sabla G, Locaputo S, Melin-Aldana H, Degen JL, Bezerra JA. Plasminogen directs the pleiotropic effects of upa in liver injury and repair. *Am J Physiol Gastrointest Liver Physiol* 2003;284:G508-515.

- 118 Shimizu M, Hara A, Okuno M, Matsuno H, Okada K, Ueshima S, Matsuo O, Niwa M, Akita K, Yamada Y, Yoshimi N, Uematsu T, Kojima S, Friedman SL, Moriwaki H, Mori H. Mechanism of retarded liver regeneration in plasminogen activator-deficient mice: Impaired activation of hepatocyte growth factor after fas-mediated massive hepatic apoptosis. *Hepatology* 2001;33:569-576.
- 119 Pediaditakis P, Lopez-Talavera JC, Petersen B, Monga SP, Michalopoulos GK. The processing and utilization of hepatocyte growth factor/scatter factor following partial hepatectomy in the rat. *Hepatology* 2001;34:688-693.
- 120 Mars WM, Zarnegar R, Michalopoulos GK. Activation of hepatocyte growth factor by the plasminogen activators upa and tpa. *Am J Pathol* 1993;143:949-958.
- 121 Maroun CR, Rowlands T. The met receptor tyrosine kinase: A key player in oncogenesis and drug resistance. *Pharmacol Ther* 2014;142:316-338.
- 122 Nakamura T, Mizuno S. The discovery of hepatocyte growth factor (hgf) and its significance for cell biology, life sciences and clinical medicine. *Proc Jpn Acad Ser B Phys Biol Sci* 2010;86:588-610.
- 123 Borowiak M, Garratt AN, Wustefeld T, Strehle M, Trautwein C, Birchmeier C. Met provides essential signals for liver regeneration. *Proc Natl Acad Sci U S A* 2004;101:10608-10613.
- 124 Okano J, Shiota G, Matsumoto K, Yasui S, Kurimasa A, Hisatome I, Steinberg P, Murawaki Y. Hepatocyte growth factor exerts a proliferative effect on oval cells through the pi3k/akt signaling pathway. *Biochem Biophys Res Commun* 2003;309:298-304.
- 125 Ozaki M, Haga S, Zhang HQ, Irani K, Suzuki S. Inhibition of hypoxia/reoxygenation-induced oxidative stress in hgf-stimulated antiapoptotic signaling: Role of pi3-k and akt kinase upon rac1. *Cell Death Differ* 2003;10:508-515.
- 126 Xiao GH, Jeffers M, Bellacosa A, Mitsuchi Y, Vande Woude GF, Testa JR. Anti-apoptotic signaling by hepatocyte growth factor/met via the phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways. *Proc Natl Acad Sci U S A* 2001;98:247-252.
- 127 Gao C, Jokerst R, Gondipalli P, Cai SR, Kennedy S, Flye MW, Ponder KP. Lipopolysaccharide potentiates the effect of hepatocyte growth factor on hepatocyte replication in rats by augmenting ap-1 activity. *Hepatology* 1999;30:1405-1416.
- 128 Puri N, Salgia R. Synergism of egfr and c-met pathways, cross-talk and inhibition, in non-small cell lung cancer. *J Carcinog* 2008;7:9.
- 129 Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC. Cross-talk between epidermal growth factor receptor and c-met signal pathways in transformed cells. *J Biol Chem* 2000;275:8806-8811.
- 130 Skov Olsen P, Boesby S, Kirkegaard P, Therkelsen K, Almdal T, Poulsen SS, Nexø E. Influence of epidermal growth factor on liver regeneration after partial hepatectomy in rats. *Hepatology* 1988;8:992-996.
- 131 Cruise JL, Knechtle SJ, Bollinger RR, Kuhn C, Michalopoulos G. Alpha 1-adrenergic effects and liver regeneration. *Hepatology* 1987;7:1189-1194.
- 132 Olsen PS, Poulsen SS, Kirkegaard P. Adrenergic effects on secretion of epidermal growth factor from brunner's glands. *Gut* 1985;26:920-927.
- 133 Knopp J, Jezova D, Rusnak M, Jaroscakova I, Farkas R, Kvetnansky R. Changes in plasma catecholamine and corticosterone levels and gene expression of key enzymes of catecholamine biosynthesis in partially hepatectomized rats. *Endocr Regul* 1999;33:145-153.
- 134 Mead JE, Fausto N. Transforming growth factor alpha may be a physiological regulator of liver regeneration by means of an autocrine mechanism. *Proc Natl Acad Sci U S A* 1989;86:1558-1562.
- 135 Webber EM, Wu JC, Wang L, Merlino G, Fausto N. Overexpression of transforming growth factor-alpha causes liver enlargement and increased hepatocyte proliferation in transgenic mice. *Am J Pathol* 1994;145:398-408.
- 136 Russell WE, Kaufmann WK, Sitaric S, Luetkeke NC, Lee DC. Liver regeneration and hepatocarcinogenesis in transforming growth factor-alpha-targeted mice. *Mol Carcinog* 1996;15:183-189.

- 137 Nakano T, Raines EW, Abraham JA, Klagsbrun M, Ross R. Lysophosphatidylcholine upregulates the level of heparin-binding epidermal growth factor-like growth factor mrna in human monocytes. *Proc Natl Acad Sci U S A* 1994;91:1069-1073.
- 138 Edwards JP, Zhang X, Mosser DM. The expression of heparin-binding epidermal growth factor-like growth factor by regulatory macrophages. *J Immunol* 2009;182:1929-1939.
- 139 Higashiyama S. Metalloproteinase-mediated shedding of heparin-binding egf-like growth factor and its pathophysiological roles. *Protein Pept Lett* 2004;11:443-450.
- 140 Ito N, Kawata S, Tamura S, Kiso S, Tsushima H, Damm D, Abraham JA, Higashiyama S, Taniguchi N, Matsuzawa Y. Heparin-binding egf-like growth factor is a potent mitogen for rat hepatocytes. *Biochem Biophys Res Commun* 1994;198:25-31.
- 141 Kiso S, Kawata S, Tamura S, Higashiyama S, Ito N, Tsushima H, Taniguchi N, Matsuzawa Y. Role of heparin-binding epidermal growth factor-like growth factor as a hepatotrophic factor in rat liver regeneration after partial hepatectomy. *Hepatology* 1995;22:1584-1590.
- 142 Yamada A, Kawata S, Tamura S, Kiso S, Higashiyama S, Umeshita K, Sakon M, Taniguchi N, Monden M, Matsuzawa Y. Plasma heparin-binding egf-like growth factor levels in patients after partial hepatectomy as determined with an enzyme-linked immunosorbent assay. *Biochem Biophys Res Commun* 1998;246:783-787.
- 143 Sakuda S, Tamura S, Yamada A, Miyagawa J, Yamamoto K, Kiso S, Ito N, Higashiyama S, Taniguchi N, Kawata S, Matsuzawa Y. Nf-kappab activation in non-parenchymal liver cells after partial hepatectomy in rats: Possible involvement in expression of heparin-binding epidermal growth factor-like growth factor. *J Hepatol* 2002;36:527-533.
- 144 Berasain C, Garcia-Trevijano ER, Castillo J, Erroba E, Lee DC, Prieto J, Avila MA. Amphiregulin: An early trigger of liver regeneration in mice. *Gastroenterology* 2005;128:424-432.
- 145 Hou Z, Yanaga K, Kamohara Y, Eguchi S, Tsutsumi R, Furui J, Kanematsu T. A new suppressive agent against interleukin-1beta and tumor necrosis factor-alpha enhances liver regeneration after partial hepatectomy in rats. *Hepatol Res* 2003;26:40-46.
- 146 Tsutsumi R, Kamohara Y, Eguchi S, Azuma T, Fujioka H, Okudaira S, Yanaga K, Kanematsu T. Selective suppression of initial cytokine response facilitates liver regeneration after extensive hepatectomy in rats. *Hepatogastroenterology* 2004;51:701-704.
- 147 Ogiso T, Nagaki M, Takai S, Tsukada Y, Mukai T, Kimura K, Moriwaki H. Granulocyte colony-stimulating factor impairs liver regeneration in mice through the up-regulation of interleukin-1beta. *J Hepatol* 2007;47:816-825.
- 148 Tsujii H, Okamoto Y, Kikuchi E, Matsumoto M, Nakano H. Prostaglandin e2 and rat liver regeneration. *Gastroenterology* 1993;105:495-499.
- 149 Goss JA, Mangino MJ, Flye MW. Kupffer cell autoregulation of il-1 production by pge2 during hepatic regeneration. *J Surg Res* 1992;52:422-428.
- 150 Goss JA, Mangino MJ, Flye MW. Prostaglandin e2 production during hepatic regeneration downregulates kupffer cell il-6 production. *Ann Surg* 1992;215:553-559; discussion 559-560.
- 151 Zhao Y, Meng C, Wang Y, Huang H, Liu W, Zhang JF, Zhao H, Feng B, Leung PS, Xia Y. Interleukin (il)-1beta inhibits beta-klotho expression and fgf19 signaling in hepatocytes. *Am J Physiol Endocrinol Metab* 2015;ajpendo 00356 02015.
- 152 Ledda-Columbano GM, Curto M, Piga R, Zedda AI, Menegazzi M, Sartori C, Shinozuka H, Bluethmann H, Poli V, Ciliberto G, Columbano A. In vivo hepatocyte proliferation is inducible through a tnf and il-6-independent pathway. *Oncogene* 1998;17:1039-1044.
- 153 Cruise JL, Houck KA, Michalopoulos GK. Induction of DNA synthesis in cultured rat hepatocytes through stimulation of alpha 1 adrenoreceptor by norepinephrine. *Science* 1985;227:749-751.
- 154 Yamada Y, Webber EM, Kirillova I, Peschon JJ, Fausto N. Analysis of liver regeneration in mice lacking type 1 or type 2 tumor necrosis factor receptor: Requirement for type 1 but not type 2 receptor. *Hepatology* 1998;28:959-970.

- 155 Kan M, Huang JS, Mansson PE, Yasumitsu H, Carr B, McKeehan WL. Heparin-binding growth factor type 1 (acidic fibroblast growth factor): A potential biphasic autocrine and paracrine regulator of hepatocyte regeneration. *Proc Natl Acad Sci U S A* 1989;86:7432-7436.
- 156 Steiling H, Wustefeld T, Bugnon P, Brauchle M, Fassler R, Teupser D, Thiery J, Gordon JI, Trautwein C, Werner S. Fibroblast growth factor receptor signalling is crucial for liver homeostasis and regeneration. *Oncogene* 2003;22:4380-4388.
- 157 Campbell JS, Hughes SD, Gilbertson DG, Palmer TE, Holdren MS, Haran AC, Odell MM, Bauer RL, Ren HP, Haugen HS, Yeh MM, Fausto N. Platelet-derived growth factor c induces liver fibrosis, steatosis, and hepatocellular carcinoma. *Proc Natl Acad Sci U S A* 2005;102:3389-3394.
- 158 Ren X, Carpenter A, Hogaboam C, Colletti L. Mitogenic properties of endogenous and pharmacological doses of macrophage inflammatory protein-2 after 70% hepatectomy in the mouse. *Am J Pathol* 2003;163:563-570.
- 159 Yamauchi H, Uetsuka K, Okada T, Nakayama H, Doi K. Impaired liver regeneration after partial hepatectomy in db/db mice. *Exp Toxicol Pathol* 2003;54:281-286.
- 160 Starzl TE, Porter KA, Putnam CW. Insulin, glucagon, and the control of hepatic structure, function, and capacity for regeneration. *Metabolism* 1976;25:1429-1434.
- 161 Furukawa K, Terayama H. Pattern of glycosaminoglycans and glycoproteins associated with nuclei of regenerating liver of rat. *Biochim Biophys Acta* 1979;585:575-588.
- 162 Vrochides D, Papanikolaou V, Pertoft H, Antoniadou AA, Heldin P. Biosynthesis and degradation of hyaluronan by nonparenchymal liver cells during liver regeneration. *Hepatology* 1996;23:1650-1655.
- 163 Della Fazio MA, Pettrossi V, Ayroldi E, Riccardi C, Magni MV, Servillo G. Differential expression of cd44 isoforms during liver regeneration in rats. *J Hepatol* 2001;34:555-561.
- 164 Ogata T, Okuda K, Ueno T, Saito N, Aoyagi S. Serum hyaluronan as a predictor of hepatic regeneration after hepatectomy in humans. *Eur J Clin Invest* 1999;29:780-785.
- 165 Ghahary A, Minuk GY, Luo J, Gauthier T, Murphy LJ. Effects of partial hepatectomy on hepatic insulinlike growth factor binding protein-1 expression. *Hepatology* 1992;15:1125-1131.
- 166 Weir E, Chen Q, DeFrances MC, Bell A, Taub R, Zarnegar R. Rapid induction of mrnas for liver regeneration factor and insulin-like growth factor binding protein-1 in primary cultures of rat hepatocytes by hepatocyte growth factor and epidermal growth factor. *Hepatology* 1994;20:955-960.
- 167 Leu JI, Crissey MA, Leu JP, Ciliberto G, Taub R. Interleukin-6-induced stat3 and ap-1 amplify hepatocyte nuclear factor 1-mediated transactivation of hepatic genes, an adaptive response to liver injury. *Mol Cell Biol* 2001;21:414-424.
- 168 Liu Y, Shao M, Wu Y, Yan C, Jiang S, Liu J, Dai J, Yang L, Li J, Jia W, Rui L, Liu Y. Role for the endoplasmic reticulum stress sensor ire1alpha in liver regenerative responses. *J Hepatol* 2015;62:590-598.
- 169 Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. *Proc Natl Acad Sci U S A* 2003;100:9946-9951.
- 170 Gu F, Nguyen DT, Stuble M, Dube N, Tremblay ML, Chevet E. Protein-tyrosine phosphatase 1b potentiates ire1 signaling during endoplasmic reticulum stress. *J Biol Chem* 2004;279:49689-49693.
- 171 Xue X, Piao JH, Nakajima A, Sakon-Komazawa S, Kojima Y, Mori K, Yagita H, Okumura K, Harding H, Nakano H. Tumor necrosis factor alpha (tnfalpha) induces the unfolded protein response (upr) in a reactive oxygen species (ros)-dependent fashion, and the upr counteracts ros accumulation by tnfalpha. *J Biol Chem* 2005;280:33917-33925.
- 172 Casado M, Callejas NA, Rodrigo J, Zhao X, Dey SK, Bosca L, Martin-Sanz P. Contribution of cyclooxygenase 2 to liver regeneration after partial hepatectomy. *Faseb j* 2001;15:2016-2018.
- 173 Heger M, van Golen RF, Broekgaarden M, Michel MC. The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. *Pharmacol Rev* 2014;66:222-307.

- 174 Dieter P, Hempel U, Kamionka S, Kolada A, Malessa B, Fitzke E, Tran-Thi TA. Prostaglandin e2 affects differently the release of inflammatory mediators from resident macrophages by lps and muramyl tripeptides. *Mediators Inflamm* 1999;8:295-303.
- 175 Yang Y, Zhao Z, Liu Y, Kang X, Zhang H, Meng M. Suppression of oxidative stress and improvement of liver functions in mice by ursolic acid via Ikb1-amp-activated protein kinase signaling. *J Gastroenterol Hepatol* 2015;30:609-618.
- 176 Hernanz R, Briones AM, Salas M, Alonso MJ. New roles for old pathways? A circuitous relationship between reactive oxygen species and cyclo-oxygenase in hypertension. *Clin Sci (Lond)* 2014;126:111-121.
- 177 Korbecki J, Baranowska-Bosiacka I, Gutowska I, Chlubek D. The effect of reactive oxygen species on the synthesis of prostanoids from arachidonic acid. *J Physiol Pharmacol* 2013;64:409-421.
- 178 Rescan C, Coutant A, Talarmin H, Theret N, Glaise D, Guguen-Guillouzo C, Baffet G. Mechanism in the sequential control of cell morphology and s phase entry by epidermal growth factor involves distinct mek/erk activations. *Mol Biol Cell* 2001;12:725-738.
- 179 Coutant A, Rescan C, Gilot D, Loyer P, Guguen-Guillouzo C, Baffet G. Pi3k-frap/mTOR pathway is critical for hepatocyte proliferation whereas mek/erk supports both proliferation and survival. *Hepatology* 2002;36:1079-1088.
- 180 Flodby P, Antonson P, Barlow C, Blanck A, Porsch-Hallstrom I, Xanthopoulos KG. Differential patterns of expression of three c/ebp isoforms, hnf-1, and hnf-4 after partial hepatectomy in rats. *Exp Cell Res* 1993;208:248-256.
- 181 Ramji DP, Foka P. Ccaat/enhancer-binding proteins: Structure, function and regulation. *Biochem J* 2002;365:561-575.
- 182 Diehl AM. Roles of ccaat/enhancer-binding proteins in regulation of liver regenerative growth. *J Biol Chem* 1998;273:30843-30846.
- 183 Hendricks-Taylor LR, Darlington GJ. Inhibition of cell proliferation by c/ebp alpha occurs in many cell types, does not require the presence of p53 or rb, and is not affected by large t-antigen. *Nucleic Acids Res* 1995;23:4726-4733.
- 184 Diehl AM, Johns DC, Yang S, Lin H, Yin M, Matelis LA, Lawrence JH. Adenovirus-mediated transfer of ccaat/enhancer-binding protein-alpha identifies a dominant antiproliferative role for this isoform in hepatocytes. *J Biol Chem* 1996;271:7343-7350.
- 185 Greenbaum LE, Li W, Cressman DE, Peng Y, Ciliberto G, Poli V, Taub R. Ccaat enhancer-binding protein beta is required for normal hepatocyte proliferation in mice after partial hepatectomy. *J Clin Invest* 1998;102:996-1007.
- 186 Yu X, Si J, Zhang Y, Dewille JW. Ccaat/enhancer binding protein-delta (c/ebp-delta) regulates cell growth, migration and differentiation. *Cancer Cell Int* 2010;10:48.
- 187 Hung JH, Su IJ, Lei HY, Wang HC, Lin WC, Chang WT, Huang W, Chang WC, Chang YS, Chen CC, Lai MD. Endoplasmic reticulum stress stimulates the expression of cyclooxygenase-2 through activation of nf-kappab and pp38 mitogen-activated protein kinase. *J Biol Chem* 2004;279:46384-46392.
- 188 Han J, Lee JD, Bibbs L, Ulevitch RJ. A map kinase targeted by endotoxin and hyperosmolarity in mammalian cells. *Science* 1994;265:808-811.
- 189 Lee JC, Young PR. Role of csb/p38/rk stress response kinase in lps and cytokine signaling mechanisms. *J Leukoc Biol* 1996;59:152-157.
- 190 Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ, Davis RJ. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. *J Biol Chem* 1995;270:7420-7426.
- 191 Moriguchi T, Toyoshima F, Gotoh Y, Iwamatsu A, Irie K, Mori E, Kuroyanagi N, Hagiwara M, Matsumoto K, Nishida E. Purification and identification of a major activator for p38 from osmotically shocked cells. Activation of mitogen-activated protein kinase kinase 6 by osmotic shock, tumor necrosis factor-alpha, and h2o2. *J Biol Chem* 1996;271:26981-26988.
- 192 Guyton KZ, Liu Y, Gorospe M, Xu Q, Holbrook NJ. Activation of mitogen-activated protein kinase by h2o2. Role in cell survival following oxidant injury. *J Biol Chem* 1996;271:4138-4142.

- 193 Lander HM, Jacovina AT, Davis RJ, Tauras JM. Differential activation of mitogen-activated protein kinases by nitric oxide-related species. *J Biol Chem* 1996;271:19705-19709.
- 194 Li H, Lin X. Positive and negative signaling components involved in tnfa α -induced nf-kappab activation. *Cytokine* 2008;41:1-8.
- 195 Janssen-Heininger YM, Poynter ME, Baeuerle PA. Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappa β . *Free Radic Biol Med* 2000;28:1317-1327.
- 196 Chen X, Zhao Y, Wang F, Bei Y, Xiao J, Yang C. MicroRNAs in liver regeneration. *Cell Physiol Biochem* 2015;37:615-628.
- 197 Kren BT, Wong PY, Shiota A, Zhang X, Zeng Y, Steer CJ. Polysome trafficking of transcripts and microRNAs in regenerating liver after partial hepatectomy. *Am J Physiol Gastrointest Liver Physiol* 2009;297:G1181-1192.
- 198 Raschzok N, Werner W, Sallmon H, Billecke N, Dame C, Neuhaus P, Sauer IM. Temporal expression profiles indicate a primary function for microRNA during the peak of DNA replication after rat partial hepatectomy. *Am J Physiol Regul Integr Comp Physiol* 2011;300:R1363-1372.
- 199 Chaveles I, Zaravinos A, Habeos IG, Karavias DD, Maroulis I, Spandidos DA, Karavias D. MicroRNA profiling in murine liver after partial hepatectomy. *Int J Mol Med* 2012;29:747-755.
- 200 Chen X, Murad M, Cui YY, Yao LJ, Venugopal SK, Dawson K, Wu J. MiRNA regulation of liver growth after 50% partial hepatectomy and small size grafts in rats. *Transplantation* 2011;91:293-299.
- 201 Yuan B, Dong R, Shi D, Zhou Y, Zhao Y, Miao M, Jiao B. Down-regulation of mir-23b may contribute to activation of the tgfbeta1/smad3 signalling pathway during the termination stage of liver regeneration. *FEBS Lett* 2011;585:927-934.
- 202 Lee YS, Nakahara K, Pham JW, Kim K, He Z, Sontheimer EJ, Carthew RW. Distinct roles for drosophila dicer-1 and dicer-2 in the siRNA/miRNA silencing pathways. *Cell* 2004;117:69-81.
- 203 Hand NJ, Master ZR, Le Lay J, Friedman JR. Hepatic function is preserved in the absence of mature microRNAs. *Hepatology* 2009;49:618-626.
- 204 Zhou J, Ju W, Wang D, Wu L, Zhu X, Guo Z, He X. Down-regulation of microRNA-26a promotes mouse hepatocyte proliferation during liver regeneration. *PLoS One* 2012;7:e33577.
- 205 Pan C, Chen H, Wang L, Yang S, Fu H, Zheng Y, Miao M, Jiao B. Down-regulation of mir-127 facilitates hepatocyte proliferation during rat liver regeneration. *PLoS One* 2012;7:e39151.
- 206 Zhang B, Pan X, Cobb GP, Anderson TA. MicroRNAs as oncogenes and tumor suppressors. *Dev Biol* 2007;302:1-12.
- 207 Ng R, Song G, Roll GR, Frandsen NM, Willenbring H. A microRNA-21 surge facilitates rapid cyclin d1 translation and cell cycle progression in mouse liver regeneration. *J Clin Invest* 2012;122:1097-1108.
- 208 Chen H, Sun Y, Dong R, Yang S, Pan C, Xiang D, Miao M, Jiao B. Mir-34a is upregulated during liver regeneration in rats and is associated with the suppression of hepatocyte proliferation. *PLoS One* 2011;6:e20238.
- 209 Cirera-Salinas D, Pauta M, Allen RM, Salerno AG, Ramirez CM, Chamorro-Jorganes A, Wanschel AC, Lasuncion MA, Morales-Ruiz M, Suarez Y, Baldan A, Esplugues E, Fernandez-Hernando C. Mir-33 regulates cell proliferation and cell cycle progression. *Cell Cycle* 2012;11:922-933.
- 210 Song G, Sharma AD, Roll GR, Ng R, Lee AY, Blelloch RH, Frandsen NM, Willenbring H. MicroRNAs control hepatocyte proliferation during liver regeneration. *Hepatology* 2010;51:1735-1743.
- 211 Marquez RT, Wendlandt E, Galle CS, Keck K, McCaffrey AP. MicroRNA-21 is upregulated during the proliferative phase of liver regeneration, targets p53, and inhibits nf-kappab signaling. *Am J Physiol Gastrointest Liver Physiol* 2010;298:G535-541.
- 212 Castro RE, Ferreira DM, Zhang X, Borralho PM, Sarver AL, Zeng Y, Steer CJ, Kren BT, Rodrigues CM. Identification of microRNAs during rat liver regeneration after partial hepatectomy and modulation by ursodeoxycholic acid. *Am J Physiol Gastrointest Liver Physiol* 2010;299:G887-897.

- 213 Yan-nan B, Zhao-yan Y, Li-xi L, Jiang Y, Qing-jie X, Yong Z. MicroRNA-21 accelerates hepatocyte proliferation in vitro via pi3k/akt signaling by targeting pten. *Biochem Biophys Res Commun* 2014;443:802-807.
- 214 Yuan Q, Loya K, Rani B, Mobus S, Balakrishnan A, Lamle J, Cathomen T, Vogel A, Manns MP, Ott M, Cantz T, Sharma AD. MicroRNA-221 overexpression accelerates hepatocyte proliferation during liver regeneration. *Hepatology* 2013;57:299-310.
- 215 Bei Y, Song Y, Wang F, Dimitrova-Shumkovska J, Xiang Y, Zhao Y, Liu J, Xiao J, Yang C. Mir-382 targeting pten-akt axis promotes liver regeneration. *Oncotarget* 2015
- 216 Raschzok N, Sallmon H, Dame C, Sauer IM. Liver regeneration after partial hepatectomy: Inconsistent results of expression screenings for human, mouse, and rat microRNAs. *Am J Physiol Gastrointest Liver Physiol* 2012;302:G470-471.
- 217 Shu J, Kren BT, Xia Z, Wong PY, Li L, Hanse EA, Min MX, Li B, Albrecht JH, Zeng Y, Subramanian S, Steer CJ. Genomewide microRNA down-regulation as a negative feedback mechanism in the early phases of liver regeneration. *Hepatology* 2011;54:609-619.
- 218 Schug J, McKenna LB, Walton G, Hand N, Mukherjee S, Essuman K, Shi Z, Gao Y, Markley K, Nakagawa M, Kameswaran V, Vourekas A, Friedman JR, Kaestner KH, Greenbaum LE. Dynamic recruitment of microRNAs to their mRNA targets in the regenerating liver. *BMC Genomics* 2013;14:264.
- 219 Benes V, Collier P, Kordes C, Stolte J, Rausch T, Muckentaler MU, Haussinger D, Castoldi M. Identification of cytokine-induced modulation of microRNA expression and secretion as measured by a novel microRNA specific qPCR assay. *Sci Rep* 2015;5:11590.
- 220 Barone M, Francavilla A, Polimeno L, Ierardi E, Romanelli D, Berloco P, Di Leo A, Panella C. Modulation of rat hepatocyte proliferation by bile salts: In vitro and in vivo studies. *Hepatology* 1996;23:1159-1166.
- 221 Ueda J, Chijiwa K, Nakano K, Zhao G, Tanaka M. Lack of intestinal bile results in delayed liver regeneration of normal rat liver after hepatectomy accompanied by impaired cyclin E-associated kinase activity. *Surgery* 2002;131:564-573.
- 222 Otao R, Beppu T, Isiko T, Mima K, Okabe H, Hayashi H, Masuda T, Chikamoto A, Takamori H, Baba H. External biliary drainage and liver regeneration after major hepatectomy. *Br J Surg* 2012;99:1569-1574.
- 223 Rodrigues AD, Lai Y, Cvijic ME, Elkin LL, Zvyaga T, Soars MG. Drug-induced perturbations of the bile acid pool, cholestasis, and hepatotoxicity: Mechanistic considerations beyond the direct inhibition of the bile salt export pump. *Drug Metab Dispos* 2014;42:566-574.
- 224 Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy. *Pharmacol Rev* 2014;66:948-983.
- 225 Chiang JY. Bile acids: Regulation of synthesis. *J Lipid Res* 2009;50:1955-1966.
- 226 Myant NB, Mitropoulos KA. Cholesterol 7 alpha-hydroxylase. *J Lipid Res* 1977;18:135-153.
- 227 Bjorkhem I, Einarsson K, Melone P, Hylemon P. Mechanism of intestinal formation of deoxycholic acid from cholic acid in humans: Evidence for a 3-oxo-delta 4-steroid intermediate. *J Lipid Res* 1989;30:1033-1039.
- 228 Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. *J Lipid Res* 2006;47:241-259.
- 229 Hylemon PB, Melone PD, Franklund CV, Lund E, Bjorkhem I. Mechanism of intestinal 7 alpha-dehydroxylation of cholic acid: Evidence that allo-deoxycholic acid is an inducible side-product. *J Lipid Res* 1991;32:89-96.
- 230 Visschers RG, Luyer MD, Schaap FG, Olde Damink SW, Soeters PB. The gut-liver axis. *Curr Opin Clin Nutr Metab Care* 2013;16:576-581.
- 231 Alnouti Y. Bile acid sulfation: A pathway of bile acid elimination and detoxification. *Toxicol Sci* 2009;108:225-246.
- 232 Chiang JYL. Bile acid metabolism and signaling. *Compr Physiol* 2013;3:1191-1212.
- 233 Hofmann AF. The enterohepatic circulation of bile acids in mammals: Form and functions. *Front Biosci (Landmark Ed)* 2009;14:2584-2598.

- 234 Woolbright BL, Jaeschke H. Critical factors in the assessment of cholestatic liver injury in vitro. *Methods Mol Biol* 2015;1250:363-376.
- 235 Zhang Y, Hong JY, Rockwell CE, Copple BL, Jaeschke H, Klaassen CD. Effect of bile duct ligation on bile acid composition in mouse serum and liver. *Liver Int* 2012;32:58-69.
- 236 Otsuki M. Pathophysiological role of cholecystokinin in humans. *J Gastroenterol Hepatol* 2000;15 Suppl:D71-83.
- 237 Hagenbuch B, Stieger B, Foguet M, Lubbert H, Meier PJ. Functional expression cloning and characterization of the hepatocyte na⁺/bile acid cotransport system. *Proc Natl Acad Sci U S A* 1991;88:10629-10633.
- 238 Stieger B, Hagenbuch B, Landmann L, Hochli M, Schroeder A, Meier PJ. In situ localization of the hepatocytic na⁺/taurocholate cotransporting polypeptide in rat liver. *Gastroenterology* 1994;107:1781-1787.
- 239 Meier PJ, Stieger B. Bile salt transporters. *Annu Rev Physiol* 2002;64:635-661.
- 240 Vaz FM, Paulusma CC, Huidekoper H, de Ru M, Lim C, Koster J, Ho-Mok K, Bootsma AH, Groen AK, Schaap FG, Oude Elferink RP, Waterham HR, Wanders RJ. Sodium taurocholate cotransporting polypeptide (slc10a1) deficiency: Conjugated hypercholanemia without a clear clinical phenotype. *Hepatology* 2015;61:260-267.
- 241 Slijepcevic D, Kaufman C, Wichers CG, Gilgioni EH, Lempp FA, Duijst S, de Waart DR, Elferink RP, Mier W, Stieger B, Beuers U, Urban S, van de Graaf SF. Impaired uptake of conjugated bile acids and hepatitis b virus pres1-binding in na⁽⁺⁾-taurocholate cotransporting polypeptide knockout mice. *Hepatology* 2015;62:207-219.
- 242 Boyer JL. Bile formation and secretion. *Compr Physiol* 2013;3:1035-1078.
- 243 Akita H, Suzuki H, Ito K, Kinoshita S, Sato N, Takikawa H, Sugiyama Y. Characterization of bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export pump. *Biochim Biophys Acta* 2001;1511:7-16.
- 244 Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, Kwiterovich P, Shan B, Barnes R, Hobbs HH. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent abc transporters. *Science* 2000;290:1771-1775.
- 245 Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, Mol CA, Ottenhoff R, van der Lugt NM, van Roon MA, et al. Homozygous disruption of the murine mdr2 p-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. *Cell* 1993;75:451-462.
- 246 Shneider BL. Expression cloning of the ileal sodium-dependent bile acid transporter. *J Pediatr Gastroenterol Nutr* 1995;20:233-235.
- 247 Ballatori N, Christian WV, Lee JY, Dawson PA, Soroka CJ, Boyer JL, Madejczyk MS, Li N. Ostalpha-ostbeta: A major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. *Hepatology* 2005;42:1270-1279.
- 248 Rao A, Haywood J, Craddock AL, Belinsky MG, Kruh GD, Dawson PA. The organic solute transporter alpha-beta, ostalpha-ostbeta, is essential for intestinal bile acid transport and homeostasis. *Proc Natl Acad Sci U S A* 2008;105:3891-3896.
- 249 Mangelsdorf DJ, Evans RM. The rxr heterodimers and orphan receptors. *Cell* 1995;83:841-850.
- 250 Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM. The nuclear receptor superfamily: The second decade. *Cell* 1995;83:835-839.
- 251 Chiang JY. Bile acid regulation of gene expression: Roles of nuclear hormone receptors. *Endocr Rev* 2002;23:443-463.
- 252 Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, Noonan DJ, Burka LT, McMorris T, Lamph WW, Evans RM, Weinberger C. Identification of a nuclear receptor that is activated by farnesol metabolites. *Cell* 1995;81:687-693.
- 253 Higashiyama H, Kinoshita M, Asano S. Immunolocalization of farnesoid x receptor (fxr) in mouse tissues using tissue microarray. *Acta Histochem* 2008;110:86-93.

- 254 Zhang L, Wang YD, Chen WD, Wang X, Lou G, Liu N, Lin M, Forman BM, Huang W. Promotion of liver regeneration/repair by farnesoid x receptor in both liver and intestine in mice. *Hepatology* 2012;56:2336-2343.
- 255 Gartung C, Matern S. Molecular regulation of sinusoidal liver bile acid transporters during cholestasis. *Yale J Biol Med* 1997;70:355-363.
- 256 Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ, Suchy FJ. Human bile salt export pump promoter is transactivated by the farnesoid x receptor/bile acid receptor. *J Biol Chem* 2001;276:28857-28865.
- 257 Kong B, Huang J, Zhu Y, Li G, Williams J, Shen S, Aleksunes LM, Richardson JR, Apte U, Rudnick DA, Guo GL. Fibroblast growth factor 15 deficiency impairs liver regeneration in mice. *Am J Physiol Gastrointest Liver Physiol* 2014;306:G893-902.
- 258 Xu Z, Ouyang L, Del Castillo-Olivares A, Pandak WM, Gil G. Alpha(1)-fetoprotein transcription factor (ftf)/liver receptor homolog-1 (lrh-1) is an essential lipogenic regulator. *Biochim Biophys Acta* 2010;1801:473-479.
- 259 Nitta M, Ku S, Brown C, Okamoto AY, Shan B. Cyp7a1: An orphan nuclear receptor that regulates liver-specific expression of the human cholesterol 7alpha-hydroxylase gene. *Proc Natl Acad Sci U S A* 1999;96:6660-6665.
- 260 Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, Mangelsdorf DJ. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. *Mol Cell* 2000;6:507-515.
- 261 Bohan A, Chen WS, Denson LA, Held MA, Boyer JL. Tumor necrosis factor alpha-dependent up-regulation of lrh-1 and mrp3(abcc3) reduces liver injury in obstructive cholestasis. *J Biol Chem* 2003;278:36688-36698.
- 262 Frankenberg T, Rao A, Chen F, Haywood J, Shneider BL, Dawson PA. Regulation of the mouse organic solute transporter alpha-beta, ostalpha-ostbeta, by bile acids. *Am J Physiol Gastrointest Liver Physiol* 2006;290:G912-922.
- 263 Out C, Hageman J, Bloks VW, Gerrits H, Sollewijn Gelpke MD, Bos T, Havinga R, Smit MJ, Kuipers F, Groen AK. Liver receptor homolog-1 is critical for adequate up-regulation of cyp7a1 gene transcription and bile salt synthesis during bile salt sequestration. *Hepatology* 2011;53:2075-2085.
- 264 Lee YK, Schmidt DR, Cummins CL, Choi M, Peng L, Zhang Y, Goodwin B, Hammer RE, Mangelsdorf DJ, Kliewer SA. Liver receptor homolog-1 regulates bile acid homeostasis but is not essential for feedback regulation of bile acid synthesis. *Mol Endocrinol* 2008;22:1345-1356.
- 265 Chawla A, Saez E, Evans RM. "Don't know much bile-ology". *Cell* 2000;103:1-4.
- 266 Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, Roth ME, Maloney PR, Willson TM, Kliewer SA. A regulatory cascade of the nuclear receptors fxr, shp-1, and lrh-1 represses bile acid biosynthesis. *Mol Cell* 2000;6:517-526.
- 267 Matakaki C, Magnier BC, Houten SM, Annicotte JS, Argmann C, Thomas C, Overmars H, Kulik W, Metzger D, Auwerx J, Schoonjans K. Compromised intestinal lipid absorption in mice with a liver-specific deficiency of liver receptor homolog 1. *Mol Cell Biol* 2007;27:8330-8339.
- 268 del Castillo-Olivares A, Gil G. Alpha 1-fetoprotein transcription factor is required for the expression of sterol 12alpha -hydroxylase, the specific enzyme for cholic acid synthesis. Potential role in the bile acid-mediated regulation of gene transcription. *J Biol Chem* 2000;275:17793-17799.
- 269 Freeman LA, Kennedy A, Wu J, Bark S, Remaley AT, Santamarina-Fojo S, Brewer HB, Jr. The orphan nuclear receptor lrh-1 activates the abcg5/abcg8 intergenic promoter. *J Lipid Res* 2004;45:1197-1206.
- 270 Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B. Identification of a nuclear receptor for bile acids. *Science* 1999;284:1362-1365.
- 271 Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, Lehmann JM. Bile acids: Natural ligands for an orphan nuclear receptor. *Science* 1999;284:1365-1368.
- 272 Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor fxr/bar. *Mol Cell* 1999;3:543-553.

- 273 Zollner G, Wagner M, Moustafa T, Fickert P, Silbert D, Gumhold J, Fuchsbichler A, Halilbasic E, Denk H, Marschall HU, Trauner M. Coordinated induction of bile acid detoxification and alternative elimination in mice: Role of fxr-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. *Am J Physiol Gastrointest Liver Physiol* 2006;290:G923-932.
- 274 Lee H, Zhang Y, Lee FY, Nelson SF, Gonzalez FJ, Edwards PA. Fxr regulates organic solute transporters alpha and beta in the adrenal gland, kidney, and intestine. *J Lipid Res* 2006;47:201-214.
- 275 Landrier JF, Eloranta JJ, Vavricka SR, Kullak-Ublick GA. The nuclear receptor for bile acids, fxr, transactivates human organic solute transporter-alpha and -beta genes. *Am J Physiol Gastrointest Liver Physiol* 2006;290:G476-485.
- 276 Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. *Cell Metab* 2005;2:217-225.
- 277 Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, Donahee M, Wang DY, Mansfield TA, Kliewer SA, Goodwin B, Jones SA. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. *Genes Dev* 2003;17:1581-1591.
- 278 Boyer JL, Trauner M, Mennone A, Soroka CJ, Cai SY, Moustafa T, Zollner G, Lee JY, Ballatori N. Upregulation of a basolateral fxr-dependent bile acid efflux transporter ostalpha-ostbeta in cholestasis in humans and rodents. *Am J Physiol Gastrointest Liver Physiol* 2006;290:G1124-1130.
- 279 Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tontonoz P, Kliewer S, Willson TM, Edwards PA. Regulation of multidrug resistance-associated protein 2 (abcc2) by the nuclear receptors pregnane x receptor, farnesoid x-activated receptor, and constitutive androstane receptor. *J Biol Chem* 2002;277:2908-2915.
- 280 Barbier O, Torra IP, Sirvent A, Claudel T, Blanquart C, Duran-Sandoval D, Kuipers F, Kosykh V, Fruchart JC, Staels B. Fxr induces the ugt2b4 enzyme in hepatocytes: A potential mechanism of negative feedback control of fxr activity. *Gastroenterology* 2003;124:1926-1940.
- 281 Lu Y, Heydel JM, Li X, Bratton S, Lindblom T, Radominska-Pandya A. Lithocholic acid decreases expression of ugt2b7 in caco-2 cells: A potential role for a negative farnesoid x receptor response element. *Drug Metab Dispos* 2005;33:937-946.
- 282 Chen WD, Wang YD, Zhang L, Shiah S, Wang M, Yang F, Yu D, Forman BM, Huang W. Farnesoid x receptor alleviates age-related proliferation defects in regenerating mouse livers by activating forkhead box m1b transcription. *Hepatology* 2010;51:953-962.
- 283 Wang X, Quail E, Hung NJ, Tan Y, Ye H, Costa RH. Increased levels of forkhead box m1b transcription factor in transgenic mouse hepatocytes prevent age-related proliferation defects in regenerating liver. *Proc Natl Acad Sci U S A* 2001;98:11468-11473.
- 284 Wang X, Krupczak-Hollis K, Tan Y, Dennewitz MB, Adami GR, Costa RH. Increased hepatic forkhead box m1b (foxm1b) levels in old-aged mice stimulated liver regeneration through diminished p27kip1 protein levels and increased cdc25b expression. *J Biol Chem* 2002;277:44310-44316.
- 285 Wang X, Kiyokawa H, Dennewitz MB, Costa RH. The forkhead box m1b transcription factor is essential for hepatocyte DNA replication and mitosis during mouse liver regeneration. *Proc Natl Acad Sci U S A* 2002;99:16881-16886.
- 286 Krupczak-Hollis K, Wang X, Dennewitz MB, Costa RH. Growth hormone stimulates proliferation of old-aged regenerating liver through forkhead box m1b. *Hepatology* 2003;38:1552-1562.
- 287 Wang X, Bhattacharyya D, Dennewitz MB, Kalinichenko VV, Zhou Y, Lepe R, Costa RH. Rapid hepatocyte nuclear translocation of the forkhead box m1b (foxm1b) transcription factor caused a transient increase in size of regenerating transgenic hepatocytes. *Gene Expr* 2003;11:149-162.
- 288 Major ML, Lepe R, Costa RH. Forkhead box m1b transcriptional activity requires binding of cdk-cyclin complexes for phosphorylation-dependent recruitment of p300/cbp coactivators. *Mol Cell Biol* 2004;24:2649-2661.
- 289 Mencialha AL, Binato R, Ferreira GM, Du Rocher B, Abdelhay E. Forkhead box m1 (foxm1) gene is a new stat3 transcriptional factor target and is essential for proliferation, survival and DNA repair of k562 cell line. *PLoS One* 2012;7:e48160.

- 290 Liu HX, Ly I, Hu Y, Wan YJ. Retinoic acid regulates cell cycle genes and accelerates normal mouse liver regeneration. *Biochem Pharmacol* 2014;91:256-265.
- 291 Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor pxxr is activated by compounds that regulate cyp3a4 gene expression and cause drug interactions. *J Clin Invest* 1998;102:1016-1023.
- 292 Denson LA, Auld KL, Schiek DS, McClure MH, Mangelsdorf DJ, Karpen SJ. Interleukin-1beta suppresses retinoid transactivation of two hepatic transporter genes involved in bile formation. *J Biol Chem* 2000;275:8835-8843.
- 293 Lo Sasso G, Celli N, Caboni M, Murzilli S, Salvatore L, Morgano A, Vacca M, Pagliani T, Parini P, Moschetta A. Down-regulation of the lxr transcriptome provides the requisite cholesterol levels to proliferating hepatocytes. *Hepatology* 2010;51:1334-1344.
- 294 Carnahan VE, Redinbo MR. Structure and function of the human nuclear xenobiotic receptor pxxr. *Curr Drug Metab* 2005;6:357-367.
- 295 Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, Willson TM, Koller BH, Kliewer SA. The nuclear receptor pxxr is a lithocholic acid sensor that protects against liver toxicity. *Proc Natl Acad Sci U S A* 2001;98:3369-3374.
- 296 Shizu R, Abe T, Benoki S, Takahashi M, Kodama S, Miyata M, Matsuzawa A, Yoshinari K. Pxxr stimulates growth factor-mediated hepatocyte proliferation by cross-talk with the foxo transcription factor. *Biochem J* 2016;473:257-266.
- 297 Pascussi JM, Gerbal-Chaloin S, Pichard-Garcia L, Daujat M, Fabre JM, Maurel P, Vilarem MJ. Interleukin-6 negatively regulates the expression of pregnane x receptor and constitutively activated receptor in primary human hepatocytes. *Biochem Biophys Res Commun* 2000;274:707-713.
- 298 Staudinger J, Liu Y, Madan A, Habeebu S, Klaassen CD. Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane x receptor. *Drug Metab Dispos* 2001;29:1467-1472.
- 299 Li CY, Renaud HJ, Klaassen CD, Cui JY. Age-specific regulation of drug-processing genes in mouse liver by ligands of xenobiotic-sensing transcription factors. *Drug Metab Dispos* 2015
- 300 Zhou J, Zhai Y, Mu Y, Gong H, Uppal H, Toma D, Ren S, Evans RM, Xie W. A novel pregnane x receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway. *J Biol Chem* 2006;281:15013-15020.
- 301 Zhou J, Febbraio M, Wada T, Zhai Y, Kuruba R, He J, Lee JH, Khadem S, Ren S, Li S, Silverstein RL, Xie W. Hepatic fatty acid transporter cd36 is a common target of lxr, pxxr, and ppargamma in promoting steatosis. *Gastroenterology* 2008;134:556-567.
- 302 Kliewer SA, Willson TM. Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane x receptor. *J Lipid Res* 2002;43:359-364.
- 303 Zhang J, Huang W, Qatanani M, Evans RM, Moore DD. The constitutive androstane receptor and pregnane x receptor function coordinately to prevent bile acid-induced hepatotoxicity. *J Biol Chem* 2004;279:49517-49522.
- 304 Columbano A, Ledda-Columbano GM, Pibiri M, Cossu C, Menegazzi M, Moore DD, Huang W, Tian J, Locker J. Gadd45beta is induced through a car-dependent, tnfr-independent pathway in murine liver hyperplasia. *Hepatology* 2005;42:1118-1126.
- 305 Yang H, Wang H. Signaling control of the constitutive androstane receptor (car). *Protein Cell* 2014;5:113-123.
- 306 Gerbal-Chaloin S, Daujat M, Pascussi JM, Pichard-Garcia L, Vilarem MJ, Maurel P. Transcriptional regulation of cyp2c9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. *J Biol Chem* 2002;277:209-217.
- 307 Waxman DJ. P450 gene induction by structurally diverse xenochemicals: Central role of nuclear receptors car, pxxr, and ppar. *Arch Biochem Biophys* 1999;369:11-23.
- 308 Ueda A, Hamadeh HK, Webb HK, Yamamoto Y, Sueyoshi T, Afshari CA, Lehmann JM, Negishi M. Diverse roles of the nuclear orphan receptor car in regulating hepatic genes in response to phenobarbital. *Mol Pharmacol* 2002;61:1-6.

- 309 Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P, Negishi M. The repressed nuclear receptor car responds to phenobarbital in activating the human cyp2b6 gene. *J Biol Chem* 1999;274:6043-6046.
- 310 Goodwin B, Hodgson E, D'Costa DJ, Robertson GR, Liddle C. Transcriptional regulation of the human cyp3a4 gene by the constitutive androstane receptor. *Mol Pharmacol* 2002;62:359-365.
- 311 Robertson GR, Field J, Goodwin B, Bierach S, Tran M, Lehnert A, Liddle C. Transgenic mouse models of human cyp3a4 gene regulation. *Mol Pharmacol* 2003;64:42-50.
- 312 Assem M, Schuetz EG, Leggas M, Sun D, Yasuda K, Reid G, Zelcer N, Adachi M, Strom S, Evans RM, Moore DD, Borst P, Schuetz JD. Interactions between hepatic mrp4 and sult2a as revealed by the constitutive androstane receptor and mrp4 knockout mice. *J Biol Chem* 2004;279:22250-22257.
- 313 Yueh MF, Mellon PL, Tukey RH. Inhibition of human ugt2b7 gene expression in transgenic mice by the constitutive androstane receptor. *Mol Pharmacol* 2011;79:1053-1060.
- 314 Wada T, Gao J, Xie W. Pxr and car in energy metabolism. *Trends Endocrinol Metab* 2009;20:273-279.
- 315 Yi YW, Kim D, Jung N, Hong SS, Lee HS, Bae I. Gadd45 family proteins are coactivators of nuclear hormone receptors. *Biochem Biophys Res Commun* 2000;272:193-198.
- 316 Yamamoto Y, Negishi M. The antiapoptotic factor growth arrest and DNA-damage-inducible 45 beta regulates the nuclear receptor constitutive active/androstane receptor-mediated transcription. *Drug Metab Dispos* 2008;36:1189-1193.
- 317 Liebermann DA, Hoffman B. Gadd45 in the response of hematopoietic cells to genotoxic stress. *Blood Cells Mol Dis* 2007;39:329-335.
- 318 Lu B, Ferrandino AF, Flavell RA. Gadd45beta is important for perpetuating cognate and inflammatory signals in t cells. *Nat Immunol* 2004;5:38-44.
- 319 Wollam J, Antebi A. Sterol regulation of metabolism, homeostasis, and development. *Annu Rev Biochem* 2011;80:885-916.
- 320 Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor lxr alpha. *Nature* 1996;383:728-731.
- 321 Yu L, Gupta S, Xu F, Liverman AD, Moschetta A, Mangelsdorf DJ, Repa JJ, Hobbs HH, Cohen JC. Expression of abcg5 and abcg8 is required for regulation of biliary cholesterol secretion. *J Biol Chem* 2005;280:8742-8747.
- 322 Kazantseva YA, Yarushkin AA, Mostovich LA, Pustyl'nyak YA, Pustyl'nyak VO. Xenosensor car mediates down-regulation of mir-122 and up-regulation of mir-122 targets in the liver. *Toxicol Appl Pharmacol* 2015;288:26-32.
- 323 Crestani M, Sadeghpour A, Stroup D, Galli G, Chiang JY. Transcriptional activation of the cholesterol 7alpha-hydroxylase gene (cyp7a) by nuclear hormone receptors. *J Lipid Res* 1998;39:2192-2200.
- 324 De Fabiani E, Mitro N, Anzulovich AC, Pinelli A, Galli G, Crestani M. The negative effects of bile acids and tumor necrosis factor-alpha on the transcription of cholesterol 7alpha-hydroxylase gene (cyp7a1) converge to hepatic nuclear factor-4: A novel mechanism of feedback regulation of bile acid synthesis mediated by nuclear receptors. *J Biol Chem* 2001;276:30708-30716.
- 325 Yang Y, Zhang M, Eggertsen G, Chiang JY. On the mechanism of bile acid inhibition of rat sterol 12alpha-hydroxylase gene (cyp8b1) transcription: Roles of alpha-fetoprotein transcription factor and hepatocyte nuclear factor 4alpha. *Biochim Biophys Acta* 2002;1583:63-73.
- 326 Zhang M, Chiang JY. Transcriptional regulation of the human sterol 12alpha-hydroxylase gene (cyp8b1): Roles of hepatocyte nuclear factor 4alpha in mediating bile acid repression. *J Biol Chem* 2001;276:41690-41699.
- 327 Chen W, Chiang JY. Regulation of human sterol 27-hydroxylase gene (cyp27a1) by bile acids and hepatocyte nuclear factor 4alpha (hnf4alpha). *Gene* 2003;313:71-82.
- 328 Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ. Hepatocyte nuclear factor 4alpha (nuclear receptor 2a1) is essential for maintenance of hepatic gene expression and lipid homeostasis. *Mol Cell Biol* 2001;21:1393-1403.

- 329 Nagaki M, Moriwaki H. Transcription factor hnf and hepatocyte differentiation. *Hepatol Res* 2008;38:961-969.
- 330 Weerachayaphorn J, Cai SY, Soroka CJ, Boyer JL. Nuclear factor erythroid 2-related factor 2 is a positive regulator of human bile salt export pump expression. *Hepatology* 2009;50:1588-1596.
- 331 Weerachayaphorn J, Mennone A, Soroka CJ, Harry K, Hagey LR, Kensler TW, Boyer JL. Nuclear factor-e2-related factor 2 is a major determinant of bile acid homeostasis in the liver and intestine. *Am J Physiol Gastrointest Liver Physiol* 2012;302:G925-936.
- 332 Barbier O, Duran-Sandoval D, Pineda-Torra I, Kosykh V, Fruchart JC, Staels B. Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating udp-glucuronosyltransferase 2b4 enzyme. *J Biol Chem* 2003;278:32852-32860.
- 333 Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR, Mangelsdorf DJ. Vitamin d receptor as an intestinal bile acid sensor. *Science* 2002;296:1313-1316.
- 334 Rust C, Wild N, Bernt C, Vennegeerts T, Wimmer R, Beuers U. Bile acid-induced apoptosis in hepatocytes is caspase-6-dependent. *J Biol Chem* 2009;284:2908-2916.
- 335 Zucchini-Pascal N, de Sousa G, Pizzol J, Rahmani R. Pregnane x receptor activation protects rat hepatocytes against deoxycholic acid-induced apoptosis. *Liver Int* 2010;30:284-297.
- 336 Olthof PB, Coelen RJ, Wiggers JK, Besselink MG, Busch OR, van Gulik TM. External biliary drainage following major liver resection for perihilar cholangiocarcinoma: Impact on development of liver failure and biliary leakage. *HPB (Oxford)* 2016;18:348-353.
- 337 Ortiz DF, Li S, Iyer R, Zhang X, Novikoff P, Arias IM. Mrp3, a new atp-binding cassette protein localized to the canalicular domain of the hepatocyte. *Am J Physiol* 1999;276:G1493-1500.
- 338 Hirohashi T, Suzuki H, Takikawa H, Sugiyama Y. Atp-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (mrp3). *J Biol Chem* 2000;275:2905-2910.
- 339 Fernandez-Barrena MG, Monte MJ, Latasa MU, Uriarte I, Vicente E, Chang HC, Rodriguez-Ortigosa CM, Elferink RO, Berasain C, Marin JJ, Prieto J, Avila MA. Lack of abcc3 expression impairs bile-acid induced liver growth and delays hepatic regeneration after partial hepatectomy in mice. *J Hepatol* 2012;56:367-373.
- 340 Holmberg-Betsholtz I, Lund E, Bjorkhem I, Wikvall K. Sterol 27-hydroxylase in bile acid biosynthesis. Mechanism of oxidation of 5 beta-cholestane-3 alpha,7 alpha,12 alpha,27-tetrol into 3 alpha,7 alpha,12 alpha-trihydroxy-5 beta-cholestanoic acid. *J Biol Chem* 1993;268:11079-11085.
- 341 Meng Z, Liu N, Fu X, Wang X, Wang YD, Chen WD, Zhang L, Forman BM, Huang W. Insufficient bile acid signaling impairs liver repair in cyp27(-/-) mice. *J Hepatol* 2011;55:885-895.
- 342 Dawson PA, Haywood J, Craddock AL, Wilson M, Tietjen M, Kluckman K, Maeda N, Parks JS. Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. *J Biol Chem* 2003;278:33920-33927.
- 343 Oelkers P, Kirby LC, Heubi JE, Dawson PA. Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (slc10a2). *J Clin Invest* 1997;99:1880-1887.
- 344 Shaulian E, Karin M. Ap-1 in cell proliferation and survival. *Oncogene* 2001;20:2390-2400.
- 345 Shaulian E, Karin M. Ap-1 as a regulator of cell life and death. *Nat Cell Biol* 2002;4:E131-136.
- 346 Chen WD, Wang YD, Meng Z, Zhang L, Huang W. Nuclear bile acid receptor fxr in the hepatic regeneration. *Biochim Biophys Acta* 2011;1812:888-892.
- 347 Yang X, Guo M, Wan YJ. Deregulation of growth factor, circadian clock, and cell cycle signaling in regenerating hepatocyte rxralpha-deficient mouse livers. *Am J Pathol* 2010;176:733-743.
- 348 Imai T, Jiang M, Kastner P, Chambon P, Metzger D. Selective ablation of retinoid x receptor alpha in hepatocytes impairs their lifespan and regenerative capacity. *Proc Natl Acad Sci U S A* 2001;98:4581-4586.
- 349 Dai G, He L, Bu P, Wan YJ. Pregnane x receptor is essential for normal progression of liver regeneration. *Hepatology* 2008;47:1277-1287.
- 350 Tien ES, Matsui K, Moore R, Negishi M. The nuclear receptor constitutively active/androstane receptor regulates type 1 deiodinase and thyroid hormone activity in the regenerating mouse liver. *J Pharmacol Exp Ther* 2007;320:307-313.

- 351 Yuan X, Yan S, Zhao J, Shi D, Yuan B, Dai W, Jiao B, Zhang W, Miao M. Lipid metabolism and peroxisome proliferator-activated receptor signaling pathways participate in late-phase liver regeneration. *J Proteome Res* 2011;10:1179-1190.
- 352 Anderson SP, Yoon L, Richard EB, Dunn CS, Cattley RC, Corton JC. Delayed liver regeneration in peroxisome proliferator-activated receptor- α -null mice. *Hepatology* 2002;36:544-554.
- 353 Yamamoto Y, Ono T, Dhar DK, Yamanoi A, Tachibana M, Tanaka T, Nagasue N. Role of peroxisome proliferator-activated receptor- γ (ppargamma) during liver regeneration in rats. *J Gastroenterol Hepatol* 2008;23:930-937.
- 354 Gazit V, Huang J, Weymann A, Rudnick DA. Analysis of the role of hepatic ppargamma expression during mouse liver regeneration. *Hepatology* 2012;56:1489-1498.
- 355 Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. *Biochim Biophys Acta* 2007;1773:283-308.
- 356 Barchetta I, Carotti S, Labbadia G, Gentilucci UV, Muda AO, Angelico F, Silecchia G, Leonetti F, Fraioli A, Picardi A, Morini S, Cavallo MG. Liver vitamin d receptor, cyp2r1, and cyp27a1 expression: Relationship with liver histology and vitamin d3 levels in patients with nonalcoholic steatohepatitis or hepatitis c virus. *Hepatology* 2012;56:2180-2187.
- 357 Schmidt DR, Holmstrom SR, Fon Tacer K, Bookout AL, Kliewer SA, Mangelsdorf DJ. Regulation of bile acid synthesis by fat-soluble vitamins a and d. *J Biol Chem* 2010;285:14486-14494.
- 358 Echchgadda I, Song CS, Roy AK, Chatterjee B. Dehydroepiandrosterone sulfotransferase is a target for transcriptional induction by the vitamin d receptor. *Mol Pharmacol* 2004;65:720-729.
- 359 Song CS, Echchgadda I, Seo YK, Oh T, Kim S, Kim SA, Cho S, Shi L, Chatterjee B. An essential role of the caat/enhancer binding protein- α in the vitamin d-induced expression of the human steroid/bile acid-sulfotransferase (sult2a1). *Mol Endocrinol* 2006;20:795-808.
- 360 Chatterjee B, Echchgadda I, Song CS. Vitamin d receptor regulation of the steroid/bile acid sulfotransferase sult2a1. *Methods Enzymol* 2005;400:165-191.
- 361 Chow EC, Maeng HJ, Liu S, Khan AA, Groothuis GM, Pang KS. 1 α ,25-dihydroxyvitamin d(3) triggered vitamin d receptor and farnesoid x receptor-like effects in rat intestine and liver in vivo. *Biopharm Drug Dispos* 2009;30:457-475.
- 362 Columbano A, Ledda-Columbano GM, Pibiri M, Concas D, Reddy JK, Rao MS. Peroxisome proliferator-activated receptor- α mice show enhanced hepatocyte proliferation in response to the hepatomitogen 1,4-bis [2-(3,5-dichloropyridyloxy)] benzene, a ligand of constitutive androstane receptor. *Hepatology* 2001;34:262-266.
- 363 Wei P, Zhang J, Egan-Hafley M, Liang S, Moore DD. The nuclear receptor car mediates specific xenobiotic induction of drug metabolism. *Nature* 2000;407:920-923.
- 364 Claudel T, Staels B, Kuipers F. The farnesoid x receptor: A molecular link between bile acid and lipid and glucose metabolism. *Arterioscler Thromb Vasc Biol* 2005;25:2020-2030.
- 365 Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. *EMBO J* 2006;25:1419-1425.
- 366 Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. *Physiol Rev* 2009;89:147-191.
- 367 Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. *J Hepatol* 2012;56:952-964.
- 368 Trauner M, Halilbasic E. Nuclear receptors as new perspective for the management of liver diseases. *Gastroenterology* 2011;140:1120-1125 e1121-1112.
- 369 Cariou B, Staels B. Fxr: A promising target for the metabolic syndrome? *Trends Pharmacol Sci* 2007;28:236-243.
- 370 Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor fxr/bar impairs bile acid and lipid homeostasis. *Cell* 2000;102:731-744.
- 371 Edwards PA, Kast HR, Anisfeld AM. Bareing it all: The adoption of lxr and fxr and their roles in lipid homeostasis. *J Lipid Res* 2002;43:2-12.

- 372 Zhang Y, Castellani LW, Sinal CJ, Gonzalez FJ, Edwards PA. Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (pgc-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor fxr. *Genes Dev* 2004;18:157-169.
- 373 Garcia-Rodriguez JL, Barbier-Torres L, Fernandez-Alvarez S, Gutierrez-de Juan V, Monte MJ, Halilbasic E, Herranz D, Alvarez L, Aspichueta P, Marin JJ, Trauner M, Mato JM, Serrano M, Beraza N, Martinez-Chantar ML. Sirt1 controls liver regeneration by regulating bile acid metabolism through farnesoid x receptor and mammalian target of rapamycin signaling. *Hepatology* 2014;59:1972-1983.
- 374 Lees E, Faha B, Dulic V, Reed SI, Harlow E. Cyclin e/cdk2 and cyclin a/cdk2 kinases associate with p107 and e2f in a temporally distinct manner. *Genes Dev* 1992;6:1874-1885.
- 375 Rizzardi LF, Coleman KE, Varma D, Matson JP, Oh S, Cook JG. Cdk1-dependent inhibition of the e3 ubiquitin ligase cbl4cdt2 ensures robust transition from s phase to mitosis. *J Biol Chem* 2015;290:556-567.
- 376 Harbour JW, Dean DC. The rb/e2f pathway: Expanding roles and emerging paradigms. *Genes Dev* 2000;14:2393-2409.
- 377 Ishida S, Huang E, Zuzan H, Spang R, Leone G, West M, Nevins JR. Role for e2f in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. *Mol Cell Biol* 2001;21:4684-4699.
- 378 Jaime M, Pujol MJ, Serratosa J, Pantoja C, Canela N, Casanovas O, Serrano M, Agell N, Bachs O. The p21(cip1) protein, a cyclin inhibitor, regulates the levels and the intracellular localization of cdc25a in mice regenerating livers. *Hepatology* 2002;35:1063-1071.
- 379 Nilsson I, Hoffmann I. Cell cycle regulation by the cdc25 phosphatase family. *Prog Cell Cycle Res* 2000;4:107-114.
- 380 Sebastian B, Kakizuka A, Hunter T. Cdc25m2 activation of cyclin-dependent kinases by dephosphorylation of threonine-14 and tyrosine-15. *Proc Natl Acad Sci U S A* 1993;90:3521-3524.
- 381 Trembley JH, Ebbert JO, Kren BT, Steer CJ. Differential regulation of cyclin b1 rna and protein expression during hepatocyte growth in vivo. *Cell Growth Differ* 1996;7:903-916.
- 382 Savkur RS, Bramlett KS, Michael LF, Burris TP. Regulation of pyruvate dehydrogenase kinase expression by the farnesoid x receptor. *Biochem Biophys Res Commun* 2005;329:391-396.
- 383 Jeoung NH, Wu P, Joshi MA, Jaskiewicz J, Bock CB, Depaoli-Roach AA, Harris RA. Role of pyruvate dehydrogenase kinase isoenzyme 4 (pdhk4) in glucose homeostasis during starvation. *Biochem J* 2006;397:417-425.
- 384 Roche TE, Hiromasa Y. Pyruvate dehydrogenase kinase regulatory mechanisms and inhibition in treating diabetes, heart ischemia, and cancer. *Cell Mol Life Sci* 2007;64:830-849.
- 385 Vander Heiden MG, Cantley LC, Thompson CB. Understanding the warburg effect: The metabolic requirements of cell proliferation. *Science* 2009;324:1029-1033.
- 386 Hamanaka RB, Chandel NS. Targeting glucose metabolism for cancer therapy. *J Exp Med* 2012;209:211-215.
- 387 Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL, Kafri R, Kirschner MW, Clish CB, Mootha VK. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. *Science* 2012;336:1040-1044.
- 388 Locasale JW. Serine, glycine and one-carbon units: Cancer metabolism in full circle. *Nat Rev Cancer* 2013;13:572-583.
- 389 Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21: From feast to famine. *Genes Dev* 2012;26:312-324.
- 390 Lin BC, Wang M, Blackmore C, Desnoyers LR. Liver-specific activities of fgf19 require klotho beta. *J Biol Chem* 2007;282:27277-27284.
- 391 Wu X, Ge H, Gupte J, Weizmann J, Shimamoto G, Stevens J, Hawkins N, Lemon B, Shen W, Xu J, Veniant MM, Li YS, Lindberg R, Chen JL, Tian H, Li Y. Co-receptor requirements for fibroblast growth factor-19 signaling. *J Biol Chem* 2007;282:29069-29072.
- 392 Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, Kuro-o M. Tissue-specific expression of betaklotho and fibroblast growth factor (fgf)

- receptor isoforms determines metabolic activity of fgf19 and fgf21. *J Biol Chem* 2007;282:26687-26695.
- 393 Wu X, Lemon B, Li X, Gupte J, Weizsmann J, Stevens J, Hawkins N, Shen W, Lindberg R, Chen JL, Tian H, Li Y. C-terminal tail of fgf19 determines its specificity toward klotho co-receptors. *J Biol Chem* 2008;283:33304-33309.
- 394 Wu X, Ge H, Lemon B, Vonderfecht S, Baribault H, Weizsmann J, Gupte J, Gardner J, Lindberg R, Wang Z, Li Y. Separating mitogenic and metabolic activities of fibroblast growth factor 19 (fgf19). *Proc Natl Acad Sci U S A* 2010;107:14158-14163.
- 395 Moldovan GL, Pfander B, Jentsch S. PcnA, the maestro of the replication fork. *Cell* 2007;129:665-679.
- 396 Kong B, Wang L, Chiang JY, Zhang Y, Klaassen CD, Guo GL. Mechanism of tissue-specific farnesoid x receptor in suppressing the expression of genes in bile-acid synthesis in mice. *Hepatology* 2012;56:1034-1043.
- 397 Cressman DE, Diamond RH, Taub R. Rapid activation of the stat3 transcription complex in liver regeneration. *Hepatology* 1995;21:1443-1449.
- 398 Li W, Liang X, Kellendonk C, Poli V, Taub R. Stat3 contributes to the mitogenic response of hepatocytes during liver regeneration. *J Biol Chem* 2002;277:28411-28417.
- 399 Kim JH, Kim JE, Liu HY, Cao W, Chen J. Regulation of interleukin-6-induced hepatic insulin resistance by mammalian target of rapamycin through the stat3-socs3 pathway. *J Biol Chem* 2008;283:708-715.
- 400 Duckett CS, Perkins ND, Kowalik TF, Schmid RM, Huang ES, Baldwin AS, Jr., Nabel GJ. Dimerization of nf-kb2 with rela(p65) regulates DNA binding, transcriptional activation, and inhibition by an i kappa b-alpha (mad-3). *Mol Cell Biol* 1993;13:1315-1322.
- 401 Yu C, Wang F, Kan M, Jin C, Jones RB, Weinstein M, Deng CX, McKeethan WL. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor fgfr4. *J Biol Chem* 2000;275:15482-15489.
- 402 Ijssennagger N, Janssen AW, Milona A, Ramos Pittol JM, Hollman DA, Mokry M, Betzel B, Berends FJ, Janssen IM, van Mil SW, Kersten S. Gene expression profiling in human precision cut liver slices upon treatment with the fxr agonist obeticholic acid. *J Hepatol* 2016
- 403 Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D. Efficacy and safety of the farnesoid x receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. *Gastroenterology* 2013;145:574-582 e571.
- 404 Li J, Pircher PC, Schulman IG, Westin SK. Regulation of complement c3 expression by the bile acid receptor fxr. *J Biol Chem* 2005;280:7427-7434.
- 405 Schaap FG, van der Gaag NA, Gouma DJ, Jansen PL. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. *Hepatology* 2009;49:1228-1235.
- 406 Dawson MI, Xia Z. The retinoid x receptors and their ligands. *Biochim Biophys Acta* 2012;1821:21-56.
- 407 Wu Y, Cai Y, Aguilo J, Dai T, Ao Y, Wan YJ. Rxralpha mRNA expression is associated with cell proliferation and cell cycle regulation in hep3b cell. *Exp Mol Pathol* 2004;76:24-28.
- 408 Standeven AM, Escobar M, Beard RL, Yuan YD, Chandraratna RA. Mitogenic effect of retinoid x receptor agonists in rat liver. *Biochem Pharmacol* 1997;54:517-524.
- 409 Ledda-Columbano GM, Pibiri M, Molotzu F, Cossu C, Sanna L, Simbula G, Perra A, Columbano A. Induction of hepatocyte proliferation by retinoic acid. *Carcinogenesis* 2004;25:2061-2066.
- 410 Sturm J, Keese M, Zhang H, Bonninghoff R, Magdeburg R, Vajkoczy P, Dono R, Zeller R, Gretz N. Liver regeneration in fgf-2-deficient mice: Vegf acts as potential functional substitute for fgf-2. *Liver Int* 2004;24:161-168.
- 411 Shmarakov IO, Jiang H, Yang KJ, Goldberg IJ, Blaner WS. Hepatic retinoid stores are required for normal liver regeneration. *J Lipid Res* 2013;54:893-908.

- 412 Anderson SP, Dunn C, Laughter A, Yoon L, Swanson C, Stulnig TM, Steffensen KR, Chandraratna RA, Gustafsson JA, Corton JC. Overlapping transcriptional programs regulated by the nuclear receptors peroxisome proliferator-activated receptor alpha, retinoid x receptor, and liver x receptor in mouse liver. *Mol Pharmacol* 2004;66:1440-1452.
- 413 Iyer M, Reschly EJ, Krasowski MD. Functional evolution of the pregnane x receptor. *Expert Opin Drug Metab Toxicol* 2006;2:381-397.
- 414 Xie W, Radomska-Pandya A, Shi Y, Simon CM, Nelson MC, Ong ES, Waxman DJ, Evans RM. An essential role for nuclear receptors sxr/pxr in detoxification of cholestatic bile acids. *Proc Natl Acad Sci U S A* 2001;98:3375-3380.
- 415 Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. *Cell* 1999;96:857-868.
- 416 Frank C, Gonzalez MM, Oinonen C, Dunlop TW, Carlberg C. Characterization of DNA complexes formed by the nuclear receptor constitutive androstane receptor. *J Biol Chem* 2003;278:43299-43310.
- 417 Blanco-Bose WE, Murphy MJ, Ehninger A, Offner S, Dubey C, Huang W, Moore DD, Trumpp A. C-myc and its target foxm1 are critical downstream effectors of constitutive androstane receptor (car) mediated direct liver hyperplasia. *Hepatology* 2008;48:1302-1311.
- 418 Donthamsetty S, Bhawe VS, Kliment CS, Bowen WC, Mars WM, Bell AW, Stewart RE, Orr A, Wu C, Michalopoulos GK. Excessive hepatomegaly of mice with hepatocyte-targeted elimination of integrin linked kinase following treatment with 1,4-bis [2-(3,5-dichloropyridyloxy)] benzene. *Hepatology* 2011;53:587-595.
- 419 Locker J, Tian J, Carver R, Concas D, Cossu C, Ledda-Columbano GM, Columbano A. A common set of immediate-early response genes in liver regeneration and hyperplasia. *Hepatology* 2003;38:314-325.
- 420 Tian J, Huang H, Hoffman B, Liebermann DA, Ledda-Columbano GM, Columbano A, Locker J. Gadd45beta is an inducible coactivator of transcription that facilitates rapid liver growth in mice. *J Clin Invest* 2011;121:4491-4502.
- 421 Chen T, Chen Q, Xu Y, Zhou Q, Zhu J, Zhang H, Wu Q, Xu J, Yu C. Src-3 is required for car-regulated hepatocyte proliferation and drug metabolism. *J Hepatol* 2012;56:210-217.
- 422 Suen CS, Berrodin TJ, Mastroeni R, Cheskis BJ, Lyttle CR, Frail DE. A transcriptional coactivator, steroid receptor coactivator-3, selectively augments steroid receptor transcriptional activity. *J Biol Chem* 1998;273:27645-27653.
- 423 Dong B, Lee JS, Park YY, Yang F, Xu G, Huang W, Finegold MJ, Moore DD. Activating car and beta-catenin induces uncontrolled liver growth and tumorigenesis. *Nat Commun* 2015;6:5944.
- 424 Kakehashi A, Hagiwara A, Imai N, Nagano K, Nishimaki F, Banton M, Wei M, Fukushima S, Wanibuchi H. Mode of action of ethyl tertiary-butyl ether hepatotumorigenicity in the rat: Evidence for a role of oxidative stress via activation of car, pxxr and ppar signaling pathways. *Toxicol Appl Pharmacol* 2013;273:390-400.
- 425 Bockhorn M, Frilling A, Benko T, Best J, Sheu SY, Trippler M, Schlaak JF, Broelsch CE. Tri-iodothyronine as a stimulator of liver regeneration after partial and subtotal hepatectomy. *Eur Surg Res* 2007;39:58-63.
- 426 Francavilla A, Carr BI, Azzarone A, Polimeno L, Wang Z, Van Thiel DH, Subbotin V, Prelich JG, Starzl TE. Hepatocyte proliferation and gene expression induced by triiodothyronine in vivo and in vitro. *Hepatology* 1994;20:1237-1241.
- 427 Fanti M, Singh S, Ledda-Columbano GM, Columbano A, Monga SP. Tri-iodothyronine induces hepatocyte proliferation by protein kinase a-dependent beta-catenin activation in rodents. *Hepatology* 2014;59:2309-2320.
- 428 Ulven SM, Dalen KT, Gustafsson JA, Nebb HI. Lxr is crucial in lipid metabolism. *Prostaglandins Leukot Essent Fatty Acids* 2005;73:59-63.
- 429 Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ. Lxr, a nuclear receptor that defines a distinct retinoid response pathway. *Genes Dev* 1995;9:1033-1045.

- 430 Miyata KS, McCaw SE, Meertens LM, Patel HV, Rachubinski RA, Capone JP. Receptor-interacting protein 140 interacts with and inhibits transactivation by, peroxisome proliferator-activated receptor alpha and liver-x-receptor alpha. *Mol Cell Endocrinol* 1998;146:69-76.
- 431 Osabe M, Negishi M. Active erk1/2 protein interacts with the phosphorylated nuclear constitutive active/androstane receptor (car; nr1i3), repressing dephosphorylation and sequestering car in the cytoplasm. *J Biol Chem* 2011;286:35763-35769.
- 432 Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, Fukusumi S, Habata Y, Itoh T, Shintani Y, Hinuma S, Fujisawa Y, Fujino M. A g protein-coupled receptor responsive to bile acids. *J Biol Chem* 2003;278:9435-9440.
- 433 Watanabe M, Houten SM, Matak C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, Schoonjans K, Bianco AC, Auwerx J. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. *Nature* 2006;439:484-489.
- 434 Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Matak C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K. Tgr5-mediated bile acid sensing controls glucose homeostasis. *Cell Metab* 2009;10:167-177.
- 435 Pols TW, Noriega LG, Nomura M, Auwerx J, Schoonjans K. The bile acid membrane receptor tgr5: A valuable metabolic target. *Dig Dis* 2011;29:37-44.
- 436 Wang YD, Chen WD, Yu D, Forman BM, Huang W. The g-protein-coupled bile acid receptor, gpbar1 (tgr5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated b cells (nf-kappab) in mice. *Hepatology* 2011;54:1421-1432.
- 437 Keitel V, Donner M, Winandy S, Kubitz R, Haussinger D. Expression and function of the bile acid receptor tgr5 in kupffer cells. *Biochem Biophys Res Commun* 2008;372:78-84.
- 438 Keitel V, Cupisti K, Ullmer C, Knoefel WT, Kubitz R, Haussinger D. The membrane-bound bile acid receptor tgr5 is localized in the epithelium of human gallbladders. *Hepatology* 2009;50:861-870.
- 439 Keitel V, Ullmer C, Haussinger D. The membrane-bound bile acid receptor tgr5 (gpbar-1) is localized in the primary cilium of cholangiocytes. *Biol Chem* 2010;391:785-789.
- 440 Keitel V, Reinehr R, Gatsios P, Rupprecht C, Gorg B, Selbach O, Haussinger D, Kubitz R. The g-protein coupled bile salt receptor tgr5 is expressed in liver sinusoidal endothelial cells. *Hepatology* 2007;45:695-704.
- 441 Reich M, Deutschmann K, Sommerfeld A, Klindt C, Kluge S, Kubitz R, Ullmer C, Knoefel WT, Herebian D, Mayatepek E, Haussinger D, Keitel V. Tgr5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro. *Gut* 2016;65:487-501.
- 442 de Graaf W, Hausler S, Heger M, van Ginhoven TM, van Cappellen G, Bennink RJ, Kullak-Ublick GA, Hesselmann R, van Gulik TM, Stieger B. Transporters involved in the hepatic uptake of (99m)tc-mebrofenin and indocyanine green. *J Hepatol* 2011;54:738-745.
- 443 de Graaf W, Bennink RJ, Heger M, Maas A, de Bruin K, van Gulik TM. Quantitative assessment of hepatic function during liver regeneration in a standardized rat model. *J Nucl Med* 2011;52:294-302.
- 444 Stieger B, Heger M, de Graaf W, Paumgartner G, van Gulik T. The emerging role of transport systems in liver function tests. *Eur J Pharmacol* 2012;675:1-5.
- 445 Handschin C, Meyer UA. Induction of drug metabolism: The role of nuclear receptors. *Pharmacol Rev* 2003;55:649-673.
- 446 Bodin K, Lindbom U, Diczfalusy U. Novel pathways of bile acid metabolism involving cyp3a4. *Biochim Biophys Acta* 2005;1687:84-93.
- 447 Araya Z, Wikvall K. 6alpha-hydroxylation of taurochenodeoxycholic acid and lithocholic acid by cyp3a4 in human liver microsomes. *Biochim Biophys Acta* 1999;1438:47-54.
- 448 Bremmelgaard A, Sjoval J. Hydroxylation of cholic, chenodeoxycholic, and deoxycholic acids in patients with intrahepatic cholestasis. *J Lipid Res* 1980;21:1072-1081.
- 449 Gnerre C, Blattler S, Kaufmann MR, Looser R, Meyer UA. Regulation of cyp3a4 by the bile acid receptor fxr: Evidence for functional binding sites in the cyp3a4 gene. *Pharmacogenetics* 2004;14:635-645.

- 450 Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Backman M, Ohlsson R, Postlind H, Blomquist P, Berkenstam A. Identification of a human nuclear receptor defines a new signaling pathway for cyp3a induction. *Proc Natl Acad Sci U S A* 1998;95:12208-12213.
- 451 Drocourt L, Ourlin JC, Pascussi JM, Maurel P, Vilarem MJ. Expression of cyp3a4, cyp2b6, and cyp2c9 is regulated by the vitamin d receptor pathway in primary human hepatocytes. *J Biol Chem* 2002;277:25125-25132.
- 452 Goodwin B, Redinbo MR, Kliewer SA. Regulation of cyp3a gene transcription by the pregnane x receptor. *Annu Rev Pharmacol Toxicol* 2002;42:1-23.
- 453 Marschall HU, Wagner M, Bodin K, Zollner G, Fickert P, Gumhold J, Silbert D, Fuchsbichler A, Sjoval J, Trauner M. Fxr(-/-) mice adapt to biliary obstruction by enhanced phase i detoxification and renal elimination of bile acids. *J Lipid Res* 2006;47:582-592.
- 454 Stedman C, Robertson G, Coulter S, Liddle C. Feed-forward regulation of bile acid detoxification by cyp3a4: Studies in humanized transgenic mice. *J Biol Chem* 2004;279:11336-11343.
- 455 Negishi M, Pedersen LG, Petrotchenko E, Shevtsov S, Gorokhov A, Kakuta Y, Pedersen LC. Structure and function of sulfotransferases. *Arch Biochem Biophys* 2001;390:149-157.
- 456 Tephly TR, Burchell B. Udp-glucuronosyltransferases: A family of detoxifying enzymes. *Trends Pharmacol Sci* 1990;11:276-279.
- 457 Radomska-Pandya A, Czernik PJ, Little JM, Battaglia E, Mackenzie PI. Structural and functional studies of udp-glucuronosyltransferases. *Drug Metab Rev* 1999;31:817-899.
- 458 Huang J, Bathena SP, Tong J, Roth M, Hagenbuch B, Alnouti Y. Kinetic analysis of bile acid sulfation by stably expressed human sulfotransferase 2a1 (sult2a1). *Xenobiotica* 2010;40:184-194.
- 459 Kitada H, Miyata M, Nakamura T, Tozawa A, Honma W, Shimada M, Nagata K, Sinal CJ, Guo GL, Gonzalez FJ, Yamazoe Y. Protective role of hydroxysteroid sulfotransferase in lithocholic acid-induced liver toxicity. *J Biol Chem* 2003;278:17838-17844.
- 460 Song CS, Echchgadda I, Baek BS, Ahn SC, Oh T, Roy AK, Chatterjee B. Dehydroepiandrosterone sulfotransferase gene induction by bile acid activated farnesoid x receptor. *J Biol Chem* 2001;276:42549-42556.
- 461 Runge-Morris M, Wu W, Kocarek TA. Regulation of rat hepatic hydroxysteroid sulfotransferase (sult2-40/41) gene expression by glucocorticoids: Evidence for a dual mechanism of transcriptional control. *Mol Pharmacol* 1999;56:1198-1206.
- 462 Sonoda J, Xie W, Rosenfeld JM, Barwick JL, Guzelian PS, Evans RM. Regulation of a xenobiotic sulfonation cascade by nuclear pregnane x receptor (pxr). *Proc Natl Acad Sci U S A* 2002;99:13801-13806.
- 463 Saini SP, Sonoda J, Xu L, Toma D, Uppal H, Mu Y, Ren S, Moore DD, Evans RM, Xie W. A novel constitutive androstane receptor-mediated and cyp3a-independent pathway of bile acid detoxification. *Mol Pharmacol* 2004;65:292-300.
- 464 Gall WE, Zawada G, Mojarrabi B, Tephly TR, Green MD, Coffman BL, Mackenzie PI, Radomska-Pandya A. Differential glucuronidation of bile acids, androgens and estrogens by human ugt1a3 and 2b7. *J Steroid Biochem Mol Biol* 1999;70:101-108.
- 465 King CD, Rios GR, Green MD, Tephly TR. Udp-glucuronosyltransferases. *Curr Drug Metab* 2000;1:143-161.
- 466 Liu W, Ramirez J, Gamazon ER, Mirkov S, Chen P, Wu K, Sun C, Cox NJ, Cook E, Jr., Das S, Ratain MJ. Genetic factors affecting gene transcription and catalytic activity of udp-glucuronosyltransferases in human liver. *Hum Mol Genet* 2014;23:5558-5569.
- 467 Kullak-Ublick GA, Stieger B, Hagenbuch B, Meier PJ. Hepatic transport of bile salts. *Semin Liver Dis* 2000;20:273-292.
- 468 Zelcer N, Reid G, Wielinga P, Kuil A, van der Heijden I, Schuetz JD, Borst P. Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (mrp) 4 (atp-binding cassette c4). *Biochem J* 2003;371:361-367.
- 469 Mueller M, Cima I, Noti M, Fuhrer A, Jakob S, Dubuquoy L, Schoonjans K, Brunner T. The nuclear receptor Irh-1 critically regulates extra-adrenal glucocorticoid synthesis in the intestine. *J Exp Med* 2006;203:2057-2062.

470 Fayard E, Auwerx J, Schoonjans K. Lrh-1: An orphan nuclear receptor involved in development, metabolism and steroidogenesis. *Trends Cell Biol* 2004;14:250-260.

471 Kir S, Zhang Y, Gerard RD, Kliewer SA, Mangelsdorf DJ. Nuclear receptors hnf4alpha and Lrh-1 cooperate in regulating cyp7a1 in vivo. *J Biol Chem* 2012;287:41334-41341.

472 Li T, Francl JM, Boehme S, Chiang JY. Regulation of cholesterol and bile acid homeostasis by the cholesterol 7alpha-hydroxylase/steroid response element-binding protein 2/microrna-33a axis in mice. *Hepatology* 2013;58:1111-1121.

473 Li H, Xu G, Shang Q, Pan L, Shefer S, Batta AK, Bollineni J, Tint GS, Keller BT, Salen G. Inhibition of ileal bile acid transport lowers plasma cholesterol levels by inactivating hepatic farnesoid x receptor and stimulating cholesterol 7 alpha-hydroxylase. *Metabolism* 2004;53:927-932.

474 Chiang JY. Regulation of bile acid synthesis. *Front Biosci* 1998;3:d176-193.

475 Wang J, Greene S, Eriksson LC, Rozell B, Reihner E, Einarsson C, Eggertsen G, Gafvels M. Human sterol 12a-hydroxylase (cyp8b1) is mainly expressed in hepatocytes in a homogenous pattern. *Histochem Cell Biol* 2005;123:441-446.

476 Bollard ME, Contel NR, Ebbels TM, Smith L, Beckonert O, Cantor GH, Lehman-McKeeman L, Holmes EC, Lindon JC, Nicholson JK, Keun HC. Nmr-based metabolic profiling identifies biomarkers of liver regeneration following partial hepatectomy in the rat. *J Proteome Res* 2010;9:59-69.

477 Schwartz CC, Berman M, Vlahcevic ZR, Halloran LG, Gregory DH, Swell L. Multicompartmental analysis of cholesterol metabolism in man. Characterization of the hepatic bile acid and biliary cholesterol precursor sites. *J Clin Invest* 1978;61:408-423.

478 Abel S, Smuts CM, de Villiers C, Gelderblom WC. Changes in essential fatty acid patterns associated with normal liver regeneration and the progression of hepatocyte nodules in rat hepatocarcinogenesis. *Carcinogenesis* 2001;22:795-804.

479 Albi E, Magni MV. The presence and the role of chromatin cholesterol in rat liver regeneration. *J Hepatol* 2002;36:395-400.

480 Xu C, Lin F, Qin S. Relevance between lipid metabolism-associated genes and rat liver regeneration. *Hepatol Res* 2008;38:825-837.

481 Field FJ, Mathur SN, LaBrecque DR. Cholesterol metabolism in regenerating liver of the rat. *Am J Physiol* 1985;249:G679-684.

482 Monte MJ, Fernandez-Tagarro M, Marin JJ. Transient changes in the expression pattern of key enzymes for bile acid synthesis during rat liver regeneration. *Biochim Biophys Acta* 2005;1734:127-135.

483 Trentalance A, Bruscalupi G, Conti Devirgiliis L, Leoni S, Mangiantini MT, Rossini L, Spagnuolo S, Erickson SK. Changes in lipoprotein binding and uptake by hepatocytes during rat liver regeneration. *Biosci Rep* 1989;9:231-241.

484 Zhao C, Dahlman-Wright K. Liver x receptor in cholesterol metabolism. *J Endocrinol* 2010;204:233-240.

485 Wang Y, Rogers PM, Su C, Varga G, Stayrook KR, Burris TP. Regulation of cholesterologenesis by the oxysterol receptor, Lxralpha. *J Biol Chem* 2008;283:26332-26339.

486 Lee MH, Lu K, Hazard S, Yu H, Shulenin S, Hidaka H, Kojima H, Allikmets R, Sakuma N, Pegoraro R, Srivastava AK, Salen G, Dean M, Patel SB. Identification of a gene, abcg5, important in the regulation of dietary cholesterol absorption. *Nat Genet* 2001;27:79-83.

487 Lu K, Lee MH, Hazard S, Brooks-Wilson A, Hidaka H, Kojima H, Ose L, Stalenhoef AF, Mietinnen T, Bjorkhem I, Bruckert E, Pandya A, Brewer HB, Jr., Salen G, Dean M, Srivastava A, Patel SB. Two genes that map to the stsl locus cause sitosterolemia: Genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by abcg5 and abcg8, respectively. *Am J Hum Genet* 2001;69:278-290.

488 Graf GA, Li WP, Gerard RD, Gelissen I, White A, Cohen JC, Hobbs HH. Coexpression of atp-binding cassette proteins abcg5 and abcg8 permits their transport to the apical surface. *J Clin Invest* 2002;110:659-669.

489 Graf GA, Yu L, Li WP, Gerard R, Tuma PL, Cohen JC, Hobbs HH. Abcg5 and abcg8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. *J Biol Chem* 2003;278:48275-48282.

490 Yu L, Hammer RE, Li-Hawkins J, Von Bergmann K, Lutjohann D, Cohen JC, Hobbs HH. Disruption of abcg5 and abcg8 in mice reveals their crucial role in biliary cholesterol secretion. *Proc Natl Acad Sci U S A* 2002;99:16237-16242.

491 Yu L, Li-Hawkins J, Hammer RE, Berge KE, Horton JD, Cohen JC, Hobbs HH. Overexpression of abcg5 and abcg8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. *J Clin Invest* 2002;110:671-680.

492 Cheng HC, Yang CM, Shiao MS. Zonation of cholesterol and glycerolipid synthesis in regenerating rat livers. *Hepatology* 1993;17:280-286.

493 Miyake JH, Wang SL, Davis RA. Bile acid induction of cytokine expression by macrophages correlates with repression of hepatic cholesterol 7alpha-hydroxylase. *J Biol Chem* 2000;275:21805-21808.

494 Stroup D, Crestani M, Chiang JY. Identification of a bile acid response element in the cholesterol 7 alpha-hydroxylase gene cyp7a. *Am J Physiol* 1997;273:G508-517.

495 Chiang JY, Kimmel R, Weinberger C, Stroup D. Farnesoid x receptor responds to bile acids and represses cholesterol 7alpha-hydroxylase gene (cyp7a1) transcription. *J Biol Chem* 2000;275:10918-10924.

496 Kim I, Ahn SH, Inagaki T, Choi M, Ito S, Guo GL, Kliewer SA, Gonzalez FJ. Differential regulation of bile acid homeostasis by the farnesoid x receptor in liver and intestine. *Lipid Res* 2007;48:2664-2672.

497 Li T, Jahan A, Chiang JY. Bile acids and cytokines inhibit the human cholesterol 7 alpha-hydroxylase gene via the jnk/c-jun pathway in human liver cells. *Hepatology* 2006;43:1202-1210.

498 Gupta S, Stravitz RT, Dent P, Hylemon PB. Down-regulation of cholesterol 7alpha-hydroxylase (cyp7a1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-jun n-terminal kinase pathway. *J Biol Chem* 2001;276:15816-15822.

499 Gupta S, Natarajan R, Payne SG, Studer EJ, Spiegel S, Dent P, Hylemon PB. Deoxycholic acid activates the c-jun n-terminal kinase pathway via fas receptor activation in primary hepatocytes. Role of acidic sphingomyelinase-mediated ceramide generation in fas receptor activation. *J Biol Chem* 2004;279:5821-5828.

500 Jung D, Kullak-Ublick GA. Hepatocyte nuclear factor 1 alpha: A key mediator of the effect of bile acids on gene expression. *Hepatology* 2003;37:622-631.

501 Chiang JY. Regulation of bile acid synthesis: Pathways, nuclear receptors, and mechanisms. *J Hepatol* 2004;40:539-551.

502 Peng S, Huo X, Rezaei D, Zhang Q, Zhang X, Yu C, Asanuma K, Cheng E, Pham TH, Wang DH, Chen M, Souza RF, Spechler SJ. In barrett's esophagus patients and barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids. *Am J Physiol Gastrointest Liver Physiol* 2014;307:G129-139.

503 Li T, Chiang JY. A novel role of transforming growth factor beta1 in transcriptional repression of human cholesterol 7alpha-hydroxylase gene. *Gastroenterology* 2007;133:1660-1669.

504 Song KH, Ellis E, Strom S, Chiang JY. Hepatocyte growth factor signaling pathway inhibits cholesterol 7alpha-hydroxylase and bile acid synthesis in human hepatocytes. *Hepatology* 2007;46:1993-2002.

505 Li T, Ma H, Chiang JY. Tgfbeta1, tnfa, and insulin signaling crosstalk in regulation of the rat cholesterol 7alpha-hydroxylase gene expression. *J Lipid Res* 2008;49:1981-1989.

506 Gerloff T, Geier A, Stieger B, Hagenbuch B, Meier PJ, Matern S, Gartner C. Differential expression of basolateral and canalicular organic anion transporters during regeneration of rat liver. *Gastroenterology* 1999;117:1408-1415.

507 Meier PJ. Molecular mechanisms of hepatic bile salt transport from sinusoidal blood into bile. *Am J Physiol* 1995;269:G801-812.

- 508 Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the oatp/ slc21 family: Phylogenetic classification as oatp/ slco superfamily, new nomenclature and molecular/functional properties. *Pflugers Arch* 2004;447:653-665.
- 509 König J, Klatt S, Dilger K, Fromm MF. Characterization of ursodeoxycholic and norursodeoxycholic acid as substrates of the hepatic uptake transporters oatp1b1, oatp1b3, oatp2b1 and ntcp. *Basic Clin Pharmacol Toxicol* 2012;111:81-86.
- 510 Roth M, Obaidat A, Hagenbuch B. Oatps, oats and octs: The organic anion and cation transporters of the slco and slc22a gene superfamilies. *Br J Pharmacol* 2012;165:1260-1287.
- 511 Green RM, Gollan JL, Hagenbuch B, Meier PJ, Beier DR. Regulation of hepatocyte bile salt transporters during hepatic regeneration. *Am J Physiol* 1997;273:G621-627.
- 512 Vos TA, Ros JE, Havinga R, Moshage H, Kuipers F, Jansen PL, Muller M. Regulation of hepatic transport systems involved in bile secretion during liver regeneration in rats. *Hepatology* 1999;29:1833-1839.
- 513 Miura T, Kimura N, Yamada T, Shimizu T, Nanashima N, Yamana D, Hakamada K, Tsuchida S. Sustained repression and translocation of ntcp and expression of mrp4 for cholestasis after rat 90% partial hepatectomy. *J Hepatol* 2011;55:407-414.
- 514 Keitel V, Burdelski M, Warskulat U, Kuhlkamp T, Keppler D, Haussinger D, Kubitz R. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. *Hepatology* 2005;41:1160-1172.
- 515 Dawson PA, Lan T, Rao A. Bile acid transporters. *J Lipid Res* 2009;50:2340-2357.
- 516 Geier A, Dietrich CG, Voigt S, Ananthanarayanan M, Lammert F, Schmitz A, Trauner M, Wasmuth HE, Boraschi D, Balasubramaniyan N, Suchy FJ, Matern S, Gartung C. Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. *Am J Physiol Gastrointest Liver Physiol* 2005;289:G831-841.
- 517 Le Vee M, Gripon P, Stieger B, Fardel O. Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1beta. *Drug Metab Dispos* 2008;36:217-222.
- 518 Zeng H, Liu G, Rea PA, Kruh GD. Transport of amphipathic anions by human multidrug resistance protein 3. *Cancer Res* 2000;60:4779-4784.
- 519 Inokuchi A, Hinoshita E, Iwamoto Y, Kohno K, Kuwano M, Uchiumi T. Enhanced expression of the human multidrug resistance protein 3 by bile salt in human enterocytes. A transcriptional control of a plausible bile acid transporter. *J Biol Chem* 2001;276:46822-46829.
- 520 Zelcer N, Saeki T, Bot I, Kuil A, Borst P. Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal na⁺-dependent bile-acid transporter. *Biochem J* 2003;369:23-30.
- 521 König J, Rost D, Cui Y, Keppler D. Characterization of the human multidrug resistance protein isoform mrp3 localized to the basolateral hepatocyte membrane. *Hepatology* 1999;29:1156-1163.
- 522 Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, Keppler D. Cotransport of reduced glutathione with bile salts by mrp4 (abcc4) localized to the basolateral hepatocyte membrane. *Hepatology* 2003;38:374-384.
- 523 Cherrington NJ, Hartley DP, Li N, Johnson DR, Klaassen CD. Organ distribution of multidrug resistance proteins 1, 2, and 3 (mrp1, 2, and 3) mRNA and hepatic induction of mrp3 by constitutive androstane receptor activators in rats. *J Pharmacol Exp Ther* 2002;300:97-104.
- 524 Csanaky IL, Aleksunes LM, Tanaka Y, Klaassen CD. Role of hepatic transporters in prevention of bile acid toxicity after partial hepatectomy in mice. *Am J Physiol Gastrointest Liver Physiol* 2009;297:G419-433.
- 525 Chang TH, Hakamada K, Toyoki Y, Tsuchida S, Sasaki M. Expression of mrp2 and mrp3 during liver regeneration after 90% partial hepatectomy in rats. *Transplantation* 2004;77:22-27.
- 526 Khan AA, Chow EC, Porte RJ, Pang KS, Groothuis GM. Expression and regulation of the bile acid transporter, osthalpha-ostbeta in rat and human intestine and liver. *Biopharm Drug Dispos* 2009;30:241-258.


- 527 Karabelyos C, Dobozy O, Szalai C, Klenjanski K, Varju K, Hadhazi A, Kiss A, Fulop AK, Madarasz B, Falus A. Elevated hepatic glucocorticoid receptor expression during liver regeneration in rats. *Pathol Oncol Res* 1999;5:107-109.
- 528 Zollner G, Marschall HU, Wagner M, Trauner M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: Pathogenetic and therapeutic considerations. *Mol Pharm* 2006;3:231-251.
- 529 Bremmelgaard A, Sjoval J. Bile acid profiles in urine of patients with liver diseases. *Eur J Clin Invest* 1979;9:341-348.
- 530 Alme B, Sjoval J. Analysis of bile acid glucuronides in urine. Identification of 3 alpha, 6 alpha, 12 alpha-trihydroxy-5 beta-cholanoic acid. *J Steroid Biochem* 1980;13:907-916.
- 531 Alme B, Bremmelgaard A, Sjoval J, Thomassen P. Analysis of metabolic profiles of bile acids in urine using a lipophilic anion exchanger and computerized gas-liquid chromatography-mass spectrometry. *J Lipid Res* 1977;18:339-362.
- 532 Gerloff T, Geier A, Roots I, Meier PJ, Gartung C. Functional analysis of the rat bile salt export pump gene promoter. *Eur J Biochem* 2002;269:3495-3503.
- 533 Plass JR, Mol O, Heegsma J, Geuken M, Faber KN, Jansen PL, Muller M. Farnesoid x receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump. *Hepatology* 2002;35:589-596.
- 534 Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, Lamba J, Kim RB, Ramachandran V, Komoroski BJ, Venkataramanan R, Cai H, Sinal CJ, Gonzalez FJ, Schuetz JD. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome p450. *J Biol Chem* 2001;276:39411-39418.
- 535 Zollner G, Fickert P, Fuchsbichler A, Silbert D, Wagner M, Arbeiter S, Gonzalez FJ, Marschall HU, Zatloukal K, Denk H, Trauner M. Role of nuclear bile acid receptor, fxr, in adaptive abc transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. *J Hepatol* 2003;39:480-488.
- 536 Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Pojer C, Zenz R, Lammert F, Stieger B, Meier PJ, Zatloukal K, Denk H, Trauner M. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. *Gastroenterology* 2001;121:170-183.
- 537 Courtois A, Payen L, Le Ferrec E, Scheffer GL, Trinquart Y, Guillouzo A, Fardel O. Differential regulation of multidrug resistance-associated protein 2 (mrp2) and cytochromes p450 2b1/2 and 3a1/2 in phenobarbital-treated hepatocytes. *Biochem Pharmacol* 2002;63:333-341.
- 538 Guo GL, Lambert G, Negishi M, Ward JM, Brewer HB, Jr., Klier SA, Gonzalez FJ, Sinal CJ. Complementary roles of farnesoid x receptor, pregnane x receptor, and constitutive androstane receptor in protection against bile acid toxicity. *J Biol Chem* 2003;278:45062-45071.
- 539 Wagner M, Halilbasic E, Marschall HU, Zollner G, Fickert P, Langner C, Zatloukal K, Denk H, Trauner M. Car and pxx agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. *Hepatology* 2005;42:420-430.
- 540 Marino PA, Gottesman MM, Pastan I. Regulation of the multidrug resistance gene in regenerating rat liver. *Cell Growth Differ* 1990;1:57-62.
- 541 Teeter LD, Estes M, Chan JY, Atassi H, Sell S, Becker FF, Kuo MT. Activation of distinct multidrug-resistance (p-glycoprotein) genes during rat liver regeneration and hepatocarcinogenesis. *Mol Carcinog* 1993;8:67-73.
- 542 Chen HL, Liu YJ, Chen HL, Wu SH, Ni YH, Ho MC, Lai HS, Hsu WM, Hsu HY, Tseng HC, Jeng YM, Chang MH. Expression of hepatocyte transporters and nuclear receptors in children with early and late-stage biliary atresia. *Pediatr Res* 2008;63:667-673.
- 543 Grassian AR, Metallo CM, Coloff JL, Stephanopoulos G, Brugge JS. Erk regulation of pyruvate dehydrogenase flux through pdk4 modulates cell proliferation. *Genes Dev* 2011;25:1716-1733.
- 544 Rolo AP, Palmeira CM, Wallace KB. Interactions of combined bile acids on hepatocyte viability: Cytoprotection or synergism. *Toxicol Lett* 2002;126:197-203.

Figure 3. Non-exhaustive list of bile acid species and bile acid analogues, chemical properties, and toxicity. LogP (octanol:water partition coefficient) values were retrieved from PubChem and were predicted with XLogP2 or XLogP3 software. The 50% lethal concentration (LC50, used for in vitro data) and 50% lethal dose (LD50, used for in vivo data) were obtained from the material safety data sheets (retrieved from the Cayman Chemicals and Spectrum Chemical website) and the Toxicological Data Network (TOXNET, <https://toxnet.nlm.nih.gov/>) as well as available literature [544] [544].

Abbreviations (bile acids excluded): NA: information not available; iv: intravenous; ip: intraperitoneal; MW: molecular weight; sc: subcutaneous; TDLO; the lowest dose causing a toxic effect.


Abbreviations (bile acids): 12-keto-LCA: 12-ketolithocholic acid / 12-oxolithocholic acid; 12-oxo-CDCA: 12-oxochenodeoxycholate / 12-oxochenodeoxycholic acid; 3,7-DiHCA : 3,7-dihydroxy-5-cholestenoic acid; 3,7-diketo-CA : 3,7-diketocholanic acid / 3,7-dioxhocholanoic acid; 3-keto-CA: 3-ketocholic acid / 3-oxocholic acid; 3-keto-LCA: 3-ketolithocholic acid / dehydrolithocholic acid; 3-SCDCA: chenodeoxycholic acid 3-sulfate; 3-S-GCDCA: glycochenodeoxycholic acid 3-sulfate; 3S-TLCA: tauroolithocholate sulfate / tauroolithocholic acid 3-sulfate; 3-sulfate CA: cholic acid 3-sulfate; 5-THCA: trihydrocoprostanic acid / (3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxycholestane-5-carboxylic acid; 6-keto-LCA: 6-ketolithocholic acid; 7-Hoca: 7 α -hydroxy-3-oxo-4-cholestenoic acid; 7-keto-DCA: 7-ketodeoxycholic acid; 7-keto-LCA: 7-ketolithocholic acid / nutriacholic acid; 7-SCDCA: chenodeoxycholic acid 7-sulfate; 7-S-GCDCA: glycochenodeoxycholic acid 7-sulfate; 7-sulfate CA: cholic acid 7-sulfate; α -MCA: α -muricholate / α -muricholic acid / α -hyocholic acid; α -PCCA: α -phocaecholate / alpha-phocaecholic acid; β -MCA: β -muricholate / β -muricholic acid / β -hyocholic acid; β -PCCA: β -phocaecholate / phocaecholic acid; ω -MCA: ω -muricholate / ω -muricholic acid / ω -hyocholic acid; ACA: allocholate / allocholic acid; AlloAVCA: alloavicholate / alloavicholic acid; AlloCDCA: allochenodeoxycholate / allochenodeoxycholic acid; AlloDCA: allodeoxycholate / allodeoxycholic acid; AlloLCA: allolithocholic acid; AlloUDCA: alloursodeoxycholic acid; ApoCA: apocholate / apocholic acid; AVCA: avicholate / avicholic acid; AVDCA: aideoxycholate / aideoxycholic acid; BCA: bitocholate / bitocholic acid; CA: cholate / cholic acid; CCA: ciliatocholate / ciliatocholic acid; CDCA: chenodeoxycholate / chenodeoxycholic acid; CGA: cygnocholate / cygnocholic acid; CSA: cholestenoic acid; DCA: deoxycholate / deoxycholic acid; DHA: dehydrocholate / dehydrocholic acid; DiHCA: dihydroxycoprostanic acid; DinorCA: dinorcholic acid; DinorCDCA: dinorchenodeoxycholic acid; DinorDCA: dinordeoxycholic acid; DinorHDCA: dinorhyodeoxycholic acid; DinorLCA: dinorlithocholic acid; DinorUDCA: dinorursodeoxycholic acid; GCA: glycocholate / glycocholic acid; GCDCA: glycochenodeoxycholate / glycochenodeoxycholic acid; GDCA: glycodeoxycholate / glycodeoxycholic acid; GHCA: glycohyocholate / glycohyocholic acid; GHDCa: glycohyodeoxycholate / glycohyodeoxycholic acid; GLCA: glycolithocholate / glycolithocholic acid; GLCA-3-S: glycolithocholate 3-sulfate / glycolithocholic acid 3-sulfate; Glyco-OCA: glyco-obeticholic acid; GUCA: glycoursocholate / glycoursocholic acid; GUDCA: glycoursodeoxycholate / glycoursodeoxycholic acid; HCA: hemulcholate / hemulcholic acid; HDCA: hyodeoxycholic acid / murideoxycholic acid; LagoDCA: lagodeoxycholic acid; LCA: lithocholate / lithocholic acid; NorCA: norcholate / norcholic acid; NorCDCA: norchenodeoxycholic acid; NorDCA: nordeoxycholic acid; NorHDCA: norhyodeoxycholic acid; NorLCA: norlithocholic acid; NorUCA: noruroscholic acid; NorUDCA: norursodeoxycholic acid; OCA: obeticholic acid / ocaliva / 6-ethylchenodeoxycholic acid / INT-747; PCA: pythocholic acid; S-LCA: lithocholic acid 3-sulfate; T- α -MC: tauro- α -muricholic acid; T- β -MC: tauro- β -muricholic acid; TCA: taurocholate / taurocholic acid; TCA-3-S: taurocholate 3-sulfate / taurocholic acid 3-sulfate; TCDCA: taurochenodeoxycholate / taurochenodeoxycholic acid; TCDCA3S: taurochenodeoxycholic acid 3-sulfate; TCDCA7S: taurochenodeoxycholic acid 7-sulfate; TDC(A): taurodeoxycholate / taurodeoxycholic acid; THCA: trihydrocoprostanic acid / coprocholic acid / 3,7,12-trihydroxycholestan-26-oic acid; THDCA: taurohyodeoxycholate / taurohyodeoxycholic acid; TLCA: tauroolithocholate / tauroolithocholic acid; TUCA: taurourscholate / taurourscholic acid; TUDCA: tauroursodeoxycholate / tauroursodeoxycholic acid; UA: ursolic acid; UCA: ursocholic acid; UCIA: ursocholanic acid; UDCA: ursodeoxycholate / ursodeoxycholic acid; VA: varanic acid; VCA: vulpecholate / vulpecholic acid.

CCA




C24H46NO7P; MW 515,628; logP 1.5 (predicted)
Receptor: NA; Species: Bovine
LC50: NA
LD50: NA

TCA-3-S




C26H45NO10S2; MW 595,763; logP 1.8 (predicted)
Receptor: NA; Species: Human
LC50: NA
LD50: NA

TCA




C26H45NO7S; MW 515,706; logP 2.2 (predicted)
Receptor: NA; Species: Human
LC50: NA
LD50: 0.02 mg/kg (oral TDLO) - rat

TUCA




C26H45NO7S; MW 515,706; logP 2.2 (predicted)
Receptor: NA; Species: Human
LC50: NA
LD50: NA

DHA




C24H34O5; MW 402,524; logP 2.6 (predicted)
Receptor: FXR (agonist), PXR (agonist)
Species: Synthetic
LC50: NA
LD50: 4000 mg/kg (oral), 750 mg/kg (iv)
1500 mg/kg (im) - Rat
3100 mg/kg (oral), 1620 mg/kg (sc)
1492 mg/kg (iv) - Mouse

T-alpha-MC



C26H45NO7S; MW 515,706; logP 2.6 (predicted)
Receptor: FXR (agonist), LXR (agonist)
Species: Mouse, Rat
LC50: NA
LD50: NA

T-beta-MC




C26H45NO7S; MW 515,706; logP 2.6 (predicted)
Receptor: FXR (agonist), LXR (agonist)
Species: Mice, Rats
LC50: NA
LD50: NA

3,7-diketo-CA




C24H36O4; MW 388,540; logP 2.9 (predicted)
1.65 (experimental); Receptor: FXR/RXR (agonist)
Species: Human & many others
LC50: NA
LD50: NA

GCA




C26H42NO6; MW 465,631; logP 2.9 (predicted)
1.65 (experimental); Receptor: FXR (agonist)
Species: Human
LC50: NA
LD50: 2.5186 mol/kg - Rat

GUCA




C26H43NO6; MW 465,631; logP 2.9 (predicted)
Receptor: NA
Species: Human
LC50: NA
LD50: NA

α-PCCA




C24H40O6; MW 424,570; logP 3.0 (predicted)
Receptor: NA; Species: Snakes, Birds
LC50: NA
LD50: NA

DinorCA




C22H36O5; MW 380,525; logP 3.0 (predicted)
Receptor: NA; Species: Human
LC50: NA
LD50: NA

TCDCA3S




C26H45NO8S2; MW 563,765; logP 3.1 (predicted)
Receptor: NA; Species: Human
LC50: NA
LD50: NA

3-keto-CA




C24H38O5; MW 406,563; logP 3.2 (predicted)
Receptor: NA; Species: Human
LC50: NA
LD50: NA

3-sulfate CA




C24H40O8S; MW 488,636; logP 3.2 (predicted)
Receptor: NA; Species: Human & many other
LC50: NA
LD50: NA

7-sulfate CA




C₂₄H₄₀O₈S; MW 488,636; logP 3.2 (predicted)
Receptor: NA; Species: Human & many other
LC₅₀: NA
LD₅₀: NA

NorCA




C₂₃H₃₈O₅; MW 394,552; logP 3.2 (predicted)
Receptor: NA; Species: Human
LC₅₀: NA
LD₅₀: NA

TCDCA7S




C₂₆H₄₅NO₉S₂; MW 579,764; logP 3.2 (predicted)
Receptor: NA; Species: Human
LC₅₀: NA
LD₅₀: NA

12-oxo-CDCA




C₂₄H₃₈O₅; MW 406,563; logP 3.3 (predicted)
Receptor: FXR (agonist); Species: Human & many other
LC₅₀: NA
LD₅₀: NA

7-keto-DCA




C₂₄H₃₈O₅; MW 406,563; logP 3.3 (predicted)
Receptor: FXR (agonist); Species: Human & many other
LC₅₀: NA
LD₅₀: NA

GHCA




C₂₆H₄₃NO₆; MW 465,631; logP 3.3 (predicted)
1.9 (experimental)
Receptor: FXR (agonist), PXR (agonist)
Species: Human
LC₅₀: NA
LD₅₀: NA

ApoCA




C₂₄H₃₈O₄; MW 390,564; logP 3.5 (predicted)
Receptor: FXR (agonist), LXR (agonist)
Species: Human
LC₅₀: NA
LD₅₀: NA

AlloAVCA




C₂₄H₄₀O₅; MW 408,579; logP 3.6 (predicted)
Receptor: NA; Species: Reptiles
LC₅₀: NA
LD₅₀: NA

ACA




C₂₄H₄₀O₅; MW 408,579; logP 3.6 (predicted)
Receptor: FXR (agonist)
Species: Human
LC₅₀: NA
LD₅₀: NA

AVCA




C₂₄H₄₀O₅; MW 408,579; logP 3.6 (predicted)
Receptor: TGR5 (agonist)
Species: Birds
LC₅₀: NA
LD₅₀: NA

CA




C₂₄H₄₀O₅; MW 408,579; logP 3.6 (predicted)
2.02 (experimental); Receptor: TGR5 (agonist)
FXR (agonist); Species: Human & many other
LC₅₀: NA
LD₅₀: 4.95 g/kg (oral); 333 mg/kg (ip)
350 mg/kg (iv) - mouse

CGA




C₂₄H₄₀O₅; MW 408,579; logP 3.6 (predicted)
Receptor: NA; Species: Geese, Plovers, Swans
LC₅₀: NA
LD₅₀: NA

PCA




C₂₄H₄₀O₅; MW 408,579; logP 3.6 (predicted)
Receptor: NA; Species: Snakes
LC₅₀: NA
LD₅₀: NA

TCDCA




C₂₆H₄₅NO₆S; MW 499,707; logP 3.6 (predicted)
Receptor: FXR (agonist); Species: Human
LC₅₀: >1000 μM (rat hepatocytes)
LD₅₀: NA

TDCA




C₂₆H₄₅NO₆S; MW 499,707; logP 3.6 (predicted)
Receptor: FXR (agonist); Species: Human
LC₅₀: NA
LD₅₀: NA

THDCA




C26H45NO6S; MW 499,707; logP 3.6 (predicted)
Receptor: LXRα (agonist); Species: Mice, Rats
LC50: NA
LD50: NA

TUDCA




C26H45NO6S; MW 499,707; logP 3.6 (predicted)
Receptor: FXR (agonist); Species: Human
LC50: >750 μM (rat hepatocytes)
LD50: NA

3-S-GCDCA




C26H43NO8S; MW 529,689; logP 3.9 (predicted)
Receptor: NA; Species: Human
LC50: NA
LD50: NA

7-S-GCDCA




C26H43NO8S; MW 529,689; logP 3.9 (predicted)
Receptor: NA; Species: Human
LC50: NA
LD50: NA

HCA




C24H40O5; MW 408,579; logP 3.9 (predicted)
Receptor: NA; Species: Fish
LC50: NA
LD50: NA

VA




C27H40O6; MW 466,659; logP 3.9 (predicted)
Receptor: NA; Species: Humans with deficiencies in the peroxisomal d-bifunctional protein
LC50: NA
LD50: NA

VCA




C24H40O5; MW 408,579; logP 3.9 (predicted)
2.8 (experimental); Receptor: NA
Species: Marsupials
LC50: NA
LD50: NA

α-MCA




C24H40O4; MW 408,579; logP 3.9 (predicted)
2.8 (experimental); Receptor: NA
Species: Mice, Rats
LC50: NA
LD50: NA

β-MCA




C24H40O4; MW 408,579; logP 3.9 (predicted)
2.8 (experimental); Receptor: NA
Species: Mice, Rats
LC50: NA
LD50: NA

ω-MCA




C24H40O4; MW 408,579; logP 3.9 (predicted)
2.8 (experimental); Receptor: NA
Species: Mice, Rats
LC50: NA
LD50: NA

NorUCA




C23H38O5; MW 394,552; logP 4.2 (predicted)
Receptor: NA; Species: Rat
LC50: NA
LD50: NA

DinorCDCA




C22H36O4; MW 364,526; logP 4.3 (predicted)
Receptor: NA; Species: Human
LC50: NA
LD50: NA

DinorDCA




C22H36O4; MW 364,526; logP 4.3 (predicted)
Receptor: NA; Species: Human
LC50: NA
LD50: NA

DinorHDCA




C22H36O4; MW 364,526; logP 4.3 (predicted)
Receptor: NA; Species: Human
LC50: NA
LD50: NA

DinorUDCA




C22H36O4; MW 364,526; logP 4.3 (predicted)
Receptor: NA; Species: Human
LC50: NA
LD50: NA

GCDCA




C₂₆H₄₃NO₅; MW 449,623; logP 4.3 (predicted)
2.12 (experimental); Receptor: FXR (agonist)
Species: Human
LC₅₀: >1000 μM (rat hepatocytes)
LD₅₀: 2.5186 mol/kg - Rat

GDCA




C₂₆H₄₃NO₅; MW 449,623; logP 4.3 (predicted)
2.12 (experimental); Receptor: NA
Species: Human
LC₅₀: NA
LD₅₀: 2.5186 mol/kg - Rat

GHDCA




C₂₆H₄₃NO₅; MW 449,623; logP 4.3 (predicted)
2.25 (experimental); Receptor: NA
Species: Human
LC₅₀: NA
LD₅₀: NA

GUDCA




C₂₆H₄₃NO₅; MW 449,632; logP 4.3 (predicted)
2.15 (experimental); Receptor: FXR (agonist)
Species: Human
LC₅₀: >1000 μM (rat hepatocytes)
LD₅₀: NA

β-PCCA




C₂₄H₄₀O₅; MW 408,579; logP 4.4 (predicted)
Receptor: NA; Species: Marine mammals, wading
birds, some song birds, snakes
LC₅₀: NA
LD₅₀: NA

BCA



C₂₄H₄₀O₅; MW 408,579; logP 4.4 (predicted)
Receptor: NA; Species: Snakes
LC₅₀: NA
LD₅₀: NA

3-SCDCA



C₂₄H₄₀O₇S; MW 472,637; logP 4.5 (predicted)
Receptor: FXR (agonist); Species: Human
LC₅₀: NA
LD₅₀: NA

7-SCDCA




C₂₄H₄₀O₇S; MW 472,637; logP 4.5 (predicted)
Receptor: NA; Species: Human
LC₅₀: NA
LD₅₀: NA

3S-TLCA




C₂₆H₄₅NO₈S₂; MW 563,765; logP 4.5 (predicted)
Receptor: NA; Species: Human
LC₅₀: NA
LD₅₀: NA

12-keto-LCA




C₂₄H₃₈O₄; MW 390,564; logP 4.6 (predicted)
Receptor: FXR (agonist)
Species: Human & many others
LC₅₀: NA
LD₅₀: NA

6-keto-LCA




C₂₄H₃₈O₄; MW 390,564; logP 4.6 (predicted)
Receptor: FXR (agonist), VDR (agonist)
Species: Human & many others
LC₅₀: NA
LD₅₀: NA

7-keto-LCA




C₂₄H₃₈O₄; MW 390,564; logP 4.6 (predicted)
Receptor: FXR/RXR (agonist)
Species: Human & many others
LC₅₀: NA
LD₅₀: NA

NorCDCA




C₂₃H₃₈O₄; MW 378,553; logP 4.6 (predicted)
Receptor: NA; Species: Human & marsupials
LC₅₀: NA
LD₅₀: NA

NorDCA




C₂₃H₃₈O₄; MW 378,553; logP 4.6 (predicted)
Receptor: NA; Species: Human
LC₅₀: NA
LD₅₀: NA

NorHDCA




C₂₃H₃₈O₄; MW 378,553; logP 4.6 (predicted)
Receptor: NA; Species: Human
LC₅₀: NA
LD₅₀: NA

NorUDCA




C23H38O4; **MW** 378,553; **logP** 4.6 (predicted)
Receptor: NA; **Species:** Human
LC50: NA
LD50: NA

AlloCDCA




C24H40O4; **MW** 392,580; **logP** 4.9 (predicted)
Receptor: NA
Species: Reptiles, birds
LC50: NA
LD50: NA

AlloDCA




C24H40O5; **MW** 408,579; **logP** 4.9 (predicted)
Receptor: NA
Species: Human & many others
LC50: NA
LD50: NA

AlloUDCA




C24H40O4; **MW** 392,580; **logP** 4.9 (predicted)
Receptor: NA
Species: Human
LC50: NA
LD50: NA

AVDCA




C24H40O4; **MW** 392,580; **logP** 4.9 (predicted)
Receptor: NA
Species: Snakes, herons
LC50: NA
LD50: NA

CDCA




C24H40O5; **MW** 392,580; **logP** 4.9 (predicted)
3.28 (experimental); **Receptor:** FXR (strong agonist)
FXR/RXR (agonist), TGR5 (agonist)
Species: Human & many others
LC50: >125 μ M (rat hepatocytes)
LD50: 4 mg/kg (oral) - Rat & Mouse

DCA




C24H40O5; **MW** 392,580; **logP** 4.9 (predicted)
3.50 (experimental); **Receptor:** FXR (agonist)
FXR/RXR (agonist), TGR5 (agonist)
Species: Human & many others
LC50: NA
LD50: 1 mg/kg (oral) - Rat & Mouse

INT-777




C27H46O5; **MW** 450,660; **logP** 4.9 (predicted)
Receptor: TGR (strong agonist); **Species:** Synthetic
LC50: NA
LD50: NA

HDCA




C24H40O4; **MW** 392,572; **logP** 4.9 (predicted)
Receptor: TGR5 (agonist), LXR (agonist)
Species: Mice, Rats
LC50: NA
LD50: NA

TLCA




C26H45NO5S; **MW** 483,708; **logP** 4.9 (predicted)
Receptor: FXR (agonist), TGR5 (agonist)
Species: Human
LC50: NA
LD50: NA

UDCA




C24H40O4; **MW** 392,58; **logP** 4.9 (predicted)
3.00 (experimental); **Receptor:** FXR (weak agonist)
PXR(agonist); **Species:** Humans, bears, nutria
LC50: >1000 μ M (rat hepatocytes)
LD50: 700 mg/kg (ip), 310 mg/kg (iv)
4600 mg/kg (oral) - Rat
1200 mg/kg (ip), 10000 mg/kg (oral) - Mouse

LagoDCA




C24H40O4; **MW** 392,58; **logP** 4.9 (predicted)
Receptor: TGR5 (agonist)
Species: Rabbit
LC50: NA
LD50: NA

GLCA-3-S




C26H43NO7S; **MW** 513,690; **logP** 5.1 (predicted)
Receptor: FXR (agonist); **Species:** Human
LC50: NA
LD50: NA

Glyco-OCA




C28H47NO5; **MW** 477,686; **logP** 5.1 (predicted)
Receptor: NA
Species: Synthetic (in-vivo conjugated)
LC50: NA
LD50: NA

THCA




C27H46O5; **MW** 450,660; **logP** 5.2 (predicted)
Receptor: NA
Species: Human (peroxisomal defects), crocodiles
LC50: NA
LD50: NA

GLCA




C₂₆H₄₃NO₄; MW 433,633; logP 5.6 (predicted)
Receptor: FXR (agonist), VDR (agonist)
Species: Human
LC₅₀: NA
LD₅₀: NA

DinorLCA




C₂₂H₃₆O₃; MW 348,527; logP 5.7 (predicted)
Receptor: NA; Species: Human
LC₅₀: NA
LD₅₀: NA

OCA




C₂₂H₃₆O₃; MW 348,527; logP 5.7 (predicted)
Receptor: FXR (strong agonist), TGR5 (agonist)
Species: Synthetic
LC₅₀: NA
LD₅₀: NA

3-keto-LCA




C₂₄H₃₈O₃; MW 374,565; logP 5.8 (predicted)
Receptor: FXR (agonist), PXR (agonist)
VDR (agonist); Species: Human
LC₅₀: NA
LD₅₀: NA

5-THCA




C₂₈H₄₈O₅; MW 464,687; logP 5.8 (predicted)
Receptor: NA; Species: Human (peroxisomal defects, Zellweger syndrome, adrenoleukodystrophy)
LC₅₀: NA
LD₅₀: NA

7-Hoca




C₂₇H₄₂O₄; MW 430,629; logP 5.9 (predicted)
Receptor: NA; Species: Human
LC₅₀: NA
LD₅₀: NA

NorLCA




C₂₇H₄₂O₄; MW 430,629; logP 5.9 (predicted)
Receptor: NA; Species: Rat
LC₅₀: NA
LD₅₀: NA

S-LCA




C₂₄H₄₀O₆S; MW 456,638; logP 5.9 (predicted)
Receptor: NA
Species: Human
LC₅₀: NA
LD₅₀: NA

3,7-DiHCA




C₂₇H₄₄O₄; MW 432,645; logP 6.0 (predicted)
Receptor: LXRA (agonist), DAF-12 (*c. elegans* agonist); Species: Human
LC₅₀: NA
LD₅₀: NA

AlloLCA




C₂₄H₄₀O₃; MW 376,581; logP 6.3 (predicted)
Receptor: NA; Species: Human
LC₅₀: NA
LD₅₀: NA

LCA




C₂₄H₄₀O₃; MW 376,581; logP 6.3 (predicted)
Receptor: PXR (agonist), FXR/RXR (agonist)
TGR5 (agonist), VDR (agonist)
Species: Human
LC₅₀: NA
LD₅₀: >75 µM (rat hepatocytes)

DiHCA




C₂₇H₄₆O₄; MW 343,661; logP 6.6 (predicted)
Receptor: NA; Species: Crocodiles
humans (peroxisomal defects)
LC₅₀: NA
LD₅₀: NA

CSA




C₂₇H₄₄O₃; MW 416,646; logP 7.1 (predicted)
Receptor: LXRA (agonist), DAF-12 (*c. elegans* agonist); Species: Human
LC₅₀: NA
LD₅₀: NA

UA




C₃₀H₄₈O₃; MW 456,711; logP 7.3 (predicted)
Receptor: TGR5 (agonist)
Species: Plants
LC₅₀: NA
LD₅₀: 637 mg/kg (ip), 8330 mg/kg (oral) - Mouse

UCIA




C₂₄H₄₀O₂; MW 360,582; logP 8.0 (predicted)
Receptor: NA; Species: Human
LC₅₀: NA
LD₅₀: NA

Scymnol




C27H48O6; MW 468,675; logP 2.7 (predicted)
Receptor: NA
Species: Elasmobranchii
(sharks, skates, rays)
LC50: NA
LD50: NA

5 α -dermophol




C27H48O6; MW 468,675; logP 2.8 (predicted)
Receptor: NA
Species: Salamander
LC50: NA
LD50: NA

5 β -dermophol




C27H48O6; MW 468,675; logP 2.8 (predicted)
Receptor: NA
Species: Salamander
LC50: NA
LD50: NA

arapaimol-B



C27H48O6; MW 468,675; logP 3.1 (predicted)
Receptor: NA
Species: Arapaima
LC50: NA
LD50: NA

5 α -petromyzonol




C24H42O4; MW 394,596; logP 3.8 (predicted)
Receptor: NA
Species: Sea lamprey, lungfish
LC50: NA
LD50: NA

5 β -petromyzonol




C24H42O4; MW 394,596; logP 3.8 (predicted)
Receptor: NA
Species: Sea lamprey
LC50: NA
LD50: NA

5 α -bufol




C27H48O5; MW 452,676; logP 3.9 (predicted)
Receptor: NA
Species: Some frogs, lungfish, coelacanth
LC50: NA
LD50: NA

5 α -chimaerol



C27H48O5; MW 452,676; logP 3.9 (predicted)
Receptor: NA
Species: White suckerfish, lungfish
LC50: NA
LD50: NA

5 β -bufol




C27H48O5; MW 452,676; logP 3.9 (predicted)
Receptor: NA
Species: Toads of genus Bufo, some frogs
LC50: NA
LD50: NA

5 β -chimaerol



C27H48O5; MW 452,676; logP 3.9 (predicted)
Receptor: NA
Species: Chimaerae, some sharks and rays
LC50: NA
LD50: NA

5 α -cyprinol




C27H48O5; MW 452,676; logP 4.0 (predicted)
Receptor: NA
Species: Carp, lungfish, coelacanth, some frogs
LC50: NA
LD50: NA

5 β -cyprinol




C27H48O5; MW 452,676; logP 4.0 (predicted)
Receptor: NA
Species: Several bony fishes, some frogs
LC50: NA
LD50: NA

Latimerol




C27H48O5; MW 452,676; logP 4.0 (predicted)
Receptor: NA
Species: Coelacanth
LC50: NA
LD50: NA

α -trichechol




C27H48O5; MW 452,676; logP 4.2 (predicted)
Receptor: NA
Species: Manatee
LC50: NA
LD50: NA


β -trichechol




C27H48O5; MW 452,676; logP 4.2 (predicted)
Receptor: NA
Species: Manatee
LC50: NA
LD50: NA

INT-767


C₂₅H₄₃Na₆O₈; MW 494,633; logP NA
Receptor: FXR (agonist), TGR5 (strong antagonist)
Species: Semi-synthetic
 LC₅₀: NA
 LD₅₀: NA

MFA-1

C₂₇H₃₂O₄; MW 420,549; logP 5.8 (predicted)
Receptor: FXR (agonist); **Species:** Synthetic
 LC₅₀: NA
 LD₅₀: NA

MFA-2

C₂₇H₃₂O₃; MW 404,55; logP 6.2 (predicted)
Receptor: FXR (agonist); **Species:** Synthetic
 LC₅₀: NA
 LD₅₀: NA

MFA-3

C₂₈H₃₄O₃; MW 418,577; logP 6.5 (predicted)
Receptor: NA; **Species:** Synthetic
 LC₅₀: NA
 LD₅₀: NA

Epub ahead of print